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Despite receiving the second largest dopaminergic projection from the ventral tegmental area 
(VTA) and having a pivotal role in conveying non-spatial information received from sensory 
cortices, the physiological functions of the lateral entorhinal cortex (LEC) are still yet to be 
fully identified. The LEC is comprised of six distinct layers, with the deep layers (layers V-VI) 
receiving projections from throughout the hippocampal formation and projecting gamma-
aminobutyric acid (GABA) rich neurones to the superficial layers (layers I-III). Preliminary 
experiments showed that superficial layers also receive the aforementioned dopaminergic 
input from the VTA, a projection which is highlighted by tyrosine hydroxylase staining. This 
staining also showing that dopamine (DA) is deposited into pools (referred to as islands) which 
span these superficial layers. Field excitatory postsynaptic potential (fEPSP) experiments 
under ex vivo conditions studied changes in amplitude, that is the size of postsynaptic 
responses from localised neurones, and whether they increase (facilitate) or decrease 
(depress) in size when introduced to various stimuli. Previous studies have shown that 
application of high concentrations of DA causes significant depression in amplitudes. 
However, low concentrations of DA show facilitations during bath application of 10 nM DA, 
or during the washout following 100 nM DA application. Pharmacological analysis of D1-like 
and D2-like DA receptor function, using the receptor antagonists SCH-23390 and sulpiride 
respectively, which indicated that both receptors play comparable roles on peak synaptic 
depression as their co-application with 100 μM DA showed no statistically significant 
difference from their individual applications. Gradient analysis during DA application, after 
exertion of the maximal DA effect, suggests that DA desensitisation, a neurological 
phenomenon during which receptors lose their sensitivity to a neurotransmitter over time, 
may be D1-receptor mediated within the LEC. This was shown during SCH-23390 application 
experiments, sequestering D1-like receptor activity (leaving only D2-like receptor activity) 
showed an absence of desensitisation, however this was not statistically significantly different 
from other experiments. Although this effect was seen with 100 μM DA, co-application with 
1000 μM DA showed no statistical significance from the controls which suggests the agonists 
competitively bind to the same sites of the receptor as DA. Application of (2R)-Amino-5-
Phosphonopentanoate (AP5), an N-Methyl-D-Aspartic Acid receptor (NMDAR) antagonist, 
showed a greater depression during DA and AP5 co-application. This indicated that recorded 
amplitudes possess a glutamatergic component to them but are not NMDA dependent. This 
glutamatergic component was further shown through paired-pulse stimulation experiments, 
in which two amplitudes are generated over short interpulse intervals (ranging from 10-1000 
ms). Paired-pulse stimulations during 100 μM DA application induced a facilitation over all 
intervals, which indicated DA affects presynaptic glutamate release probabilities. The 
combination of these components confirms that recorded amplitudes within the LEC arise 
predominantly from glutamatergic activity, with DA affecting these amplitudes indirectly by 
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1   Introduction 
1.1   The Hippocampal Formation 
1.1.1   Anatomy of the Hippocampal Formation 
With its name derived from the Greek for seahorse, due to the similarities in their shape, the 
hippocampal formation (HF) is one of the most heavily researched areas of the brain, mostly 
due to its involvements in neurological diseases. Located in the medial temporal lobe, the 
anatomical structure of the HF was first 
depicted in the early 20th century by Santiago 
Cajal (Figure 1). Cajal’s drawings were 
significantly advanced for the time the work 
was published, showing both a theorised a 
direction of synaptic impulses (represented 
by arrows in Figure 1) and also showing 
potential subregions of the HF (represented 
by letters in Figure 1). Despite Cajal 
publishing this diagram in 1909, it was not 
until over a decade later that it was first 
proven that nerve cells (a group of cells which 
include neurones) communicate through 
neurotransmitters in one given direction 
(Loewi, 1921). Similar to the depictions of 
neurotransmitter direction, the depictions of 
subregions in the HF were only theorised in 
Cajal’s work in 1909, only to be further 
supported by later findings (O'Keefe and 
Nadel, 1978). Of the subregions which Cajal 
alluded to, subregions B, C and D were all 
identified as distinct subregions (the 
entorhinal cortex (EC), subiculum and the 
dentate gyrus (DG) respectively). There is 
however a great disparity in the literature as 
to what lies within the “hippocampal 
formation”, with some authors stating that 
the EC lies outside of the HF, with others 
stating that it lies within the HF. Although this 
disparity exists, the EC shall be regarded as 
part of the HF henceforth. As well as the 
aforementioned subregions, the 
hippocampus (often referred to as the 
hippocampus proper when discussing the 
Figure 1 - A Sketch of the Rodent Hippocampal Formation. 
Santiago Ramón y Cajal’s early sketch of the hippocampal 
formation in 1909. Later studies confirmed Cajals work, 
identifying subregions which Cajal had previously alluded to. 
These subregions include the entorhinal cortex (B), the 
subiculum (C), the dentate gyrus (D), all of which are 
identified by their respective capital letter. The hippocampus 
proper, shown in the bottom left, is depicted by the two rows 
of ovals, running from CA1 at the top down to CA3. The image 
also shows Cajal’s prediction for direction of information 
transmission (represented by arrows) (Cajal, 1909). 
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actual hippocampal structure as opposed to the HF) is comprised of four areas. As the 
hippocampus proper’s layout somewhat resembles the horns of a ram, each of these areas 
are named Cornu Ammonis (CA) 1-4, after the Egyptian deity Amon (also referred to as Amun, 
Amen or Ammon) who was depicted as having ram’s horns. CA1 lies at the top of the 
hippocampus, adjacent to the subiculum. CA2 is the smallest of the areas and lies caudal to 
CA1 (Anand and Dhikav, 2012). CA3 lies approximately at the apex of the curve, bordered 
rostrally by both CA2 and CA4 (left and right respectively in Figure 1). Finally, CA4 lies in 
between CA3 and the DG, subsequently CA4 is referred to as the deep, polymorphic layer of 
the DG (Blackstad, 1956). Each hippocampal area is rich in excitatory pyramidal neurones, 
which differentiates the hippocampus proper from other regions of the HF (Graves et al., 
2013). Despite this depiction being over 100 years old, there have been no significant changes 
in the anatomical interpretations of subregion layouts since the discovery of the 
hippocampus’s CA1-3 regions (Lorente de Nò, 1934). Despite there being no significant recent 
changes to the subregions of the HF, our knowledge of the functions and role of each subunit 
continues to grow. 
 
1.1.2   Projections of the Hippocampal Formation and Parahippocampal Cortices 
 
Figure 2 - Sensory Projections to and From the Entorhinal Cortex and Projections Within the Hippocampal Formation. A 
simplified overview of the connections within the hippocampal formation. This image can be divided into three subsections, 
sensory cortices and association areas, the parahippocampal formation (namely the perirhinal and pre- and parasubiculum) 
and the hippocampal formation. All non-spatial sensory information must pass through the entorhinal cortex before entering 
the hippocampal formation. In this image, black lines represent afferent projections, their arrows represent the direction of 
the projection and the projections with two half arrow heads show afferent and efferent projections between the two 
cortices. As well as these projections, green lines represent Mossy Fibre projections from the Dentate Gyrus (DG) to CA3, 
blue lines represent Schaffer collateral projections from CA3 to CA1 and red lines represent efferent projections from layer 
III of the entorhinal cortex. The information depicted in this image was derived from a variety of sources, including O’Mara, 
2005; Llorens-Martãn et al., 2014; Xu et al., 2016; Anand and Dhikav, 2012; Witter, 2007. 
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Figure 2 shows a simplified overview of the connections within the HF, including mossy fibre 
projections (connecting the granule cells of the DG to the pyramidal cells of CA3 (Henze et al., 
2000)) and Schaffer collateral pathway (a projection between hippocampal regions CA3 and 
CA1, a region in which long-term potentiation can be easily induced (Vasuta et al., 2015)). CA2 
plays a significant intermediate role within the Schaffer collateral pathway (Llorens-Martãn 
et al., 2014) as well as directly sending efferent and receiving afferent projections from layer 
II of the LEC through the disynaptic cortico-hippocampal loop (Chevaleyre and Siegelbaum, 
2010; Rowland et al., 2013). As well as these projections, the HF also receives glutamatergic 
projections from the basolateral amygdala, which is mediated by the EC (Anacker and Hen, 
2017; Mandyam, 2013).  
 
1.1.3   The Entorhinal Cortex 
1.1.3.1   The Medial Entorhinal Cortex and The Lateral Entorhinal Cortex 
The most distal region of the HF, the EC (Brodman area 28) is divided into two distinct 
subregions, the lateral entorhinal cortex (LEC, Brodman area 28a) and the medial entorhinal 
cortex (MEC, Brodman area 28b). The latter of the two subregions is somewhat entirely 
independent from its counterpart, as the MEC has been shown to be implicated in numerous 
independent processes. These processes include spatial processing and path integration in 
spatial cognition (Van Cauter et al., 2012); projecting cortical inputs to both the hippocampus 
(proximal CA1) and the molecular layer of the DG (Knierim et al., 2013), playing a role in 
episodic memory (Lipton and Eichenbaum, 2008) as well as receiving inputs from the visual 
cortex via the postrhinal cortex (Agster and Burwell, 2013). 
 Similarly to the medial division of the EC, the lateral division forms afferent projections 
to both CA1 and the DG, where layer II of both divisions project to CA3 of the hippocampus 
through the perforant pathway (van Groen et al., 2003). However, despite these few 
similarities there are still numerous distinct differences between the two regions. Although 
both the MEC and the LEC project to CA1, it has been shown that the MEC tends to target the 
region of CA1 close to CA2 (CA1c) whereas the LEC tends to target the region of CA1 close to 
the subiculum (CA1a, Masurkar et al., 2017). Furthermore, both project to the DG, however 
the MEC projects to the middle third of the molecular layer (as was aforementioned), 
however the LEC projects to the outer third layer (Amaral et al., 2008). Finally, although both 
the LEC and the MEC receive rich afferent projections from olfactory areas, the unimodal 
input is approximately 1.5 times greater in the LEC than the MEC (approximately 75% and 
50% respectively, Burwell and Amaral, 1998). Functionally, the LEC differs from the MEC, with 
the MEC conveying spatial information to the hippocampus and the LEC conveying non-spatial 
information. This is commonly referred to as the “where versus what” model, with the MEC 
conveying “where” and the LEC conveying “what” (Knierim et al., 2013).  
 
1.1.3.2   The Role of the EC in the Formation of Sensory Memory 
As stated in the preceding chapter, the main function of the lateral division of the EC is to 
relay non-spatial information from sensory cortices to the hippocampus. Of the traditional 
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senses (not including the somatic senses), the EC receives significant efferent projections 
from three of the five cortices: Olfactory bulb (OB); auditory cortex and the occipital lobe (for 
smell, auditory and visual senses respectively). Of these senses, the relationship between the 
LEC and the olfactory system is the most documented of the three, with the term “entorhinal” 
deriving from the Greek terms “Ento“ and “Rhinal”, meaning inside and nose respectively 
(Witter et al., 2017). First identified in the late 20th century, the proposed mechanism for the 
transfer of information is comparable to that shown in Figure 2.  
As mentioned in the previous chapter, the OB projects a unimodal input to the EC via 
the piriform cortex, a projection which has been well reported in rodents and monkeys 
(Burwell and Amaral, 1998; Amaral et al., 1987 respectively). Although this projection has also 
been reported in humans, with the piriform cortex receiving the largest bulbar projection 
(Zhou et al., 2019) and subsequently projecting to both the MEC and the LEC, fewer 
publications have been published on this projection in humans than in other mammals 
(Vismer et al., 2015). Upon innervation, the EC then projects to various regions of the 
hippocampus (Figure 2; Vanderwolf, 1992), with CA1 of the hippocampus projecting back to 
the EC before the EC then further projects back to the OB in adult mice (Van Groen and Wyss, 
1990). It can therefore be concluded that the OB and the hippocampus are directly linked to 
one another, with the EC playing an intermediate role in their connection. 
 The formation of auditory memory follows a similar unimodal path to the formation 
of olfactory memory, innervating the piriform cortex (Engelien et al., 2005) before following 
the same path through the hippocampus as was aforementioned and shown in Figure 2 
(O’Mara, 2005). Furthermore, both the perirhinal cortex and (more importantly) a dorsal 
lateral strip of layer V neurones of the EC both project back to the auditory cortex (Insausti et 
al., 1987; Li et al., 2013). Similarly to the formation of auditory memory, the formation of 
visual memory is governed by the posterior parahippocampal cortex (Baldassano et al., 2013), 
before following the same path through the hippocampus as the previously mentioned senses 
(Suzuki and Amaral, 1994). Of these afferent sensory projections to the LEC and the MEC, the 
projection from the olfactory area is the strongest, followed by the projection from the visual 
areas with the projection from the auditory areas providing the weakest projection (Burwell 
and Amaral, 1998; Insausti et al., 1987).  
 
1.1.3.3   Function and Anatomy of the LEC 
As well as playing a pivotal role in the aforementioned formation of olfactory, visual and 
auditory memories, the LEC is also heavily implicated in both the polysynaptic pathway and 
the direct intra-hippocampal pathway in memory formation (Anand and Dhikav, 2012). In the 
polysynaptic pathway, afferent information arrives at layers II and III of the EC, before being 
projected throughout various subregions of the HF and finally terminating at the subiculum. 
This pathway is implicated in the formation of semantic memory (memory which is acquired 
through learning outside of personal experience) and can be divided into lateral perforant 
pathway and medial perforant pathway depending on where the fibres arose from in the EC 
(Figure 2; Petersen et al., 2013). The direct intra-hippocampal pathway however is implicated 
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in spatial and episodic memory, memory which is acquired through personal experience. This 
pathway begins at the temporal association cortex before entering the HF. Once there, layer 
III of the EC will project to CA1 and then the subiculum, before either returning to the EC or 
leaving the HF via the alveus and the fimbria (Campbell and Macqueen, 2004). If the signal 
left the HF, it then terminates in the prefrontal cortex (PFC), inferior temporal cortex or the 
temporal pole (Anand and Dhikav, 2012). In both of these pathways, the LEC conveys efferent 
information from sensory cortices, before forming afferent projections to the DG and CA1 
respectively (Morgado-Bernal, 2011). Although the LEC is predominantly implicated in non-
spatial inputs to the hippocampus, lesions in the LEC reduce the conveyance of spatial 
information, indicating that the LEC plays some role in conveying both spatial and non-spatial 
information (Hunsaker et al., 2013). The cell types and projections of both the MEC and LEC 
are somewhat undistinguishable within most animals, however they are significantly more 
distinguishable in rats than in any other mammals (Insausti, 1993). 
Anatomically speaking, The LEC itself is comprised of six distinguishable layers, with 
each layer showing a diverse interconnectivity (most notably within layers I-III), with almost 
every layer forming projections to all other layers (Figure 3). 
 
 
Figure 3 - Interconnectivity Within the Lateral Entorhinal Cortex. Different cell types in different layers of the lateral 
entorhinal cortex (LEC) and their interconnectivity throughout the subregion. The image depicts two types of neuropil, 
dendrites (shown as black lines, with the dots representing dendritic spines) and axons (red). The upper portion of the image 
shows a diverse interconnectivity within layers I-III, with layer I receiving axonal and dendritic projections from all other 
layers. The lower image shows neurones from the deeper layers V and VI and their projections throughout the LEC. This 
image was directly adapted from Canto’s work (Canto et al., 2008), which is licensed under the Creative Commons Attribution 
3.0 Unported License. 
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The role of layer I of the LEC (the layer which lies most superficial within this region) is mostly 
for receiving sensory information and infrastructural innervation, where both projections 
from other layers of the LEC (Figure 3) and afferent projections from sensory cortices 
terminate (Wouterlood et al., 1985). It has been documented extensively that layer I of the 
LEC receives afferent projections from both the OB and the olfactory cortex (Habets et al., 
1980; Room et al., 1984; Wouterlood et al., 1985), although these projections have been 
shown to terminate in the deeper lying layers II and III as well (Wouterlood and Nederlof, 
1983). Asides from these projections from external cortices, Figure 3 also shows that layer I 
receives axonal and dendritic projections from all other layers within the LEC. This provides 
the LEC with a feedback mechanism, as the inhibitory neurones in the deep layers of the LEC 
receive inputs from other regions of the hippocampus (Figure 2), subsequently depressing 
afferent projections to layer I (Ohara et al., 2018). As this layer contains few cell bodies and a 
plethora of myelinated projections, this region is easily distinguishable from deeper layers as 
layer I is substantially whiter in appearance (Ohara et al., 2009).  
Unlike layer I, layer II of the LEC contains a vast array of cell bodies, but similarly to 
layer I, contains a vast array of projections, a combination which results in a densely packed 
layer (Figure 3; Canto et al., 2008). Layer II of the LEC also contains a large number of afferent 
and efferent projections, both from within and outside of the LEC (Figure 2; Witter et al., 
2017). Figure 3 shows that layer II of the LEC may not receive inputs from deep layers of the 
LEC but receives extensive inputs from the superficial layers I and III. Multipolar neurones 
(MPNs) with laterally extending dendritic trees (one of the three subtypes of MPNs) from both 
the deep region of layer I and the superficial region of layer III were shown to project into 
layer II of the ventrolateral LEC (Wouterlood et al., 2000). Externally to the EC, layer II of the 
LEC receives cortical projections from both the parahippocampal formation and the 
presubiculum (Figure 2). Layers II and III of the LEC receive cortical projections from the 
parahippocampal cortex through two pathways, both of which terminate in the hippocampus. 
However, this projection was shown in rhesus monkeys and is yet to be shown in rodents 
(Witter et al., 2000). Layer II also receives projections from the presubiculum, an innervation 
which has been described as dense and extensive (Caballero-Bleda and Witter, 1993). 
Primarily, layer II of the LEC projects to the DG and CA2/CA3 of the hippocampus through the 
perforant pathway (Figure 2; Suh et al., 2011; Tamamaki and Nojyo, 1993). Layer II also 
directly projects to CA2, in conjunction with CA1, through the disynaptic cortico-hippocampal 
loop (Chevaleyre and Siegelbaum, 2010). A projection from this layer (in conjunction with 
layer III) back to the parahippocampal cortex has been identified, however this projection has 
only been identified in humans and is yet to be identified in rodents (Witter et al., 2000). 
Similarly to layer II of the LEC, layer III contains a vast array of cell bodies and 
projections, however this layer receives projections from both deeper layers V and VI as well 
as the superficial layer II, as is characterised in Figure 3. Layer III also forms projections with 
other regions of the HF, projecting to the DG, CA1 and the subiculum via the 
temporoammonic pathway (Figure 2; Ito and Schuman, 2011). Asides from its projections, 
layer III also receives afferent projections from the parahippocampal cortex, as was 
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mentioned in the preceding chapter. Another of these inputs to layer III from external to the 
HF comes from the amygdala, however this has been documented in the MEC and not in the 
LEC (Pikkarainen et al., 1999). Despite this, layer III has been described as “largely terra 
incognita” when compared to layers II and V, meaning the region still remains still largely 
unmapped in comparison (Witter et al., 2017). 
Layer IV (also referred to as lamina dissecans, Ld) lies between layers III and V, 
receiving projections from all other layer’s asides from the superficial layer I (Figure 3). Unlike 
the other layers in the LEC however, this layer is predominantly devoid of cell bodies, with 
the name lamina dissecans meaning “a thin layer of separation” (Braak and Braak, 1992). 
Layer IV of the LEC is substantially less distinguishable than layer IV of the MEC, although 
there is still evidence showing that the Ld is present in both (Burwell and Agster, 2008). 
The deep layers of the LEC are comprised of two layers, V and VI. The more superficial 
of these deep layers, layer V, can be subdivided into two distinct subregions, Va and Vb, with 
Va lying superior to Vb. Although layer V receives limited projections from superficial layers 
of the EC (with only layer III and potentially layer II innervating layer V), layer V projects 
extensively to both extremities of the EC, innervating layers I and VI, with some axons 
reaching the pial surface in the case of the former (Figure 3; Canto et al., 2008). These 
projections come from large MPNs, with are rich in the inhibitory neurotransmitter gamma 
aminobutyric acid (GABA), indicating that layer V provides an inhibitory role for the superficial 
layers of the LEC (Miettinen et al., 1997). Functionally, layer Va returns projections back to 
the cortical and subcortical structures, whereas layer Vb receives cortical projections from 
the subiculum and the parasubiculum (Figure 2; Ohara et al., 2018). Layer Vb also receives 
projections from the retrosplenial cortex, the region where the polysynaptic pathway of 
memory formation terminates (Czajkowski et al., 2013). Functionally, layer Vb receives 
cortical projections from the subiculum and the parasubiculum, whereas layer Va sends 
cortical projections back to the cortical and subcortical structures upon innervation (Figure 2; 
Ohara et al., 2018). 
The deepest layer in the LEC, layer VI, is similar to the most superficial layer in that it 
is identifiable by its high concentration of white matter, indicating the high number of 
neuropil present within the region. The axons projecting into this region stem from 
hippocampal/thalamic roots, receiving a rich innervation from CA1 and the subiculum (Figure 
2). Cells in this layer project their axons both back to sensory cortices and also throughout the 
EC, through the deep layers and rarely projecting to layer III (Lingenhöhl and Finch, 1991; 
Canto et al., 2008). However, the reports which describe the characteristics of layer VI does 
not distinguish whether these come from the lateral nor the medial division of the EC. 
With all this information in mind, it can therefore be concluded that afferent nerve 
fibres from a sensory cortex can innervate the superficial layers of the LEC, which in turn will 
innervate the hippocampus through the polysynaptic pathway or the intra-hippocampal 
pathway (Uva and de Curtis, 2005; Suh et al., 2011; Aggleton et al., 2010). A cascade of 
innervations throughout the hippocampus culminate in the activation of the subiculum, 
which in turn activates the deep layers of the LEC (layers V and VI). Excitatory neurones in the 
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deep layers then feedback processed information throughout the cortex, whereas inhibitory 
neurones inhibit the activity of superficial layers, suppressing the aforementioned pathways 
(Miettinen et al., 1997). 
 
1.1.3.4   Neurotransmitters in the LEC 
Although preliminary studies in the late 20th century concluded that neurones in the LEC 
communicate entirely through the neurotransmitter glutamate (Oleskevich et al., 1989; 
Umbriaco et al., 1995), recent studies have begun to show that other neurotransmitters are 
in fact present within the LEC. One study showed that the deep layers of the EC (notably layers 
V and VI) were rich in inhibitory GABAergic neurones, as was mentioned in the previous 
paragraph (Miettinen et al., 1997). Asides from these predominant neurotransmitters, mRNA 
expression analysis showed that two serotonin (5-hydroxytryptamine, 5-HT) receptor 
subtypes, 5-HT1C and 5-HT2A are heavily abundant within the LEC, with 5-HT1A, 5-HT1D, 5-HT1E, 
5-HT3 and 5-HT6 also being expressed (Wright et al., 1995; Lei, 2012). Although they are all 
serotonin receptors, each have been shown to induce different responses: 5-HT1A plays a 
significant role in spatial memory formation (Miheau and Barbara, 1999); 5-HT2A enhances 
GABAergic neurotransmitter release from deep layer MPNs (Deng and Lei, 2008) and 5-HT3 
inhibits acetylcholine release (Barnes et al., 1989). Although the other receptors have been 
identified within the LEC, their roles are still yet to be determined (Lei, 2012). The presence 
and roles of the different 5-HT receptors in the LEC indicates that there are also non-
glutamatergic modes of transmission within the region. These receptors stem from afferent 
serotonergic projections, which originate from the raphe nuclei (Witter et al., 1989). Finally, 
staining for the rate-limiting enzyme in catecholamine synthesis, tyrosine hydroxylase, 
showed that superficial layers in the LEC contains rich pools of the neurotransmitter 
dopamine. 
 
1.2   Dopamine 
1.2.1   Introduction to Dopamine 
Dopamine (DA) is a neurotransmitter of the catecholamine family, acting as both a cell-cell 
messenger within the CNS and a hormone within the PNS (Lot, 1993). Within the CNS 
however, DA is released upon activation of the reward system, primitively as a result of 
drinking, eating or copulating. The reward system (also referred to as the mesolimbic 
pathway) originates in the VTA in the midbrain, before projecting to a number of regions in 
the neocortex. The largest of these projections, the only greater projection than that to the 
LEC, projects directly to the PFC, the region of the brain associated with intelligence and 
language to name but two of its functions (Drewe, 1974; Gabrieli et al., 1998; Oades and 
Halliday, 1987). The VTA also projects extensively to the nucleus accumbens (NAc), the region 
of the brain associated with reward and subsequently addiction (Wise, 2006). As well as the 
PFC and the NAc, cells of the VTA project into the limbic system, innervating both the 
amygdala and the HF, subsequently projecting to the LEC (Tassin et al., 1989). The mesolimbic 




Figure 4 - The Projection of Dopaminergic Neurones From the Ventral Tegmental Area Throughout a Rodent Brain. A 
transverse section through a rodent brain, identifying the ventral tegmental area (VTA, red) and the dopaminergic 
projections this region produces. Although it is not identified specifically, the projections made in the mesolimbic pathway 
are identified, with the VTA projecting to the nucleus accumbens (NAc), the amygdala (AMY) and the lateral entorhinal cortex 
(LEC, a subregion of the hippocampal formation). Also shown but not directly stated is the mesocorticolimbic pathway, which 
connects the VTA to the prefrontal cortex (PFC) and the lateral septum (LS). Other projections shown includes a projection 
from the VTA to both the parabrachial nuclei (PB) and the locus coeruleus (LC). Although all these aforementioned regions 
have been identified, they are not part of a definitive pathway, however dopaminergic neurones still directly or indirectly 
innervate these regions (Christoph et al., 1986; Coizet et al., 2010; Deutch et al., 1986). The image also identifies the 
substantia nigra pars compacta (SNpc, blue) which projects to the globus pallidus (GP), the striatum (ST) and the caudate 
nucleus (CN) through the nigrostriatal pathway. The scale shown in the bottom right identifies the anatomical orientation on 
which the section lies, with A denoting anterior (i.e. the NAc lies anterior to the VTA) and M denoting medial (i.e. the LEC lies 
medial to the VTA). The information depicted in this image was refined from Swanson’s 1982 work to match this study 
(Swanson, 1982). 
 
DA is also the neurotransmitter released in the mesocortical pathway, which, like the 
mesolimbic pathway, is shown but not specifically identified from its counterpart (Figure 4). 
The mesocortical pathway follows a similar initial path to the mesolimbic pathway, however 
this pathway projects to the aforementioned NAc, the lateral septum (LS) and the prefrontal 
cortex (PFC), all of which are regions in the frontal lobe. Where the mesolimbic pathway is 
implicated in reward and addiction, the mesocortical pathway’s projection to the neocortex 
associates this pathway with cognitive function (Money and Stanwood, 2013). Asides from 
these two pathways, DA is the primary neurotransmitter involved in the nigrostriatal and 
tubular infundibular pathway. The former pathway connects dopaminergic neurones in the 
excitatory medial subregion of the substantia nigra (SN), the substantia nigra pars compacta 
(SNpc), with the striatum (ST), projecting directly to the subthalamic nucleus, the globus 
pallidus (GP) and the caudate nucleus (CN, as shown in Figure 4 (Prensa and Parent, 2001)). 
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This pathway, unlike the two aforementioned pathways, is implicated in motor and 
behavioural motivation (Gerfen and Wilson, 1996). The final dopaminergic pathway, the 
tuberoinfundibular (also referred to as the tuberohypophyseal) pathway, is not shown in 
Figure 4, as this pathway originates in the ventral hypothalamus before projecting to the 
medial eminence and the pituitary gland (Rang et al., 2019). As well as these pathways, the 
VTA also directly projects to both the parabrachial nuclei (PB) and the locus coeruleus (LC) of 
the brainstem through no definitive pathway (Figure 4). The dopaminergic projection from 
A10 of the VTA to the brainstem yields varying results, as DA supresses PB activity but 
stimulates LC activity (Chen et al., 1999; Deutch et al., 1986). Stimulation of the LC also 
promotes cellular survival of dopaminergic neurones, suggesting at a possible adaptability of 
this region (Berglöf and Strömberg, 2009). The PB also receives afferent nociceptive 
projections from the spinal cord, possibly hinting that the PB may act as one of the 
intermediate steps between the peripheral nervous system (PNS) and dopaminergic 
projections in the central nervous system (CNS) (Coizet et al., 2010).  
Although DA remains excitatory throughout the cortex, indirect dopaminergic 
innervation of the nigrostriatal pathway, subsequently the lateral habenula (LH) and 
subsequently the rostromedial tegmental nucleus (RMTg), is shown to suppress VTA activity 
through the reward prediction error circuit (Watabe-Uchida, Eshel and Uchida, 2017). Figure 
4 shows this direct projection between the SNpc and the GP internal segment, with both this 
and the striatum subsequently innervating the LH (Bourdy and Barrot, 2012). Upon 
innervation, the LH then projects to the GABA rich RMTg, which subsequently extensively 
supresses the activity of both the VTA and the SN by approximately 90% (Christoph et al., 
1986). DA also projects to the thalamus (not shown in Figure 4); however this projection is 
less extensive in the rat than in other mammals (Garcia-Cabezas et al., 2008). In this region, 
DA appears to have a positive refinement on movement, as reduced dopaminergic inputs to 
the basal ganglia results in motor complications like that seen in Parkinson’s disease (Stoessl 
et al., 2014).  
As DA is a catecholamine (as are the DA 
derivatives noradrenaline and adrenaline), DA is 
comprised of a catechol group (also referred to as a 
benzenediol, 1,2 – dihydroxybenzene) and an 
ethylamine positioned on carbon 4, a structure 
which is shown in Figure 5. This structure was first 
identified in 1910 (as mentioned in Hornykiewicz, 
2002), although it was believed that DA was purely a 
precursor for noradrenaline until 1957, where it was 
later determined that DA was itself a 
neurotransmitter (Carlsson, 1993). 
 
Figure 5 - The Chemical Structure of Dopamine. 
The structure of the neurotransmitter is comprised 
of two regions, an ethylamine (located on carbon-4 
from the benzene ring, right) and a benzenediol 
(benzine ring with two hydroxyl groups, left). 
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1.2.2   Dopamine Receptors 
1.2.2.1   The D1 Receptor Family 
The D1 family of receptors (containing receptors D1A and D5 (the latter also referred to as D1B)) 
were first identified by their characteristic of activating adenylyl cyclase (AC) to raise 
intracellular cyclic 3’5’ adenosine monophosphate (cAMP) levels (Andersen et al., 1990). D1-
like receptors do this through a cascade reaction upon activation, with D1 receptors solely 
activating AC through g-protein activation, whereas D5 receptors activate AC, PIP2 
(phosphatidylinositol-4;5-bisphosphate) and PLC (phospholipase) all through g-protein 
activation (Figure 6, Hansen and Manahan-Vaughan, 2012; Sibley et al., 1993). Both of these 
cascades however culminate in the activation of cAMP response element-binding protein 
(CREB), a family of transcription factors which bind to cAMP responsive element (CRE) sites 
on DNA (Silva et al., 1998). Binding of CREB to their respective CRE sites results in the 
expression of various genes. Some of these genes expressed by CREB include: Arc (Activity-
regulated cytoskeleton-associated protein, an ever-present protein in plasticity which alters 
synaptic strength (Korb and Finkbeiner, 2011)); c-Fos (an oncogene and an immediate early-
gene which too is associated with long-term potentiation (Kang et al., 2000)); EGR1 (Early 
growth response protein 1, which, similarly to c-Fos, is an immediate early-gene which 
regulates synaptic plasticity (Duclot and Kabbaj, 2017)) and BDNF (Brain derived neurotrophic 
factor, a protein which too is heavily implicated in cellular plasticity (Leal et al., 2017)) to name 
a few (Nishi et al., 2011). All of the aforementioned genes are expressed upon the binding of 
CREB to DNA and are all implicated in long-term neuronal plasticity, indicating that D1-like 
activation elicits long lasting effects on the neurone. 
As well as the cascade reactions that D1-like receptors initiate, Figure 6 also shows the 
amino acid sequences of both D1 and D5 and their relative topographical arrangement on the 
neuronal membrane (Sibley et al., 1993). The D1 receptor is comprised of a short amino-acid 
chain at the N-terminus (approximately 25 residues in length), seven transmembranous 
domains (culminating in three extracellular and three intracellular loops) before a long amino-
acid chain at the C-terminal (Figure 6, upper left). This COOH region in D1-like receptors is 
significantly larger than in D2-like receptors, with the C-terminal having approximately seven 
times as many residues in D1-like receptors compared to D2-like receptors (Missale et al., 
1998). 
The largest of the DA receptors with 475 residues in rats (Sibley et al., 1993), D5 
receptor posseses a very similar structure to D1, with a short N-terminal, an elongated C-
terminal and seven transmembranous regions (also with three extracellular and three 
intracellular loops, as is shown in Figure 6, upper right). The extracellular N-terminal and the 
second extracellular loop both contain a CHO group from the amino acid asparagine, an N-
Glycosylation site, which is crucial in membrane localisation for D5 receptors (Karpa et al., 
1999). Despite these similarities in overall structure, D1 and D5 have extensive differences in 
their amino acid residues, showing only an approximate 50% homology in their amino acids 




Figure 6 - The Amino Acid Structure and the Subsequent Signalling Cascade D1 and D5 Receptors. The topographical 
organisation and amino acid structure of the D1-like receptors, D1 and D5, are shown in the upper left and upper right 
respectively. The two extracellular CHO groups on asparagine residues, a region which is susceptible to N-Glycosylation, is 
also highlighted. The lower region of the image shows the cascade reaction caused by D1-like receptor activation, with the 
yellow boxes indicating intermediates in D1 signalling and blue boxes indicating intermediates in D5 signalling. A red arrow is 
used to indicate a communicative link between the two cascades, with and a negative symbol used to indicate a suppressive 
effect. Abbreviations include (when read from top to bottom, left then right): G-p (G protein); AC (Adenylyl cyclase); cAMP 
(Cyclic 3’5’ adenosine monophosphate); PKA (Protein kinase A); EPAC (Exchange protein activated by cAMP); DARPP 32 
(Phosphoprotein of 32 kDa); RAP 1 (Member of the RAS family of small GTP-binding proteins); PPtase 1 (Protein phosphatase 
1); MEK’s (Mitogen-activated kinases); ERK (Extracellular signal-related kinase); PIP3 (Phosphatidylinositol-3;4;5-
trisphosphate); PDK1 (Phosphoinositide-dependent kinase-1); PIP3K (Phosphatidylinositol-3-kinase); PIP2 
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(Phosphatidylinositol-4;5-Bisphosphate); PLC (Phospholipase C); IP3 (Inositol trisphosphate); DGL (Diacylglycerol); PKC 
(Protein kinase C); Akt P (Phosphorylated Akt); CaMK II (Calcium-calmodulin-dependent protein kinase type II); CREB (cAMP 
response element-binding protein); CREB P (Phosphorylated CREB); CRE (cAMP response element). The amino acid structures 
and topography of both D1 and D5 were taken directly from International Review of Neurobiology (Sibley et al., 1993, with 
permission) and the image depicting the cascade reaction was taken directly from Cerebral Cortex (Hansen and Manahan-
Vaughan, 2012, with permission). Although the cascade reaction image was depicted in Hansen and Manahan-Vaughan’s 
paper, the information was derived from other sources (Undieh, 2010; Beaulieu and Gainetdinov, 2011). 
 
1.2.2.2   The D2 Receptor Family 
Unlike D1-like receptors, the D2 family (comprised of D2, D3 and D4 receptors) inhibit both AC 
activation and reduce intracellular Akt levels, reducing neuronal hyperexcitability (Figure 7; 
Bozzi and Borrelli, 2013). Reduced intracellular cAMP and Akt results in a reduced activation 
of the transcription factor CREB, which subsequently reduces gene expression through CRE. 
The reduction of intracellular Akt however results in an increase in cellular glycogen synthase 
kinase 3β (GSK-3β), an enzyme that both promotes STAT transcription factors (Beurel and 
Jope, 2008) and shows implications in cellular apoptosis (Ding et al., 2007) but is 
downregulated by Akt under physiological conditions. This increase in intracellular GSK-3β 
results in an increased expression of β-Catenin from the nucleus, as GSK-3β directly 
phosphorylates β-Catenin on three separate residues, which subsequently activates the 
protein (Beurel et al., 2015). This activation results in a promotion of cellular survival by 
maintaining the transmembrane protein N-cadherin between neurones and regulating radial 
glia integrity, a precursor cell for dopaminergic neurones (Tang et al., 2009). 
 The structures of all three D2-like receptors are remarkably similar, each containing a 
short N-terminus, seven transmembranous domains and a very short c-terminus (Figure 7, 
upper). One key characteristic of these D2-like receptors is their elongated intracellular loop 
between the 5th and 6th transmembranous loop. This is also where the structures differs the 
most between receptors, with each of the three loops consisting of almost entirely different 
residues with D4 containing the shortest loop of the three. This short nature of the loop on D4 
is somewhat shown by the interactions of the receptors, with D2 and D3 receptors interacting 
with the scaffolding proteins calcium-calmodulin-dependent protein kinase type II (CaMKII) 
and β-arrestin respectively, however D4 shows no interaction with any other scaffolding 
protein (Figure 7). 
 The D2 receptor exists as two isoforms, D2S D2L (short DA D2 receptor and long DA D2 
receptor respectively), with the longer isoform containing 29 additional amino acids when 
compared to the shorter isoform (Dal Toso et al., 1989). Although these isoforms each have 
different qualities and a majority of functions remain the same (such as lowering AC activity 
to lower intracellular cAMP), there are still some minor differences between the two 
(Lindgren et al., 2003). As these isoforms differ in their third intracellular loop (the longest of 
the three), the N-terminal remains homologous between the two isoforms. This means that 
the three N-glycosylation sites on the N-terminal remain identical on all variants of D2, which 
affect calnexin interaction and cell surface expression of the DA receptor (Free et al., 2007; 
Min et al., 2015). Figure 7 also shows that β-arrestin and protein phosphatase 2A (PP2A) act 
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as scaffolding proteins, allowing D2 to form a G protein like response upon receptor activation 
(Beaulieu et al., 2005). The role that β-arrestin plays as a scaffolding protein is shown through 
its inhibition using Barbadin, a new potent drug which blocks prototypical β2-adrenergic, V2-
vasopressin and angiotensin-II type-1 receptor endocytosis (Beautrait et al., 2017). 
 
 
Figure 7 - Signal Cascade of D2-Like Receptors Alongside D1-Like Receptors and the Amino Acid Structure of D2, D3 and D4 
Receptors. The topographical organisation and amino acid structure of the D2-like receptors, D2, D3 and D4, are shown in the 
upper right, upper middle and upper left respectively. The extracellular CHO groups on asparagine residues, a region which 
is susceptible to N-Glycosylation, is also highlighted. The lower region of the image shows a comparison in the cascade 
reaction from both D1-like receptors (upper left of the lower image) and D2-like receptors (upper right of the lower image). 
Positive (+) and negative (-) symbols are used to identify facilitative and suppressive projections respectively. Abbreviations 
include (when read from top to bottom, left then right): AC (Adenylyl cyclase); PLC (Phospholipase C); cAMP (Cyclic 3’5’ 
adenosine monophosphate); PKA (Protein kinase A); DARPP-32 (Phosphoprotein of 32 kDa); ERK 1/2 (Extracellular signal-
related kinase 1/2); PP-1 (Protein phosphatase 1); CaMKII (Calcium-calmodulin-dependent protein kinase type II); βArr2 (β-
arrestin 2); PP2A (Protein phosphatase 2A); GSK-3β (Glycogen synthase kinase 3β); CREB (cAMP response element-binding 
protein). The amino acid structures and topography of D2 D3 and D4 were taken directly from International Review of 
Neurobiology (Sibley et al., 1993, with permission). Likewise, the image depicting the cascade reaction was taken directly 
from Frontiers in Cellular Neuroscience (Bozzi and Borrelli, 2013), which is licensed under the Creative Commons Attribution 
3.0 Unported License. 
The amino acid and topographical structure of D3 is very similar to that of D2, in fact the two 
have approximately a 97% homology to one another (Sibley et al., 1993). One difference 
however is in the N-glycosylation sites on the N-termini, as D2 has three binding sites whereas 
D3 only has two (with a third appearing in the first extracellular loop and a fourth in the second 
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extracellular loop for D3 receptors), however the role of these glycosylation sites on these 
extracellular loops are yet to be fully identified (Min et al., 2015). Unlike the aforementioned 
D2-like receptors, D4 contains a significantly shorter tertiary intracellular loop, yielding a 
receptor 30 amino-acids shorter than D2S with only a 41 and 39% homology to D2 and D3 
receptors respectively (Sibley et al., 1993). Despite the low homology and significant 
structural difference, D4 receptors still posseses similar properties to the other D2-like 
receptors, also reducing hyperexcitability by mediating AC activity and lowering cAMP levels. 
 
1.2.2.3   Dopamine Receptor Pharmacology 
Even thirty years before the discovery of the D2 receptor in the 1980’s, there were drugs that 
targeted DA receptors to treat psychosis (Ban, 2007). Since the discovery of DA receptors 
however, there have been a vast array of drugs identified (both clinical and non-clinical) that 
target various sites on these receptors. These drugs primarily have two modes of action, 
agonists (which help to reinforce receptor activity) and antagonists (which help to attenuate 
receptor activity). Their efficacy is often reported as an inhibitor constant, Ki, which is defined 
as the required concentration for half the effect (inhibitory or excitatory) to be observed 
(Waley, 1982). This Ki value is ultimately determined using a Dixon plot, where lower Ki values 
indicates a stronger binding affinity (the strength of the bond between the drug and the 
receptor) within the drug receptor interaction (Cornish-Bowden, 1974). 
 One of the many D1-like antagonists, SCH-23390 (also known as (R)-(+)-7-chloro-8-
hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine) was the first discovered 
selective D1-like antagonist (Bourne, 2001). This highly potent benzazepine shows a very high 
binding affinity with D1-like receptors and a very low binding affinity to D2-like receptors (as 
is shown in Table 1 (Bourne, 2001)). Although the mechanisms behind the binding between 
SCH-23390 and DA receptors is still yet to be fully identified, this drug will ultimately block 
dopamine-stimulated AC activity, sequestering the function of D1-like receptors (Breese and 
Mueller, 1985). As well as DA receptors, SCH-23390 reduces striatal acetylcholine and choline 
levels upon infusion, also showing a high affinity for 5-HT2A receptors (Ki = ~11.0nm (Bourne, 
2001)). 5-HT2A is heavily abundant within the LEC, enhancing deep layer GABAergic 
transmission (Deng and Lei, 2008), SCH-23390 being shown to be a 5-HT2 agonist (Woodward 
et al., 1992). This therefore suggests that not only does SCH-23390 application attenuate D1-
like receptor activity, it also amplifies 5-HT2A activity, which in turn increases deep layer 
GABAergic activity, which may result in a greater reduction of activity within the superficial 
LEC layers I-III. Although this poses an intriguing hypothesis, the role that SCH-23390 
application plays in LEC transmission still remains under-reported, with further 
experimentation needed to better understand this role (Caruana et al., 2006).  
Unlike SCH-23390, SKF-38393 acts as a partial D1-like receptor agonist, functionally 
facilitating DA signalling in DA receptors but only showing a weak activity (Clark et al., 2011). 
Also known as (±)-1-phenyl-2,3,4,5-tetrahydro-(1H)-3-benzazepine-7,8-diol, this drug binds 
extensively with D1-like receptors, having a higher, though not pharmacologically significant, 
binding affinity to D1 than to D5 (as is also shown in Table 1 (Bourne, 2001)). Also unlike SCH-
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23390, the mechanism of action (MOA) is known for this agonist. This group mimics the 
structure of DA, stimulating AC activity similar to that observed by DA, which gives rise to the 
agonist property of the drug (Riggs et al., 1987). SKF-38393 may also affect downstream 
components of the cascade reaction initiated by D1-like receptors, as this agonist in DA 
knockout rats still exhibits c-Fos expression (Keefe and Gerfen, 1995). This agonist also binds 
to 5-HT2A receptors; however this binding yielded a Ki value of >10,000 nm, making it 
pharmacologically insignificant (Neumeyer et al., 2003). 
One of the agonists of D2-like receptors is the ergoline derivative quinpirole, however 
this drug only affects D2 and D3 receptors and has no significant affinity for D4 receptors (Titus 
et al., 1983; Sullivan et al., 1998). Similarly to the D1-like agonist, quinpirole is shown to 
directly increase expression of c-Fos, however this effect is only seen in the presence of both 
quinpirole and SCH-38393 (the aforementioned D1-like receptor agonist). This shows that c-
Fos expression is correlated to both D1-like and D2-like receptor activation, however this 
response is mediated by the D1-like response (Keefe and Gerfen, 1995). As a D2-like agonist, 
this drug is used in animal models to test obsessive compulsive disorder and schizophrenia, 
as these disorders arise from an over excitation of D2 receptors (Rodrigo et al., 2011). 
An established D2-like receptor antagonist (Fedotova, 2012), both in research and 
clinically, sulpiride exists in two enantiomeric isoforms, R(+)sulpiride (where the 1-
ethylpyrrolidine group lies below the plane of the remaining groups in the compound) and  
S(-)sulpiride (where the 1-ethylpyrrolidine group protrudes above the plane of the remaining 
groups in the compound). Although they are chemically and functionally identical, binding to 
D2-like receptors to stimulate AC activity (Wagstaff, Fitton and Benfield, 1994), their 
orientation affects their binding affinity to D2-like receptors. S(-)sulpiride shows a significantly 
higher affinity for D2 and D3 than R(+)sulpiride, with S(-) sulpiride showing a Ki value of 15 nm 
and 13 nm for D2 and D3 receptors respectively, whereas R(+)sulpiride shows Ki values of 900 
nm and 400 nm for D2 and D3 receptors respectively. Although both these enantiomers show 
significant binding to D2 and D3 receptors, neither show any pharmacologically significant 
binding to D4 receptors, yielding Ki values of 1000 nm and 970 nm for S(-)sulpiride and 
R(+)sulpiride respectively (Bourne, 2001). Upon binding to D2 and D3 receptors, sulpiride 
elicits an antidepressant like response in the mesolimbic area (Tsukamoto et al., 1994), 
showing no effect on GABA, serotonin, norepinephrine or acetylcholine receptors (Wishart et 
al., 2006). This blockage of D2 and D3 receptors has led to sulpiride being used as an atypical 
antipsychotic, clinically being prescribed to treat symptoms associated with schizophrenia (Lai 
et al., 2012). Similar to SCH-23390, the effect of sulpiride on LEC transmission has been tested 
previously, however more experimentation with this may be required to further understand 
the role of D2-like receptors during DA application, as outlined in Aim 2 (Caruana et al., 2006). 
Asides from the interactions mentioned, all the drugs that have been discussed here 
interact with 5-HT2A and α2. Although SCH-23390 showed a high affinity for the serotonin 
receptor, all others showed a pharmacologically insignificant affinity (Ki = >10,000 nm). 
Similarly, all showed affinities towards adrenoreceptors α2, but none of these were 





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































1.2.3   Dopamine Transmission 
 
Figure 8 - Dopamine Release From Vesicles in the Presynaptic Bouton into the Synaptic Cleft. The various staged in DA 
release, from vesicle formation (top) to vesicle budding and neurotransmitter release (bottom). This diagram was taken 
directly from Pharmacological reviews (German et al., 2015, with permission). 
Although DA receptors make novel targets for therapeutic drugs (as was mentioned in the 
preceding chapter), so too can the dopaminergic production pathway be targeted for drug 
design. Prior to cellular activation (Figure 8), buds from the trans-Golgi network are released 
and transported to the synaptic bouton where DA is formed from tyrosine. DA is produced 
when tyrosine hydroxylase (the rate limiting step in DA synthesis (Levitt et al., 1965)) converts 
tyrosine into L-dihydroxyphenylalanine (L-DOPA), with aromatic acid decarboxylase (AADC) 
then converting L-DOPA into DA. At this resting stage of transmission, whilst DA transporters 
(DAT) remain inactive and internalised within vesicles, DA remains within the cytoplasm of 
the neurone. From this stage, DAT can migrate in one of two directions. Firstly the channel 
can be expressed on the surface of the bouton, where it will reuptake DA molecules into the 
neurone through active transport, a process which is coupled with the transport of one 
chloride ion and two sodium ions (2 Na+, Figure 8, bottom left; Vaughan and Foster, 2013). 
Asides from this pathway, DAT may also be degraded if the endosome which the transporter 
is enclosed in progresses down the degradation pathway, which would result in the 
endosome forming a lysosome (Figure 8, right; Daniels and Amara, 1999). DA itself however 
is formed in the cytoplasm of the neurone (through the aforementioned conversion pathway) 
19 
 
prior to synaptic vesicle packaging in the synaptic bouton (Figure 8, bottom). This packaging 
is performed by the transport protein Vesicular Monoamine Transporter-2 (VMAT2), which 
transports DA into the vesicle and protons (H+ ions) out of the vesicle through the antiporter 
VMAT2. The protonated nature of the vesicle is maintained by a H+-ATPase, which actively 
transports protons against their concentration gradient back into the vesicle (German et al., 
2015). Once DA is packaged into vesicles and an action potential invades the terminal, an 
influx of calcium ions (Ca2+) into the synaptic terminal results in activation of synaptotagmins 
(Südhof, 2012). Synaptotagmins couple with phospholipids and SNARE (soluble NSF 
attachment protein receptor) proteins, which subsequently trigger exocytosis of the DA 
neurotransmitters into the synaptic cleft (also shown in Figure 8). Simultaneously to DA being 
released into the cleft, VMAT2 is also released into the cleft, however the synaptic terminal 
briskly re-uptakes VMAT2 into clathrin-coated vesicles, which are subsequently recycled into 
endosomes. Once in the synaptic cleft, DA will bind either to a DA receptor (D1-D5), or the 
presynaptic terminal will reuptake DA through DAT (German et al., 2015). 
 
1.2.4   Dopaminergic Neurones in the LEC 
The largest cortical projection from the VTA is to the PFC, with the second largest projection 
being to the superficial layers of the EC (Oades and Halliday, 1987). These inputs somewhat 
resemble clumps which span these superficial layers of the LEC, which have previously been 
referred to as cell islands (Caruana and Chapman, 2008). DA has been previously described as 
having a bi-directional effect within the LEC (Caruana and Chapman, 2008), providing both a 
facilitative and depressive effect on the region dependent upon the concentration of tonic DA 
application (Caruana et al., 2006). These previous DA experiments test the effect that 
micromolar concentrations (often between 10 and 100 μM) of DA have on amplitudes, 
however the exact physiological concentrations of DA have yet to be reported and could be 
lower than those previously tested. Should DA exist at lower concentrations in the LEC than 
those tested previously, experiments using nanomolar concentrations of DA (1-1000 nM) may 
better indicate how the LEC functions under physiological conditions, as is outlined in Aim 1 
(Chapter 1.4). Inhibitory pyramidal neurones in layer V, which also project into the superficial 
layers of the LEC, can themselves be inhibited by DA, creating a partial facilitative effect from 
DA application as DA reduces this GABAergic suppression (Rosenkranz and Johnston, 2006). 
As DA suppresses activity in superficial layers of the LEC, an increase in the 
concentration of DA in the LEC prevents the LEC from conveying information to the 
hippocampus through the perforant pathway (Otmakhova and Lisman, 2006). Despite this 
information however, the in vivo effect which DA plays on the superficial layers of the LEC is 
yet to be fully understood, as the ex vivo effect (the effect exhibited when tissue samples are 






1.3   Plasticity 
1.3.1   An Overview of Synaptic Plasticity 
Plasticity (or a neurones ability to undergo changes over a period of time) occurs when 
synapses change their shape and function in response to stimuli or damage (von Bernhardi et 
al., 2017). The concept of plasticity was first coined in the early 20th century, with the Italian 
psychiatrist Ernesto Lugaro noting “the brain itself will change throughout life to deal with 
changes in life” (Berlucchi, 2002). The first real breakthrough in synaptic plasticity was made 
a few decades later, with Hebb’s postulate. Hebb’s postulate stated, “cells that fire together, 
wire together” (Hebb, 1949), a form of plasticity now called Hebbian plasticity (also referred 
to as heterosynaptic plasticity; synaptic-specific plasticity). Hebbian plasticity occurs in 
neurones, notably dopaminergic neurones (Ishikawa et al., 2013), where strengthening of one 
synapse results in all synapses on the postsynaptic neurone strengthening, not just the 
individual synapse (Lynch et al., 1977). This synaptic-specific plasticity differs from input-
specific plasticity (also referred to as homosynaptic plasticity) as input-specific plasticity 
occurs solely at the individual synapse that is strengthening, not across all synapses 
(Castellucci et al., 1970). Although heterosynaptic plasticity has been observed in 
dopaminergic neurones, homosynaptic plasticity is mostly observed in glutamatergic 
neurones, the most abundant excitatory neurotransmitter in the cortex and a major mediator 
of plasticity (Zhou and Danbolt, 2014). One form of homosynaptic plasticity is synaptic scaling, 
a phenomenon which acts as a negative feedback mechanism in response to elevated chronic 
activity, whereby total activity is matched by homosynaptic range (Turrigiano et al., 1998; 
Abbott and Nelson, 2000). Metaplasticity is another variant of plasticity, first denoted in 1996 
by Abraham and Bear, metaplasticity governs the form of plasticity whereby a neurone that 
has previously undergone plasticity goes through further synaptic plasticity (Abraham and 
Bear, 1996). Also referred to as LTP block, metaplasticity is a critically important 
phenomenon, as metaplasticity in neurones is a substantial promotor of long-term memory 
storage (Hulme et al., 2013). All of these are variants of activity-dependent plasticity, a 
neurological phenomenon which is widely regarded to lay the foundations of learning and 
memory (Carulli et al., 2011). 
 
1.3.2   Activity-Dependent Plasticity 
Although activity-dependent plasticity has been reported throughout the cortex, it 
predominantly affects glutamatergic neurones due to the involvement of ionotropic 
glutamate receptors (iGluRs (Rebola et al., 2010)). These receptors are ion channel-
associated, purely excitatory and is significantly faster than their metabotropic counterpart 
(Traynelis et al., 2010). The group of iGluRs includes: Kainate receptors (KARs); N-methyl-D-
aspartic acid receptors (NMDARs) and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic 
acid receptors (AMPARs), all of which are tetramers formed of different glutamatergic 
subunits (Swanson and Sakai, 2010). Of these three receptors, NMDARs and AMPARs are 
ligand-gated ion channels active on the synaptic membrane, however KARs are both active 
within the soma and on the synaptic membrane.  
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 During glutamate transmission, glutamate is released across the synapse upon release 
from the presynaptic terminal, a similar mechanism to that shown in Figure 8. Within the 
synaptic cleft, glutamate will initially bind to postsynaptic AMPARs, which in turn opens up 
the antiport channel protein, allowing an influx of Na+ ions into the postsynaptic membrane 
with potassium ions (K+) transporting out (Chater and Goda, 2014). This results in a positive 
increase in membrane potential, which in turn repels a magnesium ion (Mg2+) from blocking 
the NMDARs ion channel, a process referred to as electrostatic repulsion (Nowak et al., 1984). 
Once the Mg2+ ion has dissociated from the ion channel and a glutamate has bound to the 
ligand binding site, the channel is open and Ca2+ (as well as Na+) flows into the postsynaptic 
bouton through the NMDAR (Ghasemi et al., 2014). In this cascade of events, NMDARs act as 
a coincidence indicator, as it requires both presynaptic activity and postsynaptic activity to be 
present before the receptor becomes active (Seeburg et al., 1995; Sjöström et al., 2003). Once 
there has been an influx of Ca2+ ions into the postsynaptic terminal, the subsequent functions 
of the neurone change depending on the concentrations of Ca2+ entering the cell, with greater 
Ca2+ concentrations yielding synaptic facilitative effects and lower Ca2+ yielding depressive 
effects (as are outlined in Figure 9, left and right respectively; Malenka and Nicoll, 1993). 
Although AMPARs and NMDARs both play a comparatively significant role in the generation 
of plasticity, most variants of plasticity are NMDAR mediated (Citri and Malenka, 2008), 
whereas AMPAR plasticity occurs indirectly, with their phosphorylation state and 
postsynaptic expression providing their main contribution to synaptic plasticity (Mammen et 
al., 1997; Noel et al., 1999). This mechanism is known as spike time-dependent plasticity 
(STDP) and can both increase synaptic activity (expanded in chapter 1.3.2.1) and decrease 
synaptic activity (expanded in chapter 1.3.2.2).  
 Although activity-dependent plasticity is primarily conducted through iGluRs, there is 
evidence that the metabotropic glutamate receptors (mGluRs) also play a role in plasticity 
(Bortolotto et al., 1999). This group of receptors is significantly slower than its ionotropic 
counterpart but shows both excitatory (through mGluR1 and mGluR5) and inhibitory (through 
mGluR2, mGluR3 and all remaining mGluRs) properties (Niswender and Conn, 2010; 
Blackshaw et al., 2011). In plasticity, mGluRs have been shown to interact with clathrin-
dependent endocytosis of AMPARs (Snyder et al., 2001; Wang and Linden, 2000), mGluR5 (a 
subtype found abundantly within the hippocampus (Ferraguti and Shigemoto, 2006)) 
activates phospholipase c (PLC) through g-protein activation (Rebola et al., 2010; Popkirov 
and Manahan-Vaughan, 2010) and plays a more important role in long-term depression, as 






Figure 9 - A Simplified Overview of Presynaptic and Postsynaptic Mechanisms in Both Long-Term Potentiation and 
Depression. Upon receival of an action potential at the presynaptic terminal, long-term potentiation (LTP) or long-term 
depression (LTD) will be induced across the synapse. Left, presynaptic LTP is exhibited when there is a large influx of calcium 
ions, through both voltage-gated calcium channels (VGCCs) and presynaptic NMDARs (preNMDARs). This rise in presynaptic 
calcium drives neurotransmitter (in this case glutamate) release across the synapse, which in turn activates postsynaptic 
receptors. Upon glutamate binding, AMPARs facilitate an influx of sodium ions, which in turn expels the magnesium ion from 
NMDARs by electrostatic repulsion (Nowak et al., 1984). This repulsion results in a larger influx of calcium ions into the 
postsynaptic neurone, which facilitates eCB activation (Ohno-Shosaku et al., 2002), AMPAR exocytosis to the perisynaptic 
membrane (Citri and Malenka, 2008), early phase activation through CAMKII (Yang et al., 2004) and late phase activation 
through gene expression. Activation of postsynaptic eCB receptors, both through calcium influx and mGluR (through DAG) 
activation results in a de novo formation of lipids anandamide and 2-arachidonylglycerol, which in turn activate 
homosynaptic CB1Rs. Activation of the presynaptic CB1Rs activates RhoAGTPase, which in turn activates ROCK which 
stimulates the production of the scaffolding protein actin. Activation of the cannabinoid receptor also inhibits AC activity, 
increasing PKA activity which drives presynaptic phosphorylation of targeted proteins (P*). Right shows the mechanisms 
involved in LTD induction. Where PKA activation resulted in phosphorylation of targeted proteins, opposing activation of CaN 
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results in those targeted proteins dephosphorylating (P). VGCC and preNMDAR activities are also reduced in LTD, resulting 
in a significantly reduced influx of calcium, culminating in less glutamate being released across the synapse. This diminished 
release results in fewer AMPARs activating, thus a smaller sodium influx into the postsynaptic membrane is observed. This 
means less magnesium ions are repelled from NMDARs, with less calcium ions entering the postsynaptic neurone as a result. 
This reduction results in PP1 activation as well as glutamate binding to mGluRs, which through two separate mechanisms, 
results in AMPAR endocytosis (Snyder et al., 2001; Wang and Linden, 2000). In LTD also, eCB shows limited activity and thus, 
CB1R shows limited activity as well. In the image, arrows represent a comparison against normal activity, with larger arrows 
denoting a greater movement and smaller arrows showing a smaller movement. Abbreviations include (when read from top 
to bottom, left then right): AC (Adenylyl cyclase); PKA (Protein kinase A); DAG (Diacylglycerol); PKC (Protein kinase C); CAMKII 
(Calcium-calmodulin-dependent protein kinase type II); cAMP (Cyclic 3’5’ adenosine monophosphate); CaN (Ca2+-Sensitive 
Phosphate Calcineurin); ERK1/2 (Extracellular signal-related kinase 1/2); PP2B (Protein phosphatase 2B); PP1 (Protein 
phosphatase 1). 
 
A role for endocannabinoids (eCB) in the induction of activity-dependent plasticity has also 
been identified. These lipid-based eCB receptors are mostly found on the postsynaptic 
membrane and, upon activation by either an mGluR1 activated diacylglycerol (DAG) or by an 
influx of Ca2+, de novo forms the fatty acids anandamide and 2-arachidonylglycerol which 
either act as a retrograde messenger on either the homosynapse or the heterosynapse to 
affect synaptic function (Ohno-Shosaku et al., 2002; Devane et al., 1992; Pierre et al., 2020). 
The presynaptic type 1 cannabinoid receptor (CB1R) plays a vital role in eCB activity, although 
this receptor alone is not sufficient to generate eCB mediated plasticity both within the 
hippocampus and across the rest of the cortex (Kang-Park et al., 2007; Heifets et al., 2008). 
Stimulation of eCB, and subsequently CB1R, can be mediated through the postsynaptic 
receptors mGluRs, L-type calcium channels and the aforementioned D2 receptors (Sung et al., 
2001; Pisani et al., 2005; Tang et al., 2001). Upon activation of CB1R, the g-protein Gαi/o 
dissociates from CB1R, inhibiting presynaptic AC and subsequently stimulating PKA activity 
(Heifets and Castillo, 2009). This activation of CB1R is also reliant on presynaptic NMDAR 
(preNMDAR) activation, as the influx of Ca2+ ions (also through VGCCs as well as the 
preNMDARs) upregulates Ca2+-sensitive phosphate calcineurin (CaN). These changes in both 
CaN and PKA levels then yield bidirectional effects, with increases in PKA phosphorylating 
target proteins (producing a long-term increase in activity) and increased CaN levels 
dephosphorylating target proteins (producing a long-term decrease in activity (Cui et al., 
2016)). 
 
1.3.2.1   Long-Term Potentiation 
1.3.2.1.1   Postsynaptic Mechanisms of Long-Term Potentiation 
Of these forms of activity-dependent plasticity, long-term potentiation (LTP) was the first to 
be identified in live animals (Bliss and Lømo, 1973) and was first shown in hippocampal slices, 
which remained potentiated for a long time when stimulated at a low frequency of 0.05Hz 
(Holland and Wagner, 1998). LTP can be divided into two components, LTP induced through 
postsynaptic mechanisms and LTP induced through presynaptic mechanisms. Each of these 
mechanisms presents their own dependence to a stage in their induction throughout the 
cortex, with postsynaptic mechanisms showing a dependence on NMDAR activity throughout 
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most of the cortex and presynaptic mechanisms showing a dependence on cAMP activity in 
mossy fibres (Malenka and Bear, 2004). This importance on NMDAR activity is highlighted in 
the postsynaptic mechanisms of STDP induced LTP (t-LTP). Instigation of t-LTP requires a 
secondary pulse to generate a presynaptic spike, which is then followed by a postsynaptic 
spike ~0-20 ms after, with only LTP observed at over 40 Hz (Bi and Poo, 1998; Markram et al., 
1997; Sjöström et al., 2001). At this interval, the subthreshold is potentiated, allowing 
sufficient time for membranous Ca2+ ion concentrations to restabilise, but not sufficient time 
for the Mg2+ block to re-establish (Kampa et al., 2004). This allows for a greater influx of Ca2+ 
ions into the postsynaptic membrane, a process which affects the postsynaptic neurone in 
two phases. In the first phase, the early phase, the increased concentration of Ca2+ ions bind 
to KARs, which subsequently phosphorylates and activates AMPARs (Diering et al., 2016). This 
then leads to increased AMPAR expression onto the perisynaptic membrane, mediated by 
Rab11a (Park et al., 2004), before the receptor migrates to the postsynaptic membrane 
through diffusion (as shown in Figure 9; Citri and Malenka, 2008). As well as modulating 
AMPAR expression, this greater influx of Ca2+ ions also activates both PKC and CaMKII, both 
of which also phosphorylate AMPARs (Yang et al., 2004). PKA has been shown to support this 
CaMKII activity through protein phosphatase inhibition (via inhibition of the phosphoprotein 
inhibitor 1), with CaMKII subsequently autophosphorylating itself once activated (Blitzer et 
al., 1998; Barria et al., 1997). The combination of these events results in greater AMPAR 
expression, allowing a greater influx of Na+ and subsequently Ca2+ ions, which drives LTP 
induction. 
After the early phase has subsided (approximately one hour after first induction 
(Baltaci et al., 2018)), the second phase, the late phase, begins to take effect. The 
aforementioned influx of Ca2+ ions into the postsynaptic membrane stimulates cAMP 
production through Ca2+-sensitive AC enzymes (Chetkovich et al., 1991). Increased cAMP 
concentrations then drive PKA production, in turn activating the extracellular regulated kinase 
(ERK)/ mitogen-activated protein kinase (MAPK) pathway, which activates CREB (Koga et al., 
2019). Activated CREB then binds to CRE sites which, as was discussed in chapter 1.2.2.1, 
resulting in an increased expression of genes, including: c-Fos (Kang et al., 2000); Zif268/Egr-
1 (Thomas and Huganir, 2004); CaMKII (Mayford et al., 1996) and growth factors such as BDNF 
(Wang et al., 2018). This increase in gene expression leads to protein production, generating 
more AMPAR and NMDARs, CREBs upstream proteins and growth factors, also forming new 
synapses between neurones and altering synaptic weights (Yuste and Bonhoeffer, 2001). The 
long phase therefore acts to reduce threshold potentials, meaning a weaker presynaptic 
impulse can still yield postsynaptic activity, acting over at least twenty-four hours (Baltaci et 
al., 2018). This subsequently alludes back to Hebbian plasticity, as two neurones that have 
“fired together” have now begun to “wire together” (Hebb, 1949). 
As well as playing a subsidiary role to NMDARs in t-LTP induction, AMPARs lacking the 
GluA2 subunit (referred to as calcium-permeable AMPARs) also play an independent role in 
LTP generation to NMDARs (Park et al., 2018). The proto-oncogene family of Src kinases have 
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also been shown to increase LTP induction chances by stimulating the activity of NMDARs 
(Kalia et al., 2004; Wang and Salter, 1994). 
 
1.3.2.1.2   Presynaptic Mechanisms of Long-Term Potentiation 
Although evidence for mechanisms involved in LTP was identified a few decades after the first 
identification of LTP (Staubli et al., 1990; Salin et al., 1996), with a range of mechanisms being 
identified since (Yang and Calakos, 2013), all presynaptic mechanisms entail increases in 
presynaptic Ca2+ concentrations. This Ca2+ concentration is mediated through N-, P/Q and R-
type voltage-gated calcium channels (VGCC), with influx through R-type VGCCs significantly 
lowering the threshold for LTP induction, despite it playing a minimal role in overall Ca2+ influx 
(Qian and Noebels, 2001; Dietrich et al., 2003). Ca2+ ion influx is also mediated through 
glutamate-bound KAR channels, which also lowers the required threshold for LTP induction 
(Shin et al., 2010). This increase in intracellular Ca2+ levels leads to an increase in AC levels 
which, through cAMP mediated activity, increases PKA levels, allowing phosphorylation of 
presynaptic substrates, inducing presynaptic LTP (Castillo, 2012; Nicoll and Schmitz, 2005). 
Another identified mechanism involves retrograde signalling by nitric oxide (NO), a small 
molecule that is generated by the postsynaptic enzyme nitric oxide synthase (NOS) and can 
easily diffuse across a cell membrane (Alderton et al., 2001). This enzyme is bound to NMDAR 
at membrane resting potential, but upon NMDAR activation is activated by Calmodulin and 
Ca2+, subsequently producing NO molecules which diffuse and act on the heterosynaptic 
presynapse as a retrograde messenger (Stanton et al., 2003). This posseses a facilitative 
property through numerous MOAs, namely guanylyl cyclase activation (Zhuo et al., 1994), 
cyclic guanosine monophosphate (cGMP) activation and cGMP-dependent protein kinase 
activation (Meffert et al., 1996). LTP is also induced when NO acts on synapses between 
GABAergic and dopaminergic neurones in the VTA, despite facilitating the release of GABA 
(Nugent et al., 2007; Bains and Ferguson, 1997). As well as these mechanisms, LTP is also 
gated through mGluR7b activation and internalisation in mossy fibre synapses, a presynaptic 
glutamate receptor which plays a key role in cellular de-depression, a form of facilitation in 
which mechanisms that encode depression are reversed (Pelkey et al., 2005). As well as the 
aforementioned mechanism of LTP where CB1R upregulates presynaptic PKA, eCB-LTP has 
been induced in hippocampal neurones through inhibition of inhibitory GABAergic neurones 
(Carlson et al., 2002). Homosynaptic eCB-LTP in the hippocampus can also be induced through 
CB1R mediated FAK/ROCK pathway, which increases the expression of the presynaptic 
scaffolding protein, actin. This expression, activated by ROCK upon an increased expression 
of RhoAGTPase, subsequently increases presynaptic glutamate release (as shown in Figure 9; 
Wang et al., 2017). Heterosynaptic eCB-LTP is initiated through numerous mechanisms 
however, namely through a depression of inhibitory transmission (Carlson et al., 2002); 
through astrocytic support (Navarrete and Araque, 2010) and through dopaminergic 
signalling (Cachope et al., 2007). 
 As well as these mechanisms, the roles that preNMDARs play in LTP induction is still 
poorly understood, as preNMDARs play a much greater role in long-term depression (as 
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discussed in chapter 1.3.2.2). In both activity-dependent forms of plasticity, these 
preNMDARs show an autoreceptor function, in which neurotransmitters acts on the same 
presynaptic terminal which the neurotransmitter was released from as well as the 
postsynaptic terminal (Duguid and Smart, 2009; Sjöström et al., 2003). This autoreceptor 
function, first identified in layer II of the EC, allows a further facilitation in excitatory 
glutamate release, in which metaplastic LTP was induced through preNMDAR enhanced 
glutamate release (Berretta and Jones, 1996). This mechanism is also shown in CA1-CA3 
neurones of the hippocampus, with the two subregions of the HF being the subregions 
throughout the cortex shown to elicit this form of LTP (McGuinness et al., 2010). PreNMDARs 
are also required for LTP synthesis in projections from both the striatum and the amygdala, 
in which preNMDAR only affects cortical afferent synapses (Humeau et al., 2003; Park et al., 
2014).  
 
1.3.2.2   Long-Term Depression 
1.3.2.2.1   Postsynaptic Mechanisms of Long-Term Depression 
Similarly to LTP, long-term depression (LTD) can also be divided into its presynaptic and 
postsynaptic components, with many mechanisms of LTD showing the reverse of mechanisms 
shown in LTP. Postsynaptic LTD, like postsynaptic LTP, is dependent on postsynaptic NMDAR 
activity, with STDP mediated LTD (t-LTD) being induced when a postsynaptic spike is followed 
by a presynaptic spike (at ~0 and 20-100 ms intervals, 0.1-20 Hz (Bi and Poo, 1998; Markram 
et al., 1997; Sjöström et al., 2001)). Early phase LTD arises when a diminished Ca2+ influx is 
observed, resulting in Ca2+ switching binding switch from KAR (observed in LTP) to protein 
phosphatase 2B (PP2B (Neveu and Zucker, 1996)). This results in dephosphorylation of 
AMPARs and subsequent dynamin- and clathrin-dependent endocytosis from the reduced 
KAR activity (Collingridge et al., 2004; Derkach et al., 2007) and activation of a calcium-
dependent protein phosphatase cascade from PP2B activation (Millward et al., 1999). 
Activation of PP2B, a calcium/calmodulin-dependent phosphate calcineurin heterotrimer, 
activates protein phosphatase 1 (PP1) which activates the phosphoprotein inhibitor 1, in turn 
deactivating PP1 (Lisman, 1989). Combination of these pathways results in a suppression of 
gene expression, thus less proteins (such as the aforementioned receptors and synaptic 
weighting) are produced, which is indicated in Figure 9. As well as these biomolecules, LTD is 
heavily correlated with a dephosphorylation of both PKA and PKC, where their 
dephosphorylation both reduces their activities and also reduces AMPAR activity (Jideama et 
al., 2006; Kameyama et al., 1998; Yang et al., 2004). 
 As well as ionotropic-mediated LTD, metabotropic-mediated LTD through mGluRs 
provides a different induction mechanism to that of NMDAR induced-LTD. Activation of group 
1 (excitatory) mGluRs by glutamate neurotransmitters affects both iGluR trafficking and gene 
expression through a plethora of mechanisms (Gladding et al., 2009; Sanderson et al., 2016). 
The first mechanism in which mGluR can induce LTD is through AMPAR expression on the 
postsynaptic membrane. Group 1 mGluRs, upon activation, dephosphorylates and activates 
striatal-enriched tyrosine phosphatase (STEP), which dephosphorylates AMPARs, initiating 
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their endocytosis (Zhang et al., 2008). Where this directly affects trafficking, both the 
p38/MAPK and the ERK 1/2 pathways indirectly affect the trafficking through a cascade 
reactions, modulating G-actin which results in the endocytosis of AMPARs (Rush et al., 2002; 
Gallagher et al., 2004). This form of LTD appears to be mediated by downstream mGluR-
dependent protein synthesis, as Fragile X mental retardation protein (a protein essential in 
cognitive development) KO mice show enhanced levels of LTD, potentially providing a 
therapeutic target in other neurodevelopmental conditions (Hou et al., 2006; Bear et al., 
2004). Although mGluRs also trigger eCB activation, thus both branches of postsynaptic LTD 
can elicit an eCB-mediated response (Ohno-Shosaku et al., 2002), mGluRs have been shown 
to only contribute to short-term plasticity in hippocampal neurones (Rouach and Nicoll, 
2003). The activity of postsynaptic mGluRs is not a prerequisite for LTD induction, instead 
preNMDAR activation is required in its induction. 
 
1.3.2.2.2   Presynaptic Mechanisms of Long-Term Depression 
Where presynaptic LTP stems from an increase in presynaptic Ca2+, presynaptic LTD generally 
originates in a reduction in Ca2+ concentration, which subsequently diminishes levels of 
respective downstream biomolecules. Where the iGluR, KAR, is activated in LTP, it is the 
inhibitory metabotropic glutamate receptors mGluR2/3 that are activated in accordance with 
LTD (Tzounopoulos et al., 1998). Activation of these mGluRs leads to a g-protein linked 
reaction (through Gαi) which culminates in AC suppression and thus cAMP/PKA inhibition (Pin 
and Duvoisin, 1995). Secondly, where NO plays a facilitative heterosynaptic plastic effect, its 
effect observed on a homosynapse is depressive (Gage et al., 1997). Upon NOS stimulation 
and NO production, NO actively passes through the membrane due to its small size and 
negligible charge. Upon NO entering the homosynaptic presynaptic membrane, it acts on 
guanylyl cyclase, cGMP and PKG to alter NMDAR dependent LTD (Gage et al., 1997; Li et al., 
2003) as well as directly acting on presynaptic K+ channels (Yang et al., 2007). Although 
mGluR7b was shown to induce LTP, its counterpart (mGluR7) has been shown to induce LTD. 
Activation of the mGluR expressed on the presynaptic membrane activated PKC, which 
downregulates P/Q- VGCC activity (Pelkey et al., 2005). Finally, eCB, and subsequently the 
presynaptic CB1R, play a pivotal role in LTD, a role which is subsequently referred to as eCB-
LTD (Gerdeman et al., 2002). In CB1R-mediated LTD, similar to CB1R-mediated LTP, activation 
of CB1R through a retrograde messenger (anandamide or 2-arachidonylglycerol to name a 
couple) initiates a cascade of events, with CaN levels eventually increasing, 
dephosphorylating presynaptic targets (as indicated in Figure 9; Heifets and Castillo, 2009). 
DA receptors also contribute to this eCB-LTD generation, with the presynaptic activity and 
expression of the DA receptor D2 dictating whether LTP or LTD is observed (Xu et al., 2018).  
 Although preNMDARs play a minor role in LTP induction, as discussed in chapter 
1.3.2.1.2, they play a significant role in various forms of synaptic LTD induction (Citri and 
Malenka, 2008; Rodriguez-Moreno, Banerjee and Paulsen, 2010; Heifets and Castillo, 2009; 
Rodríguez-Moreno et al., 2013; Wang et al., 2012). In their most abundantly studied role, 
preNMDARs are necessary for STDP induced LTD (t-LTD), acting as a coincidence indicator in 
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its induction (Bender et al., 2006; Sjöström et al., 2003). STDP induced LTD is observed when 
a postsynaptic spike is followed by a presynaptic spike, as mentioned previously, yielding a 
reduced influx of Ca2+ ions into the presynaptic membrane (Karmarkar and Buonomano, 
2002). PreNMDARs play not only a fundamental role but a necessary role in t-LTD induction, 
as postsynaptic NMDAR inhibition though MK-801 (an NMDAR antagonist) showed no 
changes in LTD capabilities, however preNMDAR inhibition though MK-801 blocked LTD 
almost entirely (Rodríguez-Moreno and Paulsen, 2008). Under the expression of LTD, reduced 
preNMDAR binding results in a reduction of presynaptic Ca2+ influx, which in turn diminishes 
presynaptic neurotransmitter release, further reducing preNMDAR activity. Instigation of t-
LTD also requires postsynaptic mGluR activation, activating eCB and stimulating the 
production of retrograde messengers (Heifets and Castillo, 2009). These eCB messengers 
activate the presynaptic CB1R, activating the g-protein linked cascade and reducing 
intracellular PKA levels, diminishing presynaptic phosphorylation levels (Cui et al., 2016). This 
has meant that, similar to preNMDAR, eCB acts as a second coincidence indicator, as its 
activity in t-LTD is dependent upon the activity of both the presynaptic and postsynaptic 
receptors (Bender et al., 2006). Despite the important role that both eCB and retrograde 
signalling molecules play in presynaptic LTD, presynaptic spike pattern-dependent (p-LTD) 
experiments in rodent barrel (somatosensory) cortex concluded that neither of the 
aforementioned pathways were required to generate LTD (Rodríguez-Moreno et al., 2013; 
Banerjee et al., 2009). This preNMDAR mediated LTD can however be almost entirely 
abolished through inhibition of the NR2B subunit on the NMDAR, a subunit which is shown to 
be downregulated throughout the EC during mature stages (Massey et al., 2004; Yang et al., 
2006; Berretta and Jones, 1996). Application of the subunit antagonist, Ro 25-6981, showed 
a significant reduction in LTD (with no effect on LTP), most notably in layers II, III and V of the 
EC (Berretta and Jones, 1996). 
 
1.3.2.3   Short-Term Plasticity 
Asides from long-term plasticity, another form of plasticity exists, short-term potentiation 
(STP), which acts somewhat independently of the aforementioned forms of plasticity. STP 
occurs within the presynaptic membrane, acting between a few seconds to a few minutes 
(Citri and Malenka, 2008). This form of plasticity however differs from the early phases of 
both LTP and LTD, as STP is driven by presynaptic Ca2+ ions and few molecular mechanisms 
surrounding its induction have been observed (Zucker and Regehr, 2002). Similar to LTP and 
LTD however, the observed influx of Ca2+ ions does show a bidirectional effect, with larger 
concentrations of Ca2+ yielding potentiation and smaller concentrations of Ca2+ yielding a 
depression (Fioravante and Regehr, 2011). In STP, frequent firing of the presynaptic neurone 
results in a transient rise in presynaptic Ca2+ concentrations, which gives rise to the 
mechanisms of STP, augmentation and potentiation (also referred to as post-tetanic 
potentiation). Both augmentation and potentiation enhance presynaptic neurotransmitter 
activity by driving vesicle exocytosis through the built-up Ca2+ ions (Erulkar and Rahamimoff, 
1978; Korogod et al., 2005). The two mechanisms however have slightly different 
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downstream biomarkers, with augmentation being shorter lasting, stimulating munc13 (a 
SNARE protein regulator which is modulated by Ca2+ (Gioia et al., 2016)) and potentiation 
being longer lasting, stimulating PKA (Cheng et al., 2018). Although this frequent firing of 
presynaptic neurones provides mostly a facilitative response, there are synapses at which 
frequent firing shows a depressive effect (Zucker and Regehr, 2002). 
 There also appears to be roles for both preNMDARs, eCBs and glial interaction in STP 
generation. The former, preNMDARs, have been found to mediate glutamate transmission 
upon activation, an affect which is seen predominantly across frequency dependent short-
term facilitation in the EC (Chamberlain et al., 2008). eCBs also mediate STP, this time through 
the retrograde messenger activities of anandamide and 2-arachidonylglycerol, by which their 
interaction with CB1R affects VGCC channel induction, mediating presynaptic Ca2+ influx 
(Chevaleyre et al., 2006). The role that eCBs play in short term plasticity exist as two forms, 
depolarisation-induced suppression of inhibition and depolarisation-induced suppression of 
excitation (Llano et al., 1991; Vincent et al., 1992). Asides from preNMDARs and eCBs, glial 
interaction has been shown to play a supporting role in STP induction, with astrocytes 
enhancing transmission through their own Ca2+ signalling pathways (Sibille et al., 2015).  
 
1.3.3   Dopamine-Mediated Plasticity 
Although it was previously thought that only glutamatergic neurones could exhibit plasticity, 
more recent studies have begun to show that dopaminergic neurones can also undergo 
plasticity. DA-mediated synaptic plasticity however still remains poorly understood within the 
LEC; however this phenomenon is significantly better understood in the PFC, the only 
subregion to receive a larger dopaminergic innervation from the VTA than the EC (Oades and 
Halliday, 1987). In the PFC, both D1-like receptors and D2-like receptors contribute to both 
early-phase and late-phase plasticity, as is shown in Figure 10 (Goto et al., 2010). Early-phase 
plasticity is mediated through AMPAR and NMDARs membrane expression, a process which 
is stimulated by D1-like transmission but not D2-like transmission (Figure 10, lower; Sun et 
al., 2005). Activation of D1-like receptors activates AC and then cAMP, activity of which are 
implemented in both LTP and LTD due to their binding affinities to Ca2+ (Chetkovich et al., 
1991). PKA is then activated by cAMP, another biomolecule that is heavily implemented in 
both LTP and LTD for its interactions with CaMKII and also its role in phosphorylating AMPARs 
(Blitzer et al., 1998; Price et al., 1999). Subsequent activation of DARPP-32 and then PP-1 leads 
to greater levels of phosphorylated NMDARs as well as stimulating CREB activity, further 
driving late-phase plasticity (Nishi et al., 2016). This increased CREB activity is also driven 
through D2-like cascade, in which PLC and PKC, two other biomolecules implemented in 
plasticity due to their interactions with AMPAR are activated (Yang et al., 2004; Horne and 
Dell'Acqua, 2007). As these both affect gene expression, they are congruent with late-phase 
plasticity, a process which is stimulated by both D1-like and D2-like receptor activation 
(Yamamoto et al., 1988). Both D1-like and D2-like receptors also directly interact with 
NMDARs, through NMDAR’s GluN2A and GluN2B subunits respectively, with both DA 
receptors inhibiting NMDARs activity (Lee et al., 2002; Liu et al., 2006). Cocaine addiction has 
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been shown to strengthen this 
interaction, as well as reducing 
NMDAR’s activity with CaMKII (Liu 
et al., 2005).  
Figure 10 also shows the 
role which mGluR group II plays in 
the formation of synaptic 
plasticity, by interacting with the 
intermediate biomolecules PLC 
and ERK 1/2, which has also been 
shown in other similar reports in 
both the PFC and the HF (Otani et 
al., 1999; Zhu et al., 2017). 
Another factor in DA-mediated 
synaptic plasticity within the PFC 
seems to be the interaction 
between DA receptors and the 
serotonin receptor 5-HT1A. This 5-
HT receptor, whose postsynaptic 
abundance appears to be on 
glutamatergic neurones, 
provides interdependency in DA-
mediated plasticity (Meunier et 
al., 2017). Although experiments 
testing the role of DA in the HF 
have been performed, there is 
yet to be either a conclusive or 
proposed cascade mechanism 
like that shown in PFC (Sajikumar 
and Frey, 2004). There is a similar 
mGluR-dependency in plasticity 
formation within the LEC, but the 
serotonin receptor identified in 
the PFC (5-HT1AR) is not present 
in the LEC directly, but is present 
within the HF (Zhu et al., 2017; 
Wright et al., 1995; Polter et al. 
2012).  
One form of DA-mediated 
STP which has been studied 
within the LEC is DA receptor 
Figure 10 - Signal Cascade of Dopamine-Mediated Synaptic Plasticity. The 
cascade reaction caused by both D1 and D2 (as well as D1:D2) receptor 
activation and their role in initiation and propagation of synaptic plasticity in 
the prefrontal cortex. The predominant signalling pathway, D1/D2 receptor 
(red), is divided into two separate pathways. The first pathway (ascending) 
shows the signalling pathway which culminates in decreased cAMP response 
element-binding protein (CREB) expression. This pathway can be separated 
into two parts, the excitatory (shown by the solid lines which are D1:D2 
mediated) and the inhibitory (shown by dotted lines which is D2-mediated), 
both of which result in CREB inhibition and subsequent LTP induction 
(Yamamoto et al., 1988). The other pathway (descending) shows the signalling 
pathway which culminates in phosphorylation of both N-methyl D-aspartic 
acid (NMDA) and α-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic Acid 
(AMPA), increasing postsynaptic calcium and sodium ion influx (Sun et al., 
2005). Other signalling factors mediated by dopamine activation are also 
shown:, including brain-derived neurotropic factor (BDNF, blue); group II 
metabotropic glutamate receptor (Group II mGluR, green); nicotinic 
acetylcholine receptor (nAchR). Abbreviations include (when read from top to 
bottom, left then right): GSK-3 (Glycogen Synthase Kinase 3); PAK (p21-
Activated Kinases); ERK 1/2 (Extracellular Signal-Regulated Kinase); Rac1 (Ras-
Related C3 Botulinum Toxin Substrate 1); MEK 1/2 (Mitogen-Activated 
Kinases 1/2); PIP3 (Phosphatidylinositol-3;4;5-Triphosphate); Akt (Protein 
Kinase B); PKC (Protein Kinase C); PI3K (Phosphoinositide 3-kinase); DGL 
(Diacylglycerol); PLC (Phospholipase C); Rap 1 (Member of the RAS Family of 
Small GTP-Binding Proteins); SOS (Son of Sevenless Guanine Nucleotide 
Exchange Factors); AC (Adenylyl Cyclase); cAMP (Cyclic 3’5’ Adenosine 
Monophosphate); Grb2 (Growth Factor Receptor-Bound Protein 2); PKA 
(Protein Kinase A); DARPP-32 (Phosphoprotein of 32 kDa); PP-1 (Protein 
Phosphatase 1). The image depicting the cascade reaction was taken directly 
from Biological Psychiatry (Goto et al., 2010, with permission). 
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desensitisation. This neurological phenomenon (also referred to as DA inhibition reversal) 
arises from a prolonged exposure to the neurotransmitter, where the effect of the 
neurotransmitter exhibits on the region diminishes over time (Nimitvilai and Brodie, 2010). 
DA desensitisation was initially only reported in the VTA (Nimitvilai and Brodie, 2010), 
however it is yet to be directly reported within the LEC. These mechanisms stem from DA 
receptor concurrent stimulation over prolonged periods (Nimitvilai and Brodie, 2010) and 
show significant changes in downstream molecules (Goto et al., 2010). Phosphatidylinositol 
(PI), conventional protein kinase C (cPKC) and PLC have all been implicated in DA 
desensitisation (Nimitvilai et al., 2014). All of these biomolecules are downstream signalling 
molecules in the DA signalling cascade, confirming that DA desensitisation is self-mediated. 
 
1.3.4   Methods for Inducing Plasticity 
Despite plasticity being a crucial aspect of neurological function, it was not until the early 20th 
century that artificially induced plasticity could be induced in a laboratory (Markram et al., 
2011). Since then, two predominant forms of electrophysiology (physiology that studies the 
electrical properties of neurones) have been identified intracellular and extracellular 
recordings. Intracellular recordings provide a detailed insight into a single, specific neurone 
and its connections, it does not however provide a representation for other nearby neurones. 
There are three common forms of intracellular recording techniques, voltage clamp, current 
clamp and patch-clamp recording. The first two techniques are very similar, with voltage 
clamp maintaining membrane potential and measuring current whereas current clamp 
maintains current and measures membrane potential (Hodgkin et al., 1952; Brinstock et al., 
1975). Patch-clamping however, initially finalised in 1992, can be used to measure either of 
the aforementioned physical properties of the cell (Neher and Sakmann, 1992). There are 
numerous types of patch-clamp recording, including whole-cell (where the membrane is 
broken to allow dispersion of internal fluid) and perforated patch (where the membrane is 
made permeable to ions so the cytoplasmic contents do not get distilled within the pipette) 
to name a couple (Cahalan and Neher, 1992).  
Should the function of numerous cells in a localised region need to be measured, 
extracellular recordings can be performed, which consists of single-unit, multi-unit and field 
recordings. Similar to voltage and current clamps, single-unit and multi-unit recordings are 
also similar to one another, with single-unit recordings measuring extracellular activity on one 
neurone and multi-unit recording (using an electrode with a wider diameter) measuring 
multiple neurones (Hubel and Wiesel, 1962; Recce and O'Keefe, 1989).  
The final extracellular recording technique, field recordings, primarily records 
excitatory postsynaptic potentials, that is the change in postsynaptic membrane potentials 
driven by excitatory neurone transmission (Bliss and Lømo, 1973). Field excitatory 
postsynaptic potentials (fEPSPs) were first used in the 1960s and 70s, during which their use 
in measuring activity in both schaffer collateral-commissural pathway and the perforant path 
was well researched (Bliss and Lømo, 1973; Collingridge et al., 1983). At this time, fEPSPs were 
described as reflections in the number of localised cells discharging, subsequently indicating 
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the excitability of the region (Bliss and Lømo, 1973). Following these experiments, 
Collingridge determined that these recordings are as a result of excitatory amino-acid activity, 
later concluded to be the neurotransmitter glutamate (Collingridge et al., 1983). Although 
initial experiments showed glutamate activity primarily mediates fEPSPs, later studies showed 
that the inhibitory neurotransmitters GABA (Davies and Collingridge, 1996) and DA (Caruana 
et al., 2006) can also affect fEPSPs, with the former showing a direct regulation of fEPSPs. The 
latter however, despite the aforementioned paper showing that DA facilitates and depresses 
synaptic responses within the LEC, lacks conclusions around whether DA affects fEPSPs 
directly or indirectly, thus further experimentation is required to determine any conclusion. 
Individual extracellular postsynaptic potentials may show only a small change in potential; 
however, neurone rich regions such as the HF have many neurones often converging on a 
single neurone (Keller et al., 2018). This postsynaptic change in potential is measured by 
fEPSPs, as relative positively charged ions flood into the neurone upon activation, the 
extracellular region becomes more relatively negative (Collingridge, 1985; Bean, 2007). 
Measurement of these changes produces an extracellular waveform, an example of which is 
shown in Figure 11B. The waveform is comprised of three principal regions, each of which is 
identified in Figure 11B. The first induced region is the electrical stimulation artefact (1), the 
non-biological component of the waveform as this shows the recording electrode detecting 
the activation of the stimulating electrode. The second component (2) shows the presynaptic 
component of the waveform. Often called the fiber volley, this region shows the changes in 
membrane potential at the presynaptic terminus upon arrival of the action potential (Hawkins 
et al., 2017). Analysis of this region can show changes in Ca2+ influx, suggesting plastic changes 
occurring within the presynaptic terminal (Kamiya and Ozawa, 1998). The postsynaptic region 
(3) of the waveform is the largest and longest region of the three, occurring immediately after 
the presynaptic component, indicating the presence of a postsynaptic potential. During this 
postsynaptic potential, activation of few presynaptic cells (as shown by the fiber volley, 2) 
often leads to the activation of significantly more postsynaptic cells, owing to the dense 
nature of the HF (Keller et al., 2018). This propagation of an action potential across cells 
results in a large shift in extracellular ionic concentrations, as Na+ ions enter cells, causing the 
largest negative change in the fEPSP waveform (Stolerman, 2010). This postsynaptic 
component of the waveform can be broken down into various components to measure how 
the EPSP changes: the initial slope, the peak amplitude, the initial area and the whole area 
(Liu et al., 2008). Not only can all these components indicate the induction and subsequent 
form of synaptic plasticity, but they can also show the effects that other neurones or drug 
application has on the region. This makes fEPSP a reliable experimental technique in the 
analysis of HF (and subsequently the LEC) activity, as the regions are not only dense in MPNs, 
but also primarily communicate through excitatory transmission. 
The results seen in waveforms would be directly comparable to the induction of 
plasticity, with LTP producing a larger peak amplitude and LTD yielding a smaller peak 
amplitude. This occurs as LTP induction conformationally changes postsynaptic receptors to 
induce larger potentials, thus fEPSPs increase (Daoudal et al., 2002). LTP can be artificially 
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induced using fEPSP stimulation, with hippocampal neurones showing a significant facilitation 
after high-frequency (100 Hz for 1 second) tetanic-stimulation (Morishita et al., 2005). LTP 
can also be induced through theta-burst stimulation (5 pulses at 100 Hz several times over a 
few minutes (Larson et al., 1986)) as well as other tetanisation timeframes (25-400 Hz 
(Blundon and Zakharenko, 2008)). Where LTP is induced through high-frequency pulses over 
a short time, LTD is induced through low-frequency pulses over a long time. This protocol is 
well versed, one example of this is in hippocampal neurones, where 3 minutes of 5 Hz 
stimulation yields a significant depression in both fEPSP amplitude and in slope (Morishita et 
al., 2005). Other stimulation methods which induce LTD include: 15 minutes of 900 pules at 1 
Hz (which induces NMDAR mediated LTD (Dudek and Bear, 1992; Mulkey and Malenka, 1992)) 
and minutes-long trains of 1-3 Hz (Bear and Malenka, 1994). Stimulation mediated eCB-LTD 
also shows that both low-frequency (through 2-arachidonylglycerol mediation) and high 
frequency (mediated by anandamide through CB1R) can both induce LTD in synapses (Lerner 
and Kreitzer, 2012). As well as long-term plasticity, STP can be induced through trains (many 
pulses in quick succession) with augmentation lasting for seconds after the train and post-
tetanic potentiation (potentiation observed after tetanisation) lasting minutes after the train 
(Erulkar and Rahamimoff, 1978). 
Synaptic plasticity can also be induced through paired-pulse stimulations (PPS), where 
two pulses are delivered in quick succession over short interpulse intervals (IPIs). PPS will 
subsequently induce one of two forms of short-term plasticity, paired-pulse facilitation (PPF, 
in which an increase in postsynaptic potentials is observed) or paired-pulse depression (PPD, 
in which a decrease is observed). The mechanisms underlying PPF are predominantly through 
residual Ca2+ build-up in the presynaptic terminal, however it is also heavily dependent on the 
pool of readily releasable vesicles (Fioravante and Regehr, 2011). Over very short IPIs, PPF 
observed is at its greatest, as residual Ca2+ is at its highest from the previous action potential. 
This spike in presynaptic Ca2+ concentration will subsequently drive greater exocytosis from 
presynaptic readily releasable vesicles, increasing the presynaptic release probability. This 
relationship between IPI and the strength of PPF shown appears to be inversely proportional, 
that is increasing IPI reduces the strength of PPF elicited, as larger IPIs show a much weaker 
PPF strength (Zucker and Regehr, 2002). One crucial factor in this diminishment of power over 
time is due to the co-operative effect between Ca2+ and vesicles, in which approximately four 
Ca2+ ions are required to drive exocytosis of one vesicle (Dodge and Rahamimoff, 1967). 
Shorter IPIs will have a substantially greater concentration of presynaptic calcium and thus 
can drive significantly larger volumes of vesicle release than the lower concentrations 
observed at longer IPIs. Unlike PPF however, PPD appears to arise through mechanisms 
entirely independent of both residual presynaptic Ca2+ build up and RRP, instead being driven 
by VGCC inactivation and vesicle endocytosis and replenishment (Fioravante and Regehr, 
2011). This not only shows a reduction in intracellular Ca2+ pools, but also readily releasable 
vesicle pools, both of which contribute to a reduction in presynaptic release probabilities. 
Although PPF has been shown to be greatest at lower IPIs, very short intervals (~10 ms) are 
often still perceived as a depression when compared to the first pulse, as a multitude of 
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components (such as aforementioned post-tetanic potentiation and PPD mechanisms) will all 
contribute to total synaptic activity (Zucker and Regehr, 2002). Although previous whole-cell 
patch clamping of fan cells in the LEC showed DA increases PPF (Liu, 2020) and previous field 
experimentation further showed this (Caruana and Chapman, 2008), a greater analysis using 
both nanomolar and micromolar concentrations of DA will give a better indication into the 
role DA plays in modulating presynaptic release probabilities within the LEC (as is outlined in 
Aim 3, Chapter 1.4). 
As well as IPIs, the duration of application and how many pairs are both significant in 
which variant of plasticity is observed. Both 200 and 900 PPS at 1 Hz were shown to induce 
LTD over 15 minutes, with the latter specifically inducing mGluR mediated LTD (Jo et al., 2010; 
Mulkey and Malenka, 1992). 
 
1.4   Research Aims 
With all this information in mind, analysing not only the role that DA plays on synaptic 
transmission, but also the roles that the aforementioned antagonists play, will be crucial in 
further understanding the physiological functions of the LEC and how these functions may 
change under pathophysiological conditions. This is subsequently the broad aim of this thesis, 
which can be subdivided into three separate, more specific aims in order to assess them: 
Aim 1: To identify the role that tonic application of low concentrations of DA plays on 
 synaptic transmission within the LEC. The role that high concentrations of DA 
 (between 10-1000 μM) play on transmission is well reported (Caruana et al., 
 2006; Harvey et al., 2021), however the role that nanomolar concentrations 
 play has yet been previously tested. This will be done by measuring field 
 excitatory postsynaptic potential (fEPSP) amplitudes during tonic applications 
 of low concentration DA (1-1000 nM) and comparing them comparing against 
 high concentration experiments.  
Aim 2: To explore the roles that both D1, D2 receptors and NMDA receptors play 
 on synaptic transmission within the LEC. This will be completed through a 
 pharmacological approach, using receptor antagonists to inhibit specific 
 receptors in order to suggest their roles under physiological conditions. The 
 antagonists to be used are: SCH-23390 (a D1-like receptor antagonist); 
 sulpiride (a D2-receptor antagonist); (2R)-Amino-5-Phosphonopentanoate 
 (AP5, an NMDAR antagonist) and Barbadin (a β-arrestin antagonist). Although 
 both SCH-23390 and sulpiride have been reported previously within the LEC, 
 the antagonistic role of AP5 and Barbadin are yet to be identified in the LEC 
 (the latter of which is yet to be tested in electrophysiology at the time of 
 writing). 
Aim 3: To investigate the role that tonic application of DA may play in altering 
 presynaptic neurotransmitter release probabilities. This will further develop 
 understanding into whether DA interacts with glutamatergic neurones at their 
 presynaptic terminus, as most reports show its effect on the postsynaptic 
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 region (Nakano et al., 2010; Tritsch and Sabatini, 2012). This will be assessed 
 by delivering paired-pulsed stimulations at ranging IPIs (between 10-1000 ms), 
 in the presence of both low (100 nM) and high concentrations (100-μM) of DA. 
 Although paired-pulses have been delivered to the LEC previously (Caruana et 




2   Methods 
2.1   Slice Preparation 
Juvenile Sprague-Dawley rats (aged 14 to 21 days) were euthanised (through means of 
cervical dislocation) before being decapitated and their brains quickly removed and 
submerged in cold (~4°C), sucrose rich cutting solution saturated with 95% O2 and 5% CO2 
containing (in mM): 234.00 Sucrose; 26.00 NaHCO3; 10.00 D-Glucose; 2.00 KCl; 1.43 NaH2PO4; 
3.00 MgCl(aq); 1.00 CaCl(aq). The cerebellum and the frontal lobes were removed, including a 
section along the dorsal extent of the cortex. The brain was then flipped upside down on to 
the exposed region and was separated into the two hemispheres by means of a cut down the 
longitudinal fissure. Both hemispheres were then subsequently mounted adjacent to a block 
of sylgard and fixed to the cutting plate. Horizontal slices (340 μM thick) were prepared using 
a vibratome (VT1000S, Leica Biosystems, UK) before being transferred to a holding chamber 
containing ~31°C artificial cerebrospinal fluid (ACSF) saturated with 95% O2 and 5% CO2 
containing (in mM): 124.00 NaCl; 26.00 NaHCO3; 17.00 D-Glucose; 2.50 KCl; 1.43 NaH2PO4; 
2.00 MgCl(aq); 2.00 CaCl(aq). All chemicals (including chemicals used in the preparation of 
cutting solution) were obtained from Sigma Aldrich, Montana, USA. These slices were then 
left incubated in a heated (controlled using a StableTemp Ceramic Top Hot Plate (Cole-
Parmer, Illinois, USA)) and oxygenated holding chamber for 1 hour. 
 
2.2   Stimulation and Recording 
Slices were then transferred to and submerged in a slice chamber where ~31°C oxygenated 
ACSF was delivered to the chamber by a peristaltic pump through a negative pressure 
reservoir at a flow rate of 1.6 ml min-1. Field responses were then produced using stimulating 
bipolar tungsten electrodes and were then recorded using a pulled glass capillary (pulled using 
a two-stage pipette puller (Digitimer, UK)) filled with ACSF, attached to a chloride coated silver 
wire on an amplifier headstage (NPI electronics, Germany). A dissecting microscope and a 
stereotaxic atlas were then used to best identify the borders of layers I-II of the LEC to allow 
the accurate placement of the electrodes. The stimulating electrodes were then placed along 
layers I-II and the recording electrode was then placed caudal to the stimulating electrodes in 
layers I-III (as depicted in Figure 11A). Once inserted, the stimulating electrode delivered a 1 
ms pulse through a DS3 isolated constant current stimulator (Digitimer, UK) with a fixed 
current between 25-200 μA at 0.05 Hz. Both the timing of each stimulation and each 
unfiltered evoked response, recorded over 100 ms, was then digitised at 20 kHz and displayed 
using software (WinLTP, Ltd. WinLTP v2.20, Bristol, UK). The peak amplitude (pkAmp) of these 
responses, measured as the difference between the resting voltage and the lowest point on 
the sweep between 2 and 10 ms post stimulation, was then plotted on a pkAmp-time graph. 
If a response contained population spikes (evoked responses which indicate an electrodes 
close proximity to neuronal cell bodies), either the polarity of the stimulation was reversed 
or the electrodes were repositioned to eliminate these spikes. Once a stable 30-minute 
baseline (defined as a constant pkAmp which showed no deviation) was achieved, then 
subsequent experiments were carried out. 
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Figure 11 - Positions of Electrode Placement During Experiments and a Compartmentalised Waveform. The stimulating 
electrodes shown in Figure 11A (left, red) were placed rostral to the recording electrodes (right, black) in each slice. The 
slices shown were the three most ventral segments of the LEC which shows the largest proportions of the LEC. Figure 11B 
shows an example waveform, the one depicted being taken from an untampered control experiment. The waveform itself is 
subdivided into three subsections, the electrical stimulation artefact (1), the fiber volley (2) and the peak fEPSP amplitude 
(3).  
 
2.3   Field Experiments 
2.3.1   Dopamine Application 
Pharmacological experiments were started only once evoked field responses were stable for 
a minimum of 30 minutes. Then, ACSF containing various concentrations (ranging from 1 nM 
to 1000 µM) of dopamine hydrochloride (Sigma Aldrich, Montana, USA) was washed onto the 
slice for 30 minutes. 50 µM sodium metabisulfite (Sigma Aldrich, Montana, USA) was also 
added to the ACSF and the room was also darkened, both of which were precautions taken 
to slow DA oxidation. In the instances where additional pharmacological treatments were also 
applied as well as DA, the chemical alone was washed onto the slice for an additional 30 
minutes prior to their coapplication with DA. The chemicals included: 50 µM AP5 (Hello Bio, 
Bristol, UK); 100 µM Barbadin (Axon Medchem, Groningen, Netherlands); 10 µM SCH-23390 
(Sigma Aldrich, Montana, USA) and 50 µM sulpiride (Sigma Aldrich, Montana, USA). As SCH-
23390 is light-sensitive, the room was darkened upon preparation to prevent drug oxidation. 
Chemicals were dissolved in either water (sodium metabisulphite, AP5 and sulpiride) or 
dimethyl sulfoxide (SCH-23390 and Barbadin) and stored at -20C before being dissolved in 
ACSF when used. 
After this 30-minute application period, each chemical was then coapplied with DA for 
a further 30 minutes. After the 30-minute application of DA, ACSF alone was re-washed onto 
the slice for 60 minutes post-DA application as a “washout”. In the instance where 100 nM 
DA was applied twice, DA was again washed onto the slice following the initial washout, 




2.3.2   Paired-Pulse Stimulation 
Similarly to the aforementioned protocol, a 30-minute baseline was first achieved before 
paired-pulse stimulation (PPS) was induced. During this, 6 paired-pulse trains with logarithmic 
IPIs (10, 30, 100, 300 and 1000 ms) were delivered across 2 minutes. After this first PPS train, 
ACSF containing both DA (100 µM or 100 nM) and sodium metabisulfite (50 µM) was then 
washed onto the slice for 10 minutes. Paired-pulse trains with the same IPIs were delivered 
(again at a frequency of 0.05 Hz) for a further two minutes at the end DA application. The 
experiment was then terminated after the PPS group in the presence of DA. Each paired-
pulse, both before DA application and during DA application, were then expressed as a ratio 
(the second sweep : the first sweep) and each ratio was plotted on a logarithmic graph. 
 
2.4   Immunohistochemistry 
Instead of transferring to the holding chamber, slices which were used for 
immunohistochemical staining were transferred to a 24-well plate containing 4% 
paraformaldehyde (PFA, Sigma Aldrich, Montana, USA) in a fume hood and left for 1 hour at 
room temperature. The slices were then washed three times with 0.1 M phosphate buffered 
saline (PBS (Thermo Fischer Scientific, Massachusetts, USA)) at 20-minute intervals. The slices 
were then blocked with PBS containing 10% normal goat serum (NGS, Vector Laboratories, 
California, USA) and 1% Triton® X-100 (Sigma Aldrich, Montana, USA), which was 
subsequently incubated at room temperature for 2 hours whilst being gently shaken on a 
standard analogue shaker (VWR, Pennsylvania, USA). After 2 hours, the slices were then 
incubated in 0.1 M PBS containing 10% NGS, 0.3% Triton® X-100 and diluted primary antibody 
(rabbit anti-TH (Abcam, Cambridge, UK) at 1:1000 dilution) at 4°C for 3 days. The slices were 
then washed with 0.1 M PBS three times at 10-minute intervals. The slices were then 
incubated in 0.1 M PBS containing 10% NGS, 0.3% Triton® X-100 and diluted secondary 
antibody (goat anti-rabbit with Alexa 48 (Thermo Fischer Scientific, Massachusetts, USA) at 
1:500 dilution) at room temperature on a shaker for 3 hours. Controls were tested adjacent 
to samples, with the aforementioned secondary antibody being omitted from wells in the last 
column. The slices were then washed three times with 0.1 M PBS at 20-minute intervals 
before being transferred to a clean, frozen microscope slide. One drop of Vectashield 
containing DAPI (Vector Laboratories, California, USA) was then added to the region 
containing the LEC before a cover slide was placed over the slice. All slices were then 
individually mounted and imaged using a Hamamatsu ORCA-Flash 2.8 Digital Camera 
(Hamamatsu Photonics K.K., Shizuoka, Japan), with images being taken as either a single 
snapshot image or as a Z-stack (multiple superimposed images taken at increments of 1 μm 
through the slice). 
 
2.5   Data Analysis 
The peak fEPSP amplitude, as defined previously, of every 3 sweeps recorded by WinLTP were 
averaged, yielding an average synaptic response for each minute of the experiment. The first 
30 minutes of the experiment were then averaged, with all successive datapoints being 
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expressed as a comparative percentage of this average. This mean data and ±SEM bars were 
then plotted on a time-fEPSP graph. Once plotted, each group was tested for outliers (using 
the ROUT method of outlier identification, where the maximum false discovery rate (Q) = 
1.0%) and whether each group shows normal Gaussian-distribution (using D’Agostino and 
Pearson’s test). Experiments which saw a statistically significant deviation, with an unpaired 
t-test between the point of greatest change and its time matched control yielding P < 0.05, 
were then renormalised. This renormalisation was either to a re-established baseline during 
drug application, or to the final point before DA application if no baseline was re-established. 
Once the parametric nature of the data was identified and necessary datasets were 
renormalised, relevant statistical analysis was performed, including unpaired t-tests (when 
comparing two groups), ANOVAs (when comparing three or more groups) and ANOVAs with 
various post-hoc comparisons (when comparing three or more groups either against a control 
or against one another). Linear regression analysis was also used to statistically compare 
differences in two or more gradients in high concentration DA experiments. In all 
experiments, a threshold of P < 0.05 indicates a statistically reliable difference, with all p-
values below this threshold showing a statistically reliable difference. The data handling and 
subsequent graphical and statistical analysis were all done using Prism (Prism v9.0.0, 






3   Results - Controls and Initial Dopamine Experiments 
3.1   Tyrosine Hydroxylase Immunohistochemistry 
Figure 12 - Tyrosine Hydroxylase Staining Indicates the Presence of Dopaminergic Fibres in the Lateral Entorhinal Cortex. 
Shown is the tyrosine hydroxylase staining of the lateral entorhinal cortex from two separate rats, both of which P = 14. 
Figure 12A shows a single image of the upper region of the slice (where the lateral entorhinal cortex is located in the centre 
of the image) and Figure 12B shows a Z-Stack (where multiple individual images were captured with 1 μM separation along 
the z-axis, before being superimposed upon one another). Both figures show layers I-II of the LEC are rich in dopaminergic 
fibres, the region which all electrophysiological experiments were carried out in. Figure 12A also identifies dopaminergic 
clusters (referred to as islands), which are indicated with white arrows. A measurement scale for both the images is shown 
in the bottom right of the images, 500 μM and 100 μM for 10A and 10B respectively. 
 
There have been numerous papers which look at both the afferent dopaminergic projections 
to the LEC and their physiological role, yet experimental evidence of dopaminergic fibres 
within the region remain somewhat unreported. Immunohistochemical staining for DA fibres 
in the LEC have been examined previously (D. Caruana, personal communication, October 10, 
2018), thus the aim of this experiment was to both support these previous findings and more 
importantly to confirm that these afferent dopaminergic projections exist within the strains 
and age of animals used. The results of the tyrosine hydroxylase (TH) immunohistochemistry 
are shown in Figure 12. Two forms of image capture were used, individual snapshot (Figure 
12A) and a z-stack, capturing multiple individual snapshots 1 μm apart (along the z-axis) 
throughout the slices before being superimposed upon one another (Figure 12B). The 
presence of TH is indicative of the presence of dopaminergic fibres, meaning the LEC both 
receives a substantial afferent projection and also shows the island-like deposits (white 








3.2   Control Experiments 
3.2.1   ACSF Changeover Control 
A majority of electrophysiological 
experiments in the LEC assess the 
changes observed upon the 
introduction of a new stimulus (for 
example the introduction of DA), yet 
no reported experiments have 
looked to assess if the process of 
changing solution affects the results 
in any way. The ACSF changeover 
control (n = 5) experiment was 
subsequently carried out, which 
consisted of changing the ACSF 
source after a 30-minute baseline 
was achieved, before changing back 
to the original ACSF source after 30 
minutes (Figure 13). Throughout 
application, fEPSP depressed by an 
average of 3.419 ±1.644% of 
baseline levels, whereas the control 
experiment showed a 1.830 
±1.567% facilitation of baseline 
levels. This depression however was 
not statistically significantly 
different, [F(2,20) = 2.13, p > 0.05]. 
This was concluded by a 2x3 (group 
x time) way repeated measures 
ANOVA over the three distinct 
subregions. These three subregions 
(the baseline, application of the new 
ACSF and the washout) were all 
averaged across their respective 
whole duration, with the RM ANOVA 
being conducted on those averages. 
Given that the p-value is above the 
predetermined threshold, changing 
the ACSF source alone does not 
induce any significant change in field 
synaptic transmission. 
   





   
   
   
          
                  
               
       
   
                         
  
 
                   
                          





                                    
       
    
          
     
    
Figure 13 - Changing the Source of ACSF Showed No Significant Change 
in Synaptic Responses. Amplitudes were averaged over every minute and 
expressed as a percentage of the baseline levels for this and all successive 
figures. (A) Averaged fEPSPs before, during and after changing the source 
of ACSF. (A
1
) Example traces that were taken at three different time 
points show no change in amplitude throughout the experiment. The 
numbered traces are taken from specific time points throughout the 
experiment, corresponding with the numbers shown in A2. Stimulus 
artefacts were partially removed at the bottom. (A
2
) ACSF changeover 
control experiment superimposed on an untampered control. The ACSF 
changeover experiment shows a slight diminishment in synaptic response 
at approximately +7 min which persists throughout the changeover but 
returns swiftly after the second change in ACSF source. (B) A histogram 
showing the 2x3 RM ANOVA comparing different time points in the 
experiment (corresponding to the sweeps in A1 and their time matched 
controls). Error bars show ±SEM of the group mean. 
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3.2.2   Sodium Metabisulfite Vehicle Control 
Unlike the ACSF changeover control, 
this control, isolated application of 
the antioxidant vehicle (in these 
experiments sodium metabisulfite) 
is often reported alongside DA 
experiments as a control, in all cases 
showing no statistically significant 
difference upon application. The 
sodium metabisulfite vehicle 
control (n = 5) consisted of a 30-
minute isolated application of 50μM 
Na2S2O5 in ACSF (Figure 14). 
Application of sodium metabisulfite 
showed a small depression 
throughout its application, 
depressing by an average of 2.223 
±3.065% of baseline levels, whereas 
the control showed a 1.830% 
±1.567% facilitation of baseline 
levels during this time. This 
depression however was not 
statistically significantly different, 
[F(2,18) = 1.05, p > 0.05], as was 
confirmed by a 2x3 (group x time) 
way repeated measures ANOVA. As 
with the previous RM ANOVA, the 
experiment was divided into its 
three subsections (baseline, vehicle 
application and washout), each 
being averaged before a RM ANOVA 
was conducted on these averages. 
As the obtained p-value is 
significantly greater than the 
predetermined threshold value of 
0.05, application of the antioxidant 
vehicle elicits no significant changes 
in synaptic transmission, supporting 
previously reported experiments. 
 
 





   
   
   
          
                         
                   
       
                             
  
   
                   
   
 
                      





                                    
       
      
             
     
   
Figure 14 - Isolated Application of Sodium Metabisulfite Showed No 
Significant Change in Synaptic Responses. (A) Averaged fEPSPs before, 
during and after changing the addition of sodium metabisulfite (A1) 
Example traces that were taken at three different time points show no 
change in amplitude throughout the experiment. The numbered traces 
are taken from specific time points throughout the experiment, 
corresponding with the numbers shown in A2. Stimulus artefacts were 
partially removed at the bottom. (A2) Sodium metabisulfite control 
experiment superimposed on an untampered control. The sodium 
metabisulfite experiment shows a slight depression upon application 
(black bar) but returns to baseline levels swiftly during washout (B) A 
histogram showing the 2x3 RM ANOVA comparing different time points 
in the experiment (corresponding to the sweeps in A1 and their time 
matched controls). Error bars show ±SEM of the group mean. 
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3.3   Dopamine Applications at Low Concentrations 
3.3.1   Single Application 
Previous field experiments assessing tonic application of DA within the LEC have all looked at 
tonic application of DA at micromolar concentrations (Caruana et al., 2006; Harvey et al., 
2021). However, it may be possible that DA within LEC exists physiologically at much lower 
concentrations, thus it may be possible that analysis of nanomolar concentrations of DA may 
provide a more of an understanding of the physiological role of DA. Subsequently, multiple 
nanomolar concentrations of DA (1 nM, 10 nM, 100 nM and 300 nM, all of which n = 8) were 
individually washed onto the slice, each for a 30-minute duration once a baseline was 
achieved (as is identified by the black bars in each graph in Figure 15). The experiments were 
superimposed (Figure 15E), then divided into two distinct subregions, DA application (Figure 
15F1) and the final 15 minutes of the washout (Figure 15G1). 
 Peak analysis during DA application, would show whether or not DA application had 
any immediate or direct effect on synaptic transmission. At their peak changes in fEPSP, 
application of 1 nM and 10 nM showed a depression of baseline levels, depressing to 94.33% 
±3.564% and 91.20% ±3.700% respectively. Application of 100 nM and 300 nM however 
produced a facilitative response at their peak change in fEPSP, facilitating to 109.2% ±4.297% 
and 105.8% ±5.361% of baseline levels respectively. Of these applications however, only 10 
nM showed a statistically reliable significance compared to its time matched control, p = 
0.0200 at t = +28 minutes. All other applications were not statistically significantly different 
from their time matched controls (1 nM (p = 0.2284); 100 nM (p = 0.3450); 300 nM (p = 
0.8518)), each of which was shown using individual t-tests. Despite this insignificance, each 
test was statistically reliably different to one another, [F(4,33) = 3.76, p < 0.05] and [F(3,28) = 4.30, 
p < 0.05; see Table 2A] respectively, as concluded with a one-way ANOVA between all 
residuals. 
 Analysis of the peaks in the second region, the final 15 minutes of the experiment, 
may indicate if application of nanomolar DA elicited any indirect, long-lasting changes in LEC 
synaptic transmission. Unlike the bidirectional affect seen during DA application, all 
concentrations of DA produced a facilitative response during their washout. The largest of 
these facilitations, 1 nM, facilitated to 121.2% ±8.116% of baseline levels. The next largest 
facilitation was 100 nM DA application, which facilitated to 114.8% ±4.224% of baseline levels. 
This was followed by 300 nM, facilitating to 110.7% ±4.034% of baseline levels, with 1 nM 
facilitating the least, facilitating to 108.2% ±6.457% of baseline levels. These facilitations 
however were not statistically reliably significant either in the presence or absence of the 
control, [F(4,33) = 1.51, p > 0.05] and [F(3,28) = 0.91, p > 0.05; see Table 2B] respectively, with 
neither of the experiments passing the threshold in either one-way ANOVA. The peak change 
in fEPSP during 100 nM DA application was however statistically reliably significant from its 
time matched control (p = 0.0426, t = 76 minutes) whereas no other concentration showed 
this significance through individual t-tests between peaks and their time matched controls (1 
nM yielded p = 0.0813; 10 nM yielded p = 0.3450 and 300 nM yielded p = 0.0813). 
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Figure 15 - Application of Low Concentration 
Dopamine Elicits a Concentration Dependent 
Effect During Tonic Application and a 
Facilitative Effect After Removal. (A-D) 
Averaged fEPSPs before, during and after the 
addition of low concentration dopamine 
(abbreviated to DA when reporting traces in A1-
D1). (A1-D1) Changes in sweep sizes taken at 
aforementioned time points (also 
corresponding with the numbers shown in A2-
D2 respectively) match the changes shown by 
their accompanying graphs. Electrical 
stimulation artefacts were partially removed at 
the bottom in order to enhance the key aspects 
of the waveform. (A2-D2) Low concentration DA 
experiments superimposed on a control 
experiment. (A2) DA application shows an initial 
depression upon application, recovering to 
baseline levels prior to DA removal. Once 
removed the amplitude then begins to facilitate 
and remains facilitated until the end. (B2) DA 
application causes a gradual decrease in fEPSP 
amplitude throughout application, before 
quickly recovering to baseline levels upon 
removal. (C2 and D2) Both show a mild 
facilitative effect upon DA application, which 
both recover to baseline levels prior to DA 
removal. Both also show a facilitation upon DA 
removal, with C2 showing larger facilitations in 
both instances than D2. (E) All low 
concentration DA experiments superimposed 
upon one another. (F1) Superimposed low 
concentration DA experiments shortened to 
show only the region during which DA is applied 
(t = 0-30 minutes). (F2) A histogram comparing 
peak fEPSP facilitations of all low concentration 
DA experiments with one another (as is also 
shown in Table 2A) and the control. 
Experiments which fall below the zero line (1 
nM and 10 nM) show a depressive response, 
whereas all other experiments show a 
facilitative response. (G1) Superimposed low 
concentration experiments are this time 
shortened to show only the final 15 minutes of 
the washout (t = 75-90 minutes). (G2) A 
histogram comparing peak fEPSP facilitations of 
all low concentration DA experiments with one 
another (as is also shown in Table 2B) and the 
control. Error bars show ±SEM of the group 
mean. Asterisks (*) indicate statistically reliable 
differences between two groups. 
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Table 2 - Post Hoc Comparisons Between Low Concentration Dopamine Applications Shows No Statistically Significant 
Difference Between Any Experiment. Post hoc analysis (Dunn’s multiple comparisons test) between low concentration 
experiments of DA, showing their mean rank difference, their significance and their adjusted p-value. (A) Post hoc 
comparisons test during low concentration DA application (t = 0-30 minutes, Figure 15F). (B) Post hoc comparisons test for 
the final 15 minutes of the experiment (t = 75-90 minutes, Figure 15G). In both these multiple comparison tests, no 

















3.3.2   Repeated 100 nM Dopamine Application 
As 100 nM DA application was the only nanomolar concentration tested that showed a 
statistically significant facilitation during its washout, a successive application of 100 nM DA 
was tested to identify if the observed facilitation during washout possessed additive 
properties. Previous experiments assessing double applications of DA showed that, at 
micromolar concentrations, the second application of DA showed a substantially reduced 
effect on fEPSP (Harvey et al., 2021). This however was only tested on micromolar 
concentrations of DA, so the effect that nanomolar concentrations of DA may exhibit was yet 
to be observed. Subsequently, 100 nM DA was applied twice (n = 8), initially between 0 and 
30 minutes and secondly between 90 and 120 minutes (Figure 16). Upon initial application, 
fEPSP showed an average facilitation of  5.251% ±2.752% of baseline levels, showing a greater 
facilitation during its second application, facilitating by an average of 7.456% ±8.010% of 
baseline levels (Figure 16B1). As previous analysis showed that the facilitation during the 
application of DA was not statistically reliably significant, the peaks during DA application was 
not assessed again. Instead, the changes in baseline levels over time was measured, which 
was not shown to be statistically significant, [F(4,48) = 0.55, p > 0.05]. This was measured using 
a 2x5 (group x time) way repeated measures ANOVA, with timepoints taken from the peak in: 
in the baseline (1); during the first DA application (2); during the first washout (3); during the 
second DA application (4) and during the second washout (5), all of which correspond to the 
numbers shown in Figure 16A2. This therefore shows that although both washouts showed 
facilitation, it is very likely that the observed facilitative effect during washout is not additive. 
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Figure 16 – Sequential 
Application of 100 nM 
Dopamine Shows No 
Statistically Significant Changes 
During Either Application. (A) 
Averaged fEPSPs taken before 
any DA, during the first 
application of DA, between the 
two DA applications, during the 
second DA application and after 
the last DA application. These 
time points taken correspond to 
the numbers shown below in A2. 
(A1) Example traces taken from 
the aforementioned time points 
throughout the experiment 
show a gradual increase in the 
amplitude of the sweeps 
throughout the experiment. 
There is minimal increase 
however between the final two 
traces, which corresponds to 
the changes shown below in A2. 
Abbreviations shown are BL 
(Baseline); DA (dopamine 
application) and wash 
(washout). Electrical 
stimulation artefacts were 
partially removed at the bottom 
as this highlights the biological 
components of the waveform 
clearer. (A2) Double 100 nM DA 
application experiment 
superimposed upon an 
untampered control. The DA 
experiment shows facilitations 
during both DA applications 
(black bars) as well as during 
both washouts, but all of these 
facilitations are only temporary, 
returning back to baseline levels 
before the end of the respective 
time points (asides from 
washout 2). (B1) Both periods of 
DA application superimposed 
upon one another against the 
untampered control. (B2) A 
histogram showing the 2x5 RM 
ANOVA comparing different 
time points (corresponding to 
both the sweeps in A1 and the 
numbers in A2). Error bars show 
±SEM of the group mean.  
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4   Results - Pharmacological Analysis of Cell Types Present Within the LEC 
4.1   P  r      g     A   y     f A   g       w    100 μM        e 
As 100 μM application of DA regularly provides not only a statistically significant response, 
but also one that is repeatable and thus reliable (Harvey et al., 2021), the following 
experiments looked at coapplying 100 μM DA with various receptor inhibitors to observe the 
roles the targets play in transmission. Comparing changes in fEPSP amplitude between 
antagonist experiments and isolated 100 μM DA application experiments may subsequently 
give an indication into the role each targeted biomolecule plays in synaptic transmission, thus 
will provide evidence for their physiological role. 
 
4.1.1   AP5 and Dopamine 
The first of the targeted receptors, NMDARs, are one of the primary receptor types on 
excitatory glutamatergic neurones. Although glutamate is heavily implicated throughout the 
LEC, experiments blocking glutamatergic neurones may provide a better understanding of its 
physiological role and the role it plays in conjunction with DA.  
The NMDAR antagonist AP5 (50 μM, n = 8) was initially applied by itself once a 30-
minute baseline was achieved, before being coapplied with 100 μM DA for a further 30 
minutes (Figure 17). As Figure 17A2 shows a reduction in amplitude upon AP5 application, the 
experiment was renormalised to t = +10 minutes, as highlighted in Figure 17B. In these 
experiments, application of 100 μM DA alone showed a depression to 52.80% ±2.858% of 
baseline levels, whereas coapplication of 100 μM DA and AP5 showed a greater depression, 
depressing to 38.17% ±3.783% of baseline levels. These peak depressions observed were 
tested against their time matched controls, showing a statistically reliable significance 
between all four residuals, [F(2,14) = 128.4, p < 0.05]. Post hoc modifications on the one-way 
ANOVA compared the ranks of the three groups (the control, 100 μM DA as well as 100 μM 
DA and AP5 applications) showed that all three groups were statistically reliably different 
from each other (p < 0.05), as is reported in Table 3. This further diminishment in fEPSP upon 
NMDAR antagonist application indicates that not only are measured fEPSPs glutamatergic, 
but also that DA can directly affect these glutamatergic transmissions, presumably by forming 
synapses directly onto postsynaptic glutamatergic neurones.  
 
 
Table 3 - Coapplying Dopamine and AP5 Elicits a Statistically Significant Depression in Synaptic Transmission When 
Compared With Both Dopamine Application and the Untampered Control. Post hoc analysis (Dunnett’s T3 multiple 
comparisons test) between 100 μM DA, 100 μM DA with AP5 and the control. All experiments showed a statistically reliable 
difference from one another. 
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Figure 17 - Coapplication of the 
NMDAR Antagonist AP5 and a High 
Concentration of Dopamine Yields a 
Greater Depression than Dopamine 
on Its Own. (A) Averaged fEPSPs 
during the baseline, during AP5 
application, during AP5 and DA 
application and during the washout. 
(A1) Example traces that were taken at 
4 separate time points throughout the 
experiment (time points which 
correspond to the numbers shown in 
A2) show a minimal depression upon 
AP5 application (2), a significant 
depression upon DA application (3) 
and an approximate return to baseline 
levels once both chemicals were 
washed off (4). Electrical stimulation 
artefacts were partially removed at 
the bottom in all waveform images. 
(A2) Superimposed 100 μM DA with 50 
μM AP5 on an untampered control. 
This graph also shows a small 
depression upon AP5 application 
(lower black bar) and a greater 
depression upon AP5 DA coapplication 
(both upper and lower black bars). This 
depression then gradually returns to 
baseline levels before plateauing at 
approximately 90% after 90 minutes. 
(B) As AP5 addition was shown to 
significantly depress fEPSP amplitudes 
(p = 0.0376, see main text), the data 
was renormalised to t = +10 minutes. 
This renormalised data was then 
superimposed on two control 
experiments, 100 μM DA and the 
untampered control. (C) The dataset 
was shortened to show only the region 
in which DA and AP5 are coapplied (t = 
30-60 minutes). (C1) Data was 
renormalised to t = 0, before all 
aforementioned datasets were 
superimposed upon one another. (C2) 
A histogram comparing the peak fEPSP 
depressions during DA and AP5 
coapplication. Error bars show ±SEM 
of the group mean. Asterisks (*) 
indicate statistically reliable 
differences between two groups. 
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4.1.2   SCH-23390, Sulpiride and Dopamine  
Previous papers have shown that a high concentration of DA plays a predominantly 
depressive role within the LEC, however coapplication with the D1-like receptor antagonist 
(SCH-23390) and the D2-like receptor antagonist (sulpiride) with DA significantly reduces the 
depressive effect that DA plays on synaptic transmission (Caruana et al., 2006). These 
experiments aimed to not only replicate the results shown previously, but also for a 
comparison between the two to be made.  
The D1-like receptor antagonist SCH-23390 (10 μM, n = 8) and the D2-like receptor 
antagonist sulpiride (50 μM, n = 8), as well as the coapplication of both the antagonists (n = 
8) were initially applied for 30 minutes once a 30-minute baseline was achieved. Each isolated 
drug application, as well as their coapplication, yielded a significant reduction on fEPSP 
amplitude, so all three datasets were subsequently renormalised (Figure 18D). These 
experiments, as well as isolated DA application and an untampered control, were 
superimposed and then broken down into two different subsections, initial onset of DA-
mediated fEPSP depression (the initial 10 minutes of DA application, Figure 18E) and the 
entirety of the 30-minute DA application period (Figure 18F). The 30-minute DA application 
was then subdivided into two further subsections, the peak fEPSP depression (Figure 18F2) 
and the final 18 minutes of DA application (Figure 18F3). 
 Analysis of the first of these subregions (initial onset of DA-mediated fEPSP 
depression) using linear regression analysis would indicate any changes in the rate at which 
DA reaches its maximum observed effect, the shallower the slope the longer DA takes to elicit 
its maximum affect. This initial 10 minutes was further constricted to minutes 3-8, before a 
straight line of best fit for each experiment was generated (Figure 18E). Each experimental 
line of best fit showed a statistical significance from zero (as is shown by the key in Figure 
18E1), showing that each experimental condition elicited a significant effect on postsynaptic 
responses. Comparison between each gradient showed that experiments using DA 
antagonists were statistically reliably different to experiments without antagonists, but they 
were not significant between themselves. This was shown using a simple linear regression 
analysis, which compared each experiment by assessing the SEM of the gradient and its 
degrees of freedom. This therefore shows that application of DA antagonists suppresses the 
cellular mechanisms underpinning DA-induced fEPSP depression, resulting in DA taking 
significantly longer for it to exhibit its maximum affect. These results do however suggest that 
this rate is neither D1-like nor D2-like receptor-mediated, as there was no statistically reliable 
difference between any of the antagonist application experiments. 
 The second of these subregions, peak fEPSP depression by DA, was shown to be 
statistically significant in all instances where 100 μM DA was applied to the slice. SCH-23390 
application depressed responses to 67.55% ±3.104% of baseline levels, sulpiride application 
depressed responses to 67.54% ±3.527% of baseline levels and their coapplication depressed 
responses to 64.56% ±3.190% of baseline levels. Although coapplication of SCH-23390 and 
sulpiride appeared to show a slightly greater depression in fEPSP amplitude, the three groups 
were not statistically significant from one another, [F(2,21) = 0.2755, p > 0.05], as was indicated 
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using a one-way ANOVA. All three of these observed changes in responses did however show 
a smaller reduction in amplitude compared to isolated 100 μM DA application, which showed 
a depression to 48.69% ±2.171% of baseline levels at its peak effect. Statistical analysis 
between DA application with and without antagonists confirmed this observation, as the p-
value was below the threshold, [F(4,27) = 33.17, p < 0.05], as shown using a one-way ANOVA 
with post hoc comparisons (Table 4) and reported graphically in Figure 18F2. As DA antagonist 
application showed statistically reliable differences from both the control and 100 μM DA 
application, the DA-mediated response was not entirely blocked but instead was significantly 
reduced. However, similarly to the results shown in the previous paragraph, these results 
suggest that effect is neither D1-like nor D2-like receptor-mediated, as there was no 
statistically reliable significance between any of the DA antagonist application experiments 
(as concluded in the post hoc analysis). 
 Lastly, gradient analysis of each experimental condition after DA had exerted its 
maximum effect on fEPSP amplitude (in these experiments this was defined as the final 18 
minutes) may indicate the different roles each DA receptor may play in DA desensitisation, 
potentially suggesting one receptor may lose its sensitivity to DA faster than the other. The 
gradient of each experiment was then tested against zero, which concluded that experiments 
which contained SCH-23390 were not statistically non-zero, with its isolated application and 
its coapplication with sulpiride yielding [F(1,150) = 0.75, p > 0.05] and [F(1,150) = 0.21, p > 0.05] 
respectively. These results were shown through a linear regression analysis, similar to that 
shown two paragraphs ago, which also showed that all three other experiments were 
statistically reliably non-zero (p = 0.0053 and p = 0.0173 for isolated DA application and the 
coapplication of DA and sulpiride respectively). Although experiments in which SCH-23390 
was applied was not shown to be statistically significant from zero, the gradients (as well as 
the standard error of the slope) of each experiment are not statistically significant from one 
another, [F(4,4) = 1.104, p > 0.05], as was shown by the one-way ANOVA with post hoc 
modifications shown in Table 5. These results therefore indicate that SCH-23390 may in fact 
block DA desensitisation during application as neither experiment that applied the D1-like 
antagonist showed a statistically significant difference from zero. However, as the one-way 
ANOVA shows that there is no statistical significance between the slopes of each experimental 
condition, it may be the case that addition of D1-like and D2-like receptor antagonists shows 
no change in DA desensitisation, however this test showed a reduced statistical power 











Figure 18 - Application of the D1-Like Receptor 
Antagonist SCH-23390, the D2-Like Receptor 
Antagonist Sulpiride and Their Coapplication 
Significantly Reduces Both the Onset and the Peak 
of 100 μM Dopamine-Mediated fEPSP Depression, 
but Only SCH-23390 Showed Some Effect on 
Dopamine Desensitisation. (A-C) Averaged fEPSPs 
during the baseline, during DA antagonist 
application, during DA antagonist and DA 
coapplication and during the washout. (A1-C1) 
Example traces taken from highlighted time points 
across the experiment (corresponding to the 
numbers shown in A2-C2) match the changes shown 
by their accompanying graphs, showing little 
change when the DA antagonist is added (2), a large 
change when DA is added (3) and returning to 
baseline levels (4). Electrical stimulation artefacts 
were partially removed at the bottom as this is the 
non-biological component to the waveform. (A2-C2) 
All experiments show respective DA antagonist 
experiments superimposed upon an untampered 
control. (D) As all DA antagonist experiments 
showed statistically significant changes upon 
application when compared to their time matched 
controls (see main text), all experiments were 
renormalised to t = 0, which was subsequently 
superimposed upon the untampered control. (E) 
The dataset was shortened to show only the initial 
10 minutes of DA application, highlighting the onset 
of DA-mediated depression. (E1) Data was 
renormalised to the first point (t = +1 minute) and a 
straight line of best fit was plotted through minutes 
+3-8 for each experiment. The gradient of each line, 
as well as each lines comparison against zero, is 
shown in the key. (E2) A histogram comparing the 
gradients shown in E1. (F) The dataset was 
shortened to show only the region in which DA 
antagonists and 100 μM DA are coapplied together 
(t = 0-30 minutes). (F1) Data was again 
renormalised, this time again to the time point t = 
+1 minute, before a straight line of best fit is then 
plotted through points between +12-30 minutes for 
each experiment. The gradient of each line, as well 
as each lines comparison against zero, is shown in 
the key. (F2 and F3) Histograms showing 
comparisons between peak fEPSP facilitation during 
DA application and the gradients of the lines of best 
fit produced in F1. Error bars show ±SEM of the 
group mean. Asterisks (*) indicate statistically 
reliable differences between two groups and “ns” is 
used to identify groups which are not statistically 
significant from one another. 
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Table 4 - Coapplication of Dopamine Antagonists With Dopamine Shows a Statistically Significant Difference From the 
Control and Dopamine Application, However No Statistically Significant Difference is Shown Between Antagonists. Post 
hoc analysis (Dunnett’s T3 multiple comparisons test) between 100 μM DA, 100 μM DA with SCH-23390, 100 μM DA with 
sulpiride, 100 μM DA with both SCH-23390 and sulpiride and the control. The results show a range of comparisons are not 















Table 5 - There is No Statistically Significant Difference Between Gradients in Any Dataset Following Dopamine Exerting 
its Maximum Effect on Synaptic Transmission. Post hoc analysis (Dunnett’s T3 multiple comparisons test) between 100 μM 
DA, 100 μM DA with SCH-23390, 100 μM DA with sulpiride, 100 μM DA with both SCH-23390 and sulpiride and the control. 
The summary for all comparisons shows no statistically significant difference between any groups (p > 0.05).  
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4.2   P  r      g     A   y     f A   g       w    1000 μM Dopamine 
4.2.1   Barbadin and Dopamine 
The final of the three receptor antagonists, Barbadin, targets the scaffolding protein β-
arrestin. This protein is one of the two scaffolding proteins which allow D2 receptors to elicit 
a G protein like response upon DA receptor activation, as was outlined in Chapter 1.2.2.2. This 
inhibition of D2 receptor activation using Barbadin may therefore sequester the effect that D2 
receptors play in synaptic transmission, without affecting D1-like receptors (as β-arrestin is 
not present in the D1-like receptor cascade reaction). Although 100 μM DA provides a 
significant and reliable response, DA-mediated desensitisation is not always observed. 
Previous experiments using 1000 μM DA however (Harvey et al., 2021) showed 
desensitisation during every experiment, so this concentration was chosen so that the 
potential effect elicited by these antagonists on desensitisation could be observed.  
Barbadin (30 μM, n = 8) was initially applied by itself for 30 minutes once the 30-
minute baseline was achieved, before being coapplied with 1000 μM DA for a further 30 
minutes (Figure 19). Application of Barbadin resulted in a depression in fEPSP amplitude, 
through an unknown mechanism, so the data was renormalised to t = +25 minutes (Figure 
19B). This experiment was, as with previous experiments, broken down into two subsections, 
the first 10 minutes of DA application (to compare peak fEPSP depressions) and the final 20 
minutes of DA application (to compare linear regressions). Application of 1000 μM DA showed 
a substantial depression in amplitude, depressing to 54.81% ±4.975% of baseline levels and 
an even greater depression to 50.23% ±1.537% of baseline levels when coapplied with 
Barbadin. Although addition of Barbadin appeared to enhance the depressive effect, the two 
peak changes in fEPSP were not shown to be statistically significant (p > 0.9999) by a one-way 
ANOVA with post hoc comparisons analysis. This therefore also shows that, under these 
experimental conditions, Barbadin had no statistically significant effect on the maximal 
depression that DA elicits on postsynaptic glutamatergic transmission. 
As well as the peak depression during the first 10 minutes of DA application, the 
gradient in the final 20 minutes was also assessed. Comparing the gradients of isolated DA 
application and coapplication of DA and Barbadin showed that both were statistically non-
zero (p = 0.0008 and p < 0.0001 respectively), however there was no statistically reliable 
difference between the two [F(1,227) = 0.13, p > 0.05]. These results from a linear regression 
analysis, as shown in Figure 19C and 19C2, shows that Barbadin plays no effect on DA 




                                    
    
  





                         
      
   
Figure 19 - Coapplying Barbadin and 1000 μM Dopamine 
Shows No Statistically Reliable Changes in Either Peak 
Depression or Dopamine Desensitisation. (A) Averaged 
fEPSPs taken from the baseline, Barbadin application, 
Barbadin and DA application and the washout. The numbers 
in both A1 and A2, taken at various time points throughout the 
experiment correspond to one another. (A1) Example traces 
taken at different time points throughout the experiment 
match the changes shown in the accompanying graph. 
Addition of Barbadin causes a significant diminishment of 
amplitude (2) which then depresses further upon the 
application of DA (3). Stimulus artefacts were partially 
removed at the bottom. (A2) Superimposed Barbadin with 
1000 μM DA experiment superimposed onto an untampered 
control. The upper black bar indicates the region in which DA 
is applied (t = 30-60 minutes) and the lower black bar indicates 
the region which Barbadin is applied (t = 0-60 minutes). (B) As 
application of 30 μM Barbadin produced a statistically 
significant change in fEPSP amplitude (p < 0.0001, see main 
text), the experiment was renormalised to t = +25 minutes 
and superimposed onto both 1000 μM DA and the 
untampered control. (C) The experiment was shortened to 
show only the DA application period (t = 30-60 minutes). (C1) 
All three experiments are renormalised to the first point (t = 0 
minutes) before a straight line of best fit is plotted through 
points between +10-30 minutes for each experiment, allowing 
sufficient time for DA to have a maximal effect on fEPSP 
amplitude. The gradient of each line, as well as the statistical 
comparison against zero, is shown in the key placed to the 
right of the graph. (C2 and C3) A histogram comparing the 
gradients produced in F1 and the peak depression 
respectively. Error bars show ±SEM of the group mean. 
Asterisks (*) indicate statistically reliable differences between 
two groups. In both histograms, the control is statistically 
significant from all experiments using DA, however these DA 
experiments are not statistically significant from one another. 
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4.2.2   SCH-23390, Sulpiride and Dopamine  
Chapter 4.2.1 showed that DA desensitisation may be mediated through D1-like receptors as 
blockage of β-Arrestin, thus D2-like receptors, showed no change in desensitisation. This 
however contradicts with previous experiments in other parts of the cortex, which show 
desensitisation is through D2-like receptors (Kim et al., 2003; Nimitvilai et al., 2014 as further 
elaborated in Chapter 5.3.2.1.2), so further testing using previously tested antagonists was 
performed to test the reliability and repeatability of the previous outcome. The following 
experiments were therefore designed to assess the role of both SCH-23390 and sulpiride on 
DA desensitisation when coapplied with 1000 μM DA because, as was mentioned in the 
previous paragraph, 1000 μM DA reliably induces DA desensitisation during its application.  
The D1-like antagonist SCH-23390 (10 μM, n = 8) and the D2-like antagonist sulpiride 
(50 μM, n = 8) were again initially applied by themselves for 30 minutes once a 30-minute 
baseline was achieved, before being coapplied with 1000 μM DA for a further 30 minutes 
(Figure 20). Of both these experiments, only sulpiride showed a statistically significant 
depression during its application, so that experiment was renormalised to t = +29 minutes. 
Application of 1000 μM DA appeared to elicit a similar response in each experimental group, 
with SCH-23390 and DA depressing amplitude to 47.32% ±3.586% of baseline levels, sulpiride 
and DA depressing amplitude to 52.19% ±3.683% of baseline levels and 1000 μM alone 
depressing amplitude to 54.81% ±4.975% of baseline levels. Statistical analysis between the 
groups confirmed this, as a one-way ANOVA showed a statistical significance between the 
experimental groups from the untampered control, [F(3,21) = 38.83, p < 0.05], but not between 
themselves [F(2,16) = 0.85, p > 0.05]. This non-significance observed on peak fEPSP during DA 
application, as is shown in Figure 20C2, matches the results shown when Barbadin was 
coapplied with 1000 μM DA, but contradicts with the results shown when the same 
antagonists were coapplied with the lower 100 μM DA (Figures 19 and 18 respectively). This 
suggests that the observed fEPSP depression during 1000 μM DA application acts entirely 
independently to antagonist application, a phenomenon which was not observed at any lower 
concentration. 
The experiment was then shortened to show only region where DA was applied 
(Figure 20D1), with a subsequent linear regression analysis being performed on the final 20 
minutes, ensuring DA had exerted its maximum effect on fEPSP amplitude. This linear 
regression analysis (Figure 20D1) produced lines of best fit for each experiment, with each 
lines gradient and statistical difference from zero both reported in the accompanying key. 
Although all gradients produced in experiments containing DA were statistically non-zero, 
comparisons between each gradient (and their respective SEMs) showed no statistical 
significance between the groups [F(3,4) = 2.40, p > 0.05]. The one-way ANOVA comparing these 
gradients, as well as their SEMs, is shown in Figure 20D2. This statistical insignificance shows 
that despite DA antagonists showing statistically significant changes under lower 
concentrations of DA, higher concentrations of DA in the presence of antagonists elicits no 



























Figure 20 - Neither Application of the D1-Like Receptor Antagonist SCH-23390 or the D2-Like Receptor Antagonist Sulpiride 
With 1000 μM Dopamine Elicit Significant Changes in Peak Depression or Dopamine Desensitisation. (A and B) Averaged 
fEPSPs taken from time points corresponding to the numbers indicated in A2 and B2. (A1 and B1) Example traces taken 
throughout the experiment, during the baseline (1), drug application (2), drug and DA coapplication (3) and washout (4). 
Amplitudes represented by these traces matches the changes shown in the adjacent graph. Electrical stimulation artefacts 
were partially removed at the bottom in order to show the biological components to the waveform clearer. (A2 and B2) 100 
μM DA with 10 μM SCH-23390 (A2) and 50 μM sulpiride (B2) experiments each superimposed on an untampered control. 
Both experiments show similar responses, showing a gradual depression during drug application (lower black bar) before 
rapidly depressing upon DA application (upper black bar) (C1) All DA with DA antagonist experiments were superimposed on 
one another. (C2) A histogram comparing peak fEPSP facilitation during DA application. (D1) The experiment was 
renormalised to the first point (t = 0) and shortened to show just the DA application region (t = 0-30 minutes). A straight line 
of best fit is then plotted through points between +10-30 minutes for each experiment, with the lines gradient and its 
statistical comparison against zero, is shown in the accompanying key. (D2) A histogram comparing the gradients produced 
in D1. Error bars show ±SEM of the group mean.  
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4.3   Paired-Pulse Stimulation Tests 
As mentioned in Chapter 1.3.4, methods for inducing plasticity, PPS across short IPIs 
moderate presynaptic release probabilities in glutamatergic neurones. Previous studies 
showed an optimum facilitation between 20-30 ms IPIs (Schulz et al., 1994), however this 
paper looked at PPS within the hippocampus proper instead of the LEC directly. These 
experiments therefore aim to assess if the LEC posseses similar paired-pulse characteristics 
to the hippocampus, also providing a greater understanding of the role which glutamatergic 
and dopaminergic neurones play within the LEC. 
 
4.3.1   Low Concentration Dopamine (100 nM) 
Once the baseline was achieved, paired-pulses at logarithmic IPIs (10, 30, 100, 300 and 1000 
ms) were delivered prior to DA application. 100 nM DA (n = 6) was then applied for 10 
minutes, allowing sufficient time for DA to elicit its maximal effect, before paired-pulses (at 
the same IPIs as aforementioned) were again delivered to the slices. Pulse two was then 
expressed as a ratio of pulse one, with each paired-pulse being superimposed onto the same 
logarithmic graph (Figure 21). Although 100 nM application of DA previously showed a 
facilitation during application (see Chapter 3.3.1), application of 100 nM after the first PPS 
showed no statistical change in amplitude. Although this may indicate that 100 nM 
application of DA is not facilitative, neither dataset were statistically significant and both had 
changes in their respective parameters. 
 Comparing differences in IPIs before and after DA application was then analysed in 
two separate ways, comparing each IPI before and after DA application together, and 
comparing each IPI against one another. Comparisons between individual IPIs showed no 
identifiable change after DA application when compared to before application. Individual t-
tests confirmed this, as 10 ms (p = 0.9805), 30 ms (p = 0.6991), 100 ms (p = 0.8182), 300 ms 
(p = 0.8182) and 1000 ms (p = 0.1320) were all above the statistical threshold. This therefore 
shows that application of 100 nM DA had no significant effect on the release probability 
within the presynaptic neurone, as none of these paired-pulses intervals showed any change. 
Although IPIs were not statistically significantly different between themselves, IPIs were 
statistically reliably different from one another. This was shown both before DA application 
[F(4,11) = 43.09, p < 0.05] and during DA application [F(4,11) = 53.03, p < 0.05]. As individual IPIs 
before and during DA application were not statistically significantly different from one 
another, they can be treated as similar. Post-hoc modifications of the previously tested one-
way ANOVA between IPIs was then performed in IPIs during DA application. This post-hoc 
comparison showed that only 10 ms was statistically significantly different from all other IPIs, 
showing statistical significance from 30 ms (p = 0.0003), 100 ms (p = 0.0004), 300 ms (p = 
0.0014) and 1000 ms (p = 0.0016). Each of these post hoc comparisons between IPIs during 
DA application are shown in Table 6. This comparison further reinforces the previous 
statement, as the same IPI interval curve is shown both before and during application, thus 
DA showed no statistical changes on IPI ratios at this concentration. 
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Figure 21 - Application of 100 nM Dopamine Produces No Statistically Reliable Changes in Paired-Pulse Ratios. (A) Averaged 
fEPSPs were taken from two timepoints across the experiment, baseline (1) and during DA application (2), time points which 
correspond to the numbers shown in A2. (A1) Example traces from the baseline and during DA application match the changes 
observed throughout the experiment, with DA application showing a minor (yet not significant) change in fEPSP amplitude. 
Electrical stimulation artefacts were partially removed at the bottom to best highlight the biological components of the 
waveform. (A2) 100 nM DA application (black bar) superimposed onto an untampered control, with vertical dotted lines 
(indicated at t = 0 and +10 minutes) indicating the time point which paired-pulses were delivered. (B) Comparisons between 
paired-pulses prior to DA application and during DA application. (B1) Paired-pulse ratios (measured as sweep 1 compared 
against sweep 2) from both before DA application (grey) and during DA application (black) were superimposed upon one 
another on a logarithmic scale.  (B2) Paired-pulse sweeps at noted interpulse intervals (IPI) both before DA and during DA 
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4. .2   H g      e  r             e (100 μM) 
Although 100 nM application showed no statistically significant difference in either its single 
application (Chapter 3.3.1) or in paired-pulse experiments (Chapter 4.3.1), 100 μM DA was 
tested again because of its reliability of yielding a consistently statistically significant response 
(as mentioned and shown throughout Chapter 4.1.2). Similarly to 100 nM DA paired-pulse 
experiments, paired-pulses (at the same logarithmic IPIs as mentioned previously) were 
delivered prior to and during DA application before both ratios (again pulse two to pulse one) 
were superimposed on a logarithmic graph (Figure 22). 100 μM DA (n = 6) was then applied 
for 10 minutes, again allowing sufficient time for DA to exert its maximal effect on fEPSP 
amplitude. This maximal effect, at which a depression in amplitude to 40.66% ±2.529% of 
baseline levels, was shown to be significantly statistically different from the time matched 
control (p < 0.0001), indicating that the concentration of DA was large enough to significantly, 
and reliably, alter fEPSP amplitudes. 
 This experimental group was then analysed through the same parameters as 100 nM 
application PPS was, by assessing IPIs within each experimental group as well as IPIs between 
one another both before and during DA application. Unlike 100 nM PPS however, all IPIs were 
statistically significantly different during DA application compared to before application of 
DA. Confirmed by individual t-tests between each IPI, 10 ms (p = 0.0022), 30 ms (p = 0.0022), 
100 ms (p = 0.0087), 300 ms (p = 0.0325) and 1000 ms (p = 0.0087) all yielded p-values below 
the required threshold (p < 0.05). As each of these IPIs showed statistical significance between 
themselves, comparisons between each other would be tested in both before and during DA 
application datasets. Comparison of IPIs before DA application showed a similar response to 
that observed in 100 nM application, also showing a statistically reliable significance before 
100 μM application [F(4,17) = 71.76, p < 0.05]. In fact, before DA application IPI ratios in both 
100 nM and 100 μM PPS experiments were very similar to one another (p = 0.2222), as shown 
by a t-test between each IPI within the two experiments. Comparing IPIs during DA application 
also showed a statistically reliable difference between ranks also showed statistical 
significance, [F(4,14) = 9.00, p < 0.05], as also confirmed by a one-way ANOVA. The post hoc 
comparisons for this ANOVA, as well as the post hoc comparisons from 100 nM DA PPS, is 
shown in Table 6. This indicates that a high-concentration application of DA plays a significant 
role in affecting presynaptic release probability, as all IPIs assessed here show not only a 














Figure 22 - Application of 100 μM Dopamine Produces Statistically Significant Changes in Paired-Pulse Ratios. (A) Averaged 
fEPSPs were taken from two timepoints across the experiment, baseline (1) and during DA application (2), time points which 
correspond to the numbers shown in A2. (A1) Example traces from the baseline and during DA application match the changes 
observed throughout the experiment, with DA application showing a large (and significant) fEPSP depression. Electrical 
stimulation artefacts were partially removed at the bottom to best show the biological components to the waveform. (A2) 
100 μM DA application (black bar) superimposed onto an untampered control, with vertical dotted lines (indicated at t = 0 
and +10 minutes) indicating the time point which paired-pulses were delivered. (B) Comparisons between paired-pulses prior 
to DA application and during DA application. (B1) Paired-pulse ratios (measured as sweep 1 compared against sweep 2) from 
both before DA application (grey) and during DA application (black) were superimposed upon one another on a logarithmic 
scale. Asterisks (*) indicate statistically reliable differences within IPIs. (B2) Paired-pulse sweeps at noted interpulse intervals 
(IPI) both before DA and during DA superimposed upon one another. Error bars shown in A2 and B1 show ±SEM of the group 
mean. 
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Table 6 – Statistically Significant Differences Between Second Pulses in Paired-Pulse Experiments Differs Between Low 
Concentration (100 nM) and High Concentration (100 μM) Dopamine Application Experiments.  Post hoc analysis (Dunn’s 
multiple comparisons test) between the second pulse during paired-pulse experiments at different interpulse intervals (IPIs) 
compared against one another. Comparisons were made between 10, 30, 100, 300 and 1000 ms IPIs during both 100 nM 
and 100 μM DA application experiments. These results show statistically significantly different comparisons (p < 0.05) and 
comparisons which were not statistically reliably different (p > 0.05). 
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5   Discussion 
As was mentioned in the introduction, the LEC plays a crucial role in the conversion and 
storage of non-spatial memory but the exact mechanisms underlying synaptic plasticity 
mediated by DA, most notably receptor desensitisation to the neurotransmitter, still remains 
somewhat unknown. The experiments performed here, in comparison and conjunction with 
prior experiments completed in this field, aim to further understand these mechanisms. 
 
5.1   Summary of Experimental Findings 
These experimental findings show that previous and subsequent dopaminergic experiments 
are physiologically relevant as the superficial layers I and II of the LEC possess rich pools of 
dopaminergic deposits. Controls assessing changing solutions and vehicle addition (changing 
ACSF or addition of sodium metabisulphite) both showed no statistically significant changes 
in responses. Application of nanomolar concentrations of DA showed a statistically reliable 
depression during application during 10 nM addition, as well as a statistically reliable 
facilitation during 100 nM DA washout. High concentrations of DA not only showed statistical 
difference from the untampered control but coapplication with receptor antagonists also 
allowed subsequent identification of the roles many biomolecules play in the physiological 
functions of the LEC. These antagonist applications showed that NMDA plays a facilitative role 
on transmission in the presence of DA, increasing the size and amplitude of fEPSP responses, 
as antagonist coapplication with DA depresses amplitude greater than DA alone. DA itself 
however plays an entirely depressive role at high concentrations, with DA antagonist 
application diminishing this depression. Application of very high concentrations of DA 
appeared to saturated receptors which prevented antagonists from affecting responses, 
indicating the antagonists used possessed a competitive MOA (as was shown by both DA 
antagonists and Barbadin). Finally, not only does DA affect glutamatergic postsynaptic 
receptors, as seen by the depression during DA application, but paired-pulse experiments 
indicates that DA also affects glutamatergic neurones on the presynapse as well.  
 
5.2   Justification of Methods 
The physiological intercranial temperature of a rat fluctuates between 36.5-38.5C (Briese, 
1998), however slices were placed in a holding chamber and experiments were performed in 
solutions around 31-32C. Studies have shown that electrophysiological recordings at 
physiological temperatures (~37C) can induce spontaneous seizures, which may be in part 
due to neuronal hypoxia, as oxygen may fail to penetrate the slice to reach inner cells. 
Reducing this temperature (to 32C) showed a reduction in the metabolic demand of 
neurones, as well as slowing the kinetics of seizure-generating components, such as K+ ions 
(Morris et al., 2016). Experiments were therefore performed at 32C, as this ensured slices 
would not become epileptic during the experiment. 
Whilst the rat brain was being sliced, sucrose rich cold (4C) cutting solution (also 
referred to as low sodium ACSF or sucrose ACSF) was used during slicing with the brain in the 
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Vibratome. Without this protective solution, an influx of Na+ into the cell would result in an 
osmolarity gradient imbalance, forcing water into the cells, inducing neuronal swelling and 
subsequent cytolysis (Aghajanian and Rasmussen, 1989). The equiosmolar replacement of 
NaCl with sucrose (subsequently reducing this excessive addition of sodium) prevents this 
neuronal swelling, subsequently allowing greater amplitudes to be recorded as more 
neurones survive surgery (Ting et al., 2014). During this procedure, the solution is held at ~4C 
(the conventional cutting temperature) because this both prevents cellular damage and 
hardens the brain for cleaner slices to be made (Ballanyi and Ruangkittisakul, 2008). Although 
slicing at 4C is the conventional temperature and was successful in these experiments, recent 
studies have shown that slicing at physiological temperatures may also be a viable option 
(Huang and Uusisaari, 2013; Ankri et al., 2014). 
 Once slices were cut and placed into the ACSF holding chamber, they were left for 
approximately 1 hour for a “protective recovery” stage. First described in 2003, the protective 
recovery period gradually reintroduces Na+ ions to the slice to ensure the osmolarity gradient 
is maintained, preventing cytolysis (Fiala et al., 2003). Other papers show that 1 hour in a 
protective recovery state is sufficient enough for glycogen granules reappearing in astrocytic 
processing (Fiala et al., 2003), but most importantly is sufficient time for ex vivo synaptic 
recovery (Kirov, Sorra and Harris, 1999; Schurr et al., 1984). 
 As DA is an unstable chemical under certain conditions, numerous precautionary 
measures were taken in order to extend its activity and slow its oxidation. Firstly, addition of 
the antioxidant sodium metabisulfite is itself reduced in the presence of H2O2, a by-product 
formed in the autoxidation of DA in Neuro-2A cells (Pedrosa and Soares-da-Silva, 2002). This 
reduction protects the cell from the cytotoxic product, slowing any potential degradative 
effect that DA plays on the neurone. Applying 50 μM of the antioxidant has previously shown 
to slow DA oxidation whilst showing no statistical changes in fEPSP measurements during its 
isolated application (Yang and Seamans, 1996; Caruana et al., 2006), thus this concentration 
was co-applied with DA in these experiments. Secondly, the room was darkened to stymie 
the rapidly oxidising nature of the catechol group into its quinoid form, with light exposure 
accounting for approximately 20% this oxidative nature (Sánchez-Rivera et al., 2003). 
 During statistical analysis of datasets using one-way ANOVAs, a Tukey test was 
selected when using a multiple comparisons test. Although the power of the significance (p < 
0.05) is significantly reduced during these comparisons, the datasets were not analysed using 
tests that alter this power (such as the Bonferroni or the Šídák corrections (Blakesley et al., 
2009)) due to the size and nature of these experiments. It may there be perceived to be 
beneficial to show type two errors (false negatives) than it may be to show type one errors 
(false positives), as initially accepting the null hypothesis would require further testing to 
disprove, whereas initially rejecting the null hypothesis may lead experimental attention 
elsewhere. Furthermore, datasets which were shown to contain outliers, using the ROUT 
method, were removed to ensure the datasets showed accurate results and were not misled 
by any one experiment. The ROUT method identifies outliers by generating a nonlinear 
regression curve, analysing residuals and removing subsequent outliers (Motulsky and Brown, 
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2006). The parameters were set to the middle of the ROUT scale, Q = 1.0%, to ensure the 
removal of outliers was strict enough to remove datasets that were outliers, but not so strict 
as to remove experiments that may have resulted from a physiological effect. These 
parameters were then applied to each dataset, eight individual experiments being 
subsequently removed, two of which were control experiments and six of which contained 
DA receptor antagonists. The two control experiments (one ACSF changeover and one sodium 
metabisulfite control) were likely caused by inconsistencies in solution preparation, with 
varying temperatures and excessive bubbling likely accounting for the diminishment. The 
remaining six experiments each contained DA receptor antagonists, which highlighted the 
varying effects DA application had on responses. The outliers were removed using method to 
avoid scientific bias, as only experiments which statistically differ from the others are 
removed, rather than ones which best yield a favourable result. 
 
5.3   Analysis of Results 
5.3.1   Controls and Initial Dopamine Experiments 
5.3.1.1   Tyrosine Hydroxylase Immunohistochemistry 
As all successive experiments used DA (asides from control experiments), 
immunohistochemical staining for the enzyme TH would confirm the presence of 
dopaminergic fibres within the region. These results show there is a clear presence of 
dopaminergic fibres within the LEC, also showing some a clear resemblance of clusters of 
richer TH deposits (as previously alluded to in previous TH staining (D. Caruana, person and 
Chapman, 2008)). All control experiments in this dataset were conducted alongside slices, in 
which secondary antibody was omitted, none of which showed these dopaminergic fibres. No 
statistical analysis was performed on these experiments, but a visual comparison between 
samples and the controls showed that DA is evidently present within layers I-III of the LEC, 
thus subsequent DA experiments can be deemed valid. These clusters of dopaminergic cells 
within the LEC may also account for the variation in amplitude between experiments, as 
electrodes placed within these islands may show a greater depression upon DA application 
than electrodes placed outside these islands.  
 
5.3.1.2   Control Experiments 
These control experiments were designed to test if either changing the source of ACSF or 
adding the vehicle would significantly alter the response, as both these changes would be 
used in all successive experiments. Although both experiments showed a small depression, 
neither showed a statistically significant difference, as was concluded by a RM ANOVA. This 
indicates that both control variables have no significant effect on any underlying mechanisms 
in fEPSP induction, with further experimentation likely removing the small diminishment 
observed. It is likely that the small diminishment observed is due to inconsistencies in solution 
preparation methods, specifically fluctuations in temperature or excessive bubbling during 
application, factors which can be attributed to initial inexperience using the 
electrophysiological apparatus. As vehicle addition showed no statistical significance, it is 
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therefore congruent with previous experiments testing the same parameter, which also 
showed that isolated application of sodium metabisulphite showed no statistically significant 
change in amplitude (Caruana and Chapman, 2008). The ACSF changeover experiment 
however cannot be compared against any previous experiments, as although the control will 
have likely been tested in labs, no reports were present within the literature. 
 
5.3.1.3   Single Application of Low Concentration Dopamine 
As most previous experiments looked at the role which high concentration DA plays within 
the LEC, this experimental group was created to identify the role which nanomolar 
concentrations of DA, a potentially more physiologically viable range, may play in affecting 
transmission. Although each nanomolar concentration of DA elicited different responses 
during DA application and during the washout, individual t-tests comparing peak changes in 
fEPSP against their time matched controls showed that 10 nM application of DA elicited a 
statistically significant response. During DA application, the lower nanomolar concentrations 
(1 and 10 nM DA) showed a depression in fEPSP amplitudes, whereas the higher 
concentrations (100 and 300 nM DA) showed facilitation. Although these higher 
concentrations failed to show a statistically reliable significance, they did show that the LEC 
may potentially possess some facilitative properties. Previous experiments which showed this 
facilitation showed that 1-10 μM DA facilitated fEPSP amplitude during application (Caruana 
et al., 2006), however recent experiments testing these same parameters have failed to 
replicate this facilitative response. This lack of replicability could be as a consequence of many 
factors, such as strain and age of the rat, the electrophysiological equipment itself and also 
the experimenter performing the tests. What has been shown, in both these experiments and 
in the aforementioned report, is that application of lower concentrations of DA generates a 
facilitation whereas application of higher concentrations elicits a depression. This facilitation 
may therefore have a physiological component to it, as inhibitory GABAergic MPNs within 
deep layers of the LEC (layers V-VI) can themselves be inhibited by DA (Rosenkranz and 
Johnston, 2006), which may induce a temporary facilitative effect. For this to be confirmed 
however, more testing using these parameters would need to be performed and statistically 
significant results would need to be obtained. 
The amplitude during washout also differs for each experiment, however this shows 
no correlative pattern, with 1 nM DA eliciting the largest rebound (119.6% ±9.148%), followed 
by 100 nM, 10 nM and 300 nM eliciting the smallest rebound (108.5% ±3.600%). Despite there 
being no clear pattern with these rebounds, the rebound observed by 100 nM was shown to 
be statistically significantly different from its time matched control. This therefore means that 
it is very likely that an underlying mechanism causes these facilitations. One mechanism, as 
mentioned in the previous paragraph, could be long term inhibition of deep layer inhibitory 
neurones, which (as inhibition of inhibitory neurones prevents their firing) may lead to an 
increase in activity within the superficial layers. Another mechanism, as further outlined in 
Figure 10, could be that D1-like/D2-like receptor activation (but not saturation) may induce a 
cascade which culminates in temporarily increased AMPAR and NMDAR expression on 
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glutamatergic neurones, increasing excitatory activity through early-phase plasticity 
induction (Sun et al., 2005). This suggests that although underlying mechanisms may 
contribute to the observed effect, more testing, such as elongating experiments after the 60-
minute washout is complete, may provide more information into the results seen. DA induced 
facilitation may also play a key role in memory formation, as increased activity may lead to 
greater sensitivity of the HF when responding to weaker stimuli, meaning a greater amount 
of non-spatial information may be conserved and processed. 
 
5.3.1.4   Repeated Application of Low Concentration Dopamine 
As 100 nM applications of DA produced a statistically significant facilitation during its washout 
(as elaborated in the previous chapter), repeated addition of 100 nM DA may indicate if this 
facilitation is through cellular mechanisms or not. The second application of DA showed a 
similar magnitude of facilitation to the first application, showing a small facilitation upon 
application, rising to 111.4% ±8.219% and 109.1% ±3.787% of baseline levels respectively. 
However, a RM ANOVA showed that neither facilitation during DA application was statistically 
significantly different which, similar to previous experiments using nanomolar DA, concludes 
that although facilitation may be physiological, more testing for a significant result would be 
required before any conclusions can be drawn. 
 Furthermore, these results also cannot be compared against previous experiments, as 
no previous reports in the LEC have looked at nanomolar concentrations of DA, as the lowest 
concentration previously studied was 1 μM (Caruana et al., 2006; Caruana and Chapman, 
2008; Glovaci and Chapman, 2015). Although not in the LEC, one study looked at the tonic 
application of DA in the stomatogastric ganglion, a region of the stomach which contains the 
lateral pyloric neurone, a dopaminergic neurone which expresses only D1-like receptors 
(Rodgers, Krenz and Baro, 2011). This experiment showed that nanomolar concentrations of 
DA can regulate the densities of voltage-gated ion currents through multiple mechanisms, 
one such proposed includes maximum potassium ion channel conductance. This experiment 
looked at dopaminergic neurones in lateral pyloric neurones as opposed to the LEC neurones, 
but it may give some indication into how nanomolar concentrations of DA may affect 
neighbouring neurones through D1-like receptors, a concept which is yet to be brought into 
the HF. 
 
5.3.2   Pharmacological Analysis of Cell Types Present Within the LEC 
5.3.2.1   A   g      A   y    w    100 μM        e 
5.3.2.1.1   AP5 with 100 μM        e 
The allosteric modulator of the NMDAR antagonist, AP5 was used to identify the role which 
glutamatergic neurones play within basal transmission of the LEC and how tonic application 
of 100 μM DA may affect this. The experiment conclusively shows that AP5 application 
significantly changes amplitudes both before and during its coapplication with DA. The 
concentration of 50 μM AP5 was chosen because at this concentration, NMDAR activity is 
reduced to approximately 0% activity in wild type cells when compared to the control (Chen 
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et al., 2015). Initially, AP5 application in isolation significantly depressed fEPSP amplitude, 
with the dataset subsequently being renormalised as a result of this change. This fEPSP has 
been shown in previous experiments which look at the role NMDARs have within the 
hippocampus, as CA1 fEPSPs significantly depress (although substantially more in CA1 than in 
the LEC) upon AP5 application (Kang et al., 2017). This depressive effect is however 
physiologically relevant, as NMDAR inhibition reduces excitatory glutamate efficiency, 
reducing both maximal excitability and measured fEPSP. This reduction in excitability is 
further shown during DA application, as DA and AP5 coapplication is significantly lower than 
DA alone (as shown in Chapter 4.1.1). As NMDARs are found both on the presynaptic and the 
postsynaptic membrane, bath application of AP5 would inhibit NMDAR activity on both 
membranes. This would subsequently reduce both presynaptic and postsynaptic Ca2+ influx, 
diminishing neurotransmitter exocytosis within the presynaptic terminal and sequestering 
postsynaptic cascade events triggered by Ca2+ influx through NMDARs. Despite the 
aforementioned Ca2+ sequestering playing a key role in the formation of LTD (Figure 9), a RM 
ANOVA (2x2) showed no statistically reliable difference between the baseline and the 
washout. Although this indicates that no form of long-term plasticity was induced, the 
experimental parameters were not designed to induce LTP or LTD and AP5 would block any 
NMDAR mediated LTD as NMDAR-LTD is predominantly activity dependent (Lüscher and 
Malenka, 2012). 
 
5.3.2.1.2   Dopamine Antagonists with 100 μM        e 
Similarly to NMDA inhibition, coapplication of both D1-like and D2-like antagonists with DA 
showed statistically significant changes in fEPSP amplitudes. Despite a comprehensive 
pharmacokinetic analysis of AP5 showing a concentration at which it is fully potent, 
definitively categorising these DA antagonists’ pharmacokinetics has posed somewhat of a 
greater challenge. As such, neither the D1-like antagonist (SCH-23390) nor the D2-like 
antagonist (sulpiride) are yet to have their pharmacokinetics fully identified, thus no definitive 
concentration at which 100% of receptors have been saturated has been alluded to previously. 
One previous experiment however showed application of 100 μM DA with 10 μM SCH-23390 
or 50 μM sulpiride both showed a statistically significant result, so these concentrations were 
replicated here (Caruana et al., 2006). Isolated application of both these drugs significantly 
depressed fEPSP amplitude, with each experiment subsequently being renormalised as a 
result of this significance. This result however differs from the aforementioned experiments 
looking at these antagonists, which showed no change in amplitude, despite SCH-23390 being 
used at a higher concentration (50 μM in the previous experiment compared to 10 μM here 
(Caruana et al., 2006)). However, as was mentioned in Chapter 5.3.1.3, as previous aspects of 
that paper also have not been replicated, this change may too be as a result of changes in 
other control variables (age and strain of rat or electrophysiological apparatus to name a 
couple) that these results differed from one another. As the aforementioned paper and this 
report are (as of time of writing) the only two reports testing these experimental conditions, 
the results obtained through this experiment cannot be supported. Furthermore, as 
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coapplication of both SCH-23390 and sulpiride is also yet to be reported elsewhere, the 
results obtained in that experiment also cannot be cross-referenced against any other yet 
published article. 
 The first analysed aspect of the superimposed DA antagonists with DA was the 
gradient during the initial onset of DA-mediated fEPSP suppression. This analysis concluded 
that all experiments which used DA were statistically non-zero and DA antagonists showed a 
statistically reliable difference to isolated DA application. This difference will be due to two 
different factors, peak fEPSP depression and the time taken for DA to exert its maximum 
effect on fEPSP. The former factor, peak fEPSP depression is significant in determining this 
gradient as fEPSP depression in the presence of DA antagonists is significantly less than 
without DA antagonists (thus Δy is less in the presence of DA antagonists). The latter factor is 
significant in determining the gradient as the time taken for maximum dopaminergic effect is 
longer in the presence of DA antagonists (~12 minutes) than in the absence of these 
antagonists (~8 minutes). This delay and suppression of depression of amplitude is due to the 
DA antagonists binding to DA receptors, both of which show partial antagonism to their 
respective receptors at a saturated concentration. Their individual applications show a 
suppression in dopaminergic neurone efficiency, with subsequent action potentials, thus 
postsynaptic glutamate activity, being supressed. Their coapplication also showed little 
difference from individual applications, suggesting that there is no significant change in 
receptor blocking as increasing antagonist concentration showed no significant change in 
depression. Although this DA onset gradient is yet to be tested with these parameters outside 
this experiment, this statistically reliable significance concludes that application of DA 
antagonists dampens the onset gradient. 
 The second analysed aspect of DA antagonist application is the attenuation of the 
affect 100 μM DA elicits on response. In the presence of either (or both) antagonists, fEPSP 
depression is restricted by approximately 15% of baseline levels (25% less depression than DA 
application without the antagonists, which itself showed a 20% depression). In these 
experiments, both DA antagonists display non-competitive binding properties to their 
respective receptors. Primarily, if these antagonists were competitive, each experiment 
would gradually slope towards the 100 μM DA control as the antagonist dissociates from 
receptors due to the high concentration of DA. Secondly, coapplication of both antagonists 
not only still shows DA-mediated depression, but this experiment also shows no statistically 
significant changes from each antagonist individually. This indicates the antagonists are non-
competitive as the effects are not superimposable (where if both antagonists were 
competitive, a significantly smaller depression would be observed as both D1-like and D2-like 
receptors would be occupied). Furthermore, preliminary reports looking at these antagonists 
show that although SCH-23390 shows a high affinity for D1-like receptors and sulpiride shows 
a high affinity for D2-like receptors, both drugs show some interaction with both receptor 
subtypes (Bourne, 2001). Therefore, it may be inferred from this experiment that both 
antagonists bind to their receptive receptors through a non-competitive mechanism whilst 
also showing some binding to the other receptor subtype. 
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 The final analysed aspect of DA antagonist and 100 μM DA complication experiments 
assessed the final 18 minutes of DA application, the period immediately after peak depression 
was observed for each experiment. A one-way ANOVA comparing the slope of each 
experiment showed no statistically significant differences, though linear regression 
comparisons showed that all experiments which used SCH-23390 showed no statistically 
significant difference from zero. As all other experiments which did not include this D1-like 
receptor antagonist were statistically non-zero, it indicates that D1-like receptors may be the 
types of DA receptors which are responsible for dopaminergic desensitisation within the LEC. 
Use of sulpiride supports this as blocking only D2-like receptors (thus only D1-like receptors 
will be present during sulpiride application) shows not only statistical significance from zero, 
but also shows the steepest gradient of all experiments (m = 0.3588). This D1-mediated 
desensitisation is supported within the literature, with Kim et al. reporting the same 
conclusion (Kim et al., 2003). Although this experiment and the aforementioned paper show 
the prominence of D1-like receptors in desensitisation, the general consensus surrounding 
literature states that D2-like receptors are the main DA subtypes which exhibit desensitisation 
(Nimitvilai et al., 2014 and Nimitvilai and Brodie, 2010). Despite this, blocking D1-like 
receptors (using SCH-23390) to isolate D2-like receptors appeared to show no desensitisation, 
as these experiments showed no statistical significance from zero, however this showed no 
statistical significance. However, despite all these experiments showing DA desensitisation, 
most studies were conducted in other regions of the brain (mostly the VTA). This could 
suggest that dopaminergic neurones in the LEC behave differently compared to dopaminergic 
neurones in other regions of the brain, however concluding this would require further, more 
extensive experimentation and repeatable results when compared to other cortical regions. 
 Despite the two receptor antagonists affecting two separate receptors, with limited 
interaction for the other respective receptor (Bourne, 2001), their effects shown through 
these experiments contradicts the information shown in the D1/D2 signalling mediated 
plasticity pathway, Figure 10. This figure indicates that AC activity, activated by D1-like activity 
and inhibited by D2-like activity, resulted in greater AMPAR and NMDAR expression in 
glutamatergic neurones. This modulation of postsynaptic iGluRs may suggest that fEPSPs 
would be different under each antagonist application, with a greater depression likely being 
observed through SCH-23390 application, as inhibiting D1-like receptor activation in turn 
reduces AC levels, thus yielding a greater depression than what would be observed through 
sulpiride application. If this were to be observed, it would be likely that their coapplication 
with lie between the two results, with the AMPAR and NMDAR concentration modulations 
cancelling out one another, however the observed results contradicts this.  
 The conclusion that can be drawn from all these experiments is that at their current 
concentrations, the DA antagonists were unable to fully inhibit the effect of DA on 
transmission. This may be due to the antagonists’ inability to fully inhibit DA activity, hence 
explaining why the pharmacokinetics surrounding the antagonists is somewhat scarce, as 
differentiating between maximal and minimal activity remains challenging. Alternatively, not 
observing a complete inhibition of DA activity may be because the antagonist concentration 
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applied was not large enough, something which a comprehensive concentration-activity 
curve would indicate. This could therefore be an avenue which could have been further 
explored, as observing the percentage decrease in peak fEPSP compared to 100 μM DA 
application without antagonists across ranging concentrations could be used to generate 
concentration-activity curves for both SCH-23390 and sulpiride, subsequently better 
understanding both. 
 
5.3.2.2   Antagonist Analy    w    1000 μM        e 
5.3.2.2.1   Barbadin with 1000 μM        e 
As of completing the Barbadin experiments, the β-arrestin antagonist was a very novel drug, 
only being discovered about a year prior to its use in its experiments (Beautrait et al., 2017). 
At the time of writing, only a handful of papers have previously used Barbadin (Beautrait et 
al., 2017; Aberoumandi et al., 2019; Zhang et al., 2019; Khalid and Chang, 2020; Wang et al., 
2019), none of which have looked at the role that Barbadin plays in fEPSPs, let alone the role 
of Barbadin in the LEC. This therefore meant that not only was the previous experiment the 
first use of Barbadin in the LEC and the HF, but also the first experiment using Barbadin in 
fEPSP research. The disadvantage of this however is that no previous data exists into viable 
concentrations that could be applied during the experiment, which was observed during 100 
μM Barbadin application. Application at this concentration resulted in fEPSP collapse soon 
after its coapplication with DA so the dataset was abandoned. Subsequently, 30 μM Barbadin 
would be used to assess β-arrestin, the D2 receptor scaffolding protein, function in synaptic 
transmission. Tonic application of this β-arrestin antagonist before and during coapplication 
with DA significantly diminished fEPSP amplitude compared to the untampered control but 
not compared to 1000 μM DA itself. This statistical insignificance of Barbadin is further shown 
in both peak fEPSP depression and in the gradient during the final 20 minutes of DA 
application. This initial diminishment in amplitude may be physiologically relevant, as 
Barbadin blocks internalisation through clathrin adaptor protein 2 (AP2) interaction, 
preventing neurones from recycling cleaved neurotransmitters and thus pools of 
neurotransmitters would diminish. This statistical insignificance compared to 1000 μM DA 
may too be physiologically relevant, as Barbadin has not previously been shown to permeate 
the neuronal membrane, preventing its binding with β-arrestin. 
 
5.3.2.2.2   Dopamine Antagonists w    1000 μM        e 
Unlike when coapplied with 100 μM DA, coapplication of 1000 μM DA with SCH-23390 
showed no statistically significant change during its application. Although this was not 
statistically reliably different at t = 30 (p = 0.0503), fEPSP amplitude showed a gradual 
reduction during SCH-23390 application, indicating an effect was observed during drug 
application, even if this was not significant. Sulpiride however did show statistical significance 
during its application and was subsequently renormalised. Although previous experiments 
applying sulpiride showed no statistically significant changes during its application (during its 
coapplication with 100 μM DA; Caruana et al., 2006), the depression observed during the D2-
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like antagonists’ application may be physiologically relevant, however determining this would 
require further testing. This Previous dopaminergic experiments in the LEC showed that 1000 
μM DA, the concentration used in conjunction with Barbadin, is highly concentrated enough 
to fully saturate DA receptors. This saturation is characterised by the observed recovery even 
throughout the washout phase, whereas 100 μM DA will rapidly return to baseline. Although 
DA antagonists should theoretically block the observed changes in fEPSP amplitude mediated 
by DA, saturation with 1000 μM DA occupies DA receptor active sites, preventing antagonist 
binding. This may go some way to determining the underlying mechanisms of how the 
antagonists block DA suppression, as these experiments (unlike the 100 μM DA experiments) 
shows the drug interaction may bind to the receptors through a competitive mechanism. 
The results seen when coapplying 1000 μM DA with these receptor antagonists, as 
well as when coapplied with Barbadin, appear to possess a metaplastic effect. This variant of 
plasticity, similar to Hebbian plasticity, is heavily dependent upon NMDAR activity, which is in 
turn theorised to alter Ca2+ related activities (Izumi et al., 1992). This dependency is further 
shown as activities of other postsynaptic receptors, namely AMPAR and mGluRs, act entirely 
independently of metaplasticity (Zorumski and Izumi, 2012). Subsequently, metaplasticity 
induced through prolonged DA exposure would culminate in a reduction in DA’s efficacy 
during its application, a phenomenon that was observed in all experiments which applied 
both 100 μM and 1000 μM DA (this experimental group as well as the last group). Despite 
this, the exact mechanisms underlying metaplasticity still remains somewhat idiopathic, 
however these results should aid in further understanding the phenomenon, as neither D1-
like, D2-like nor β-arrestin show any effect on the metaplastic affect at the tested parameters 
within the LEC. 
 
5.3.2.3   Paired-Pulse Stimulation Analysis 
PPS experiments were used to determine if DA mediated glutamatergic transmission through 
acting on the glutamatergic presynapse within the LEC, affecting presynaptic glutamate 
release probabilities. Previous studies looked at how PPS and high concentration DA affect 
these release probabilities (Caruana and Chapman, 2008), however this study did not assess 
PPS and low concentrations DA. Although the application of 100 nM DA showed no 
statistically reliable difference, as was also observed during its single application, the response 
elicited was different from previous experiments, showing a slight depression upon 
application. The two cannot be compared however, as parameters between experiments 
differ, with PPS potentially inhibiting the facilitative properties of 100 nM DA, suggesting a 
potential presynaptic release mechanism to the previously observed facilitation. The ratios 
observed in both parameters in this experiment are also congruent to those shown previously, 
with IPIs shorter than 30 ms (10 ms (Hamam et al., 2007; Bouras and Chapman, 2003) and 20 
ms (Waldbaum and Dudek, 2009; Jiang et al., 2000)), showing a depression during the second 
pulse. This experimental group also showed no difference before and during DA application, 
thus concluding that although DA had elicited an insignificant change in amplitude, this 
facilitation was not driven through a mechanism based on presynaptic glutamate release.  
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 PPS during high concentration DA application however shows a change from paired-
pulse depression into a paired-pulse facilitation. Although this facilitation is greater at shorter 
IPIs (10, 30 and 100), all IPIs showed a statistically significant facilitation compared to before 
DA application. The longest IPI paired-pulse, 1000 ms, was also shown to be statistically 
significant, despite the two pulses acting as two entirely independent action potentials (Jonas, 
2000). Although a facilitation after 1 second is yet to be reported elsewhere, this may likely 
be because shorter facilitative IPIs had been delivered to the slice prior to the delivery of 1000 
ms IPI pulses which may affect presynaptic pools to alter presynaptic release probabilities. 
This may also be due to activation of mechanisms associated with early-phase LTP generation 
(Sun et al., 2005). Of these different IPIs, 30 ms yielded the largest PPR (1.383 ±0.106), an IPI 
which had also been shown in previous experiments, often being described as the “optimal 
PPF IPI”. At this IPI the presynaptic release probability is at its highest, with extracellular Ca2+ 
pools restabilising and intracellular pools not yet fully clearing, a second sweep will initiate an 
influx of more calcium into the presynaptic terminal, leading to a greater exocytosis of 
neurotransmitters (Caruana and Chapman, 2008; Jo et al., 2010; Zucker and Regehr, 2002). 
This therefore shows a presynaptic influence that DA has on glutamatergic neurones, where 
most evidence would suggest that DA acts on the postsynaptic neurone (Nakano et al., 2010; 
Tritsch and Sabatini, 2012), supporting the aforementioned experiments which tested PPS in 
the LEC (Liu, 2020; Caruana and Chapman, 2008). Although this presynaptic release 
probability is yet to have an exact mechanism proposed, it is likely that this occurs through 
VGCC and subsequently Ca2+ mediation, as altering both these to increase intracellular Ca2+ 
concentrations would facilitate presynaptic neurotransmitter release, altering the terminals 
probability. Should this occur through presynaptic VGCC activation, it would match one such 
previous study by Berretta and Jones (Berretta and Jones, 1996). In their study, it was shown 
that preNMDARs induce LTP in EC layer II, whereas it is predominantly involved in LTD 
induction across the rest of the brain. Although this experiment showed a similar result to this 
experiment, their facilitation observed at 50 ms IPI was insignificant, whereas these show 
statistically significantly reliable differences. In order to identify the presynaptic mechanisms 
in which DA affects neurotransmitter release, a range of further experiments would need to 
be performed, such as blocking glutamate transmission (through AP5 inhibition of NMDARs, 
a concept which was tested in the aforementioned paper), blocking DA receptors (through 
SCH-23390 or sulpiride application and their coapplication) as well as potentially targeting 
other downstream molecules and assessing their function in paired-pulse facilitation. 
 
5.4   Clinical Significance 
5.4.1   Depression 
5.4.1.1   Overview of Depression 
Depression has been described as a multifaceted neurological disorder, in which a variety of 
dysfunctions all contribute to significant cortical activity suppression (Hasler, 2010). This 
neurological disorder affects more than 300 million people worldwide and is the world’s 
leading cause of disability as reported by the World Health Organisation (WHO). Depression 
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has been shown to affect women more than men, but age is an irrelevant factor as people 
from all ages can be diagnosed with the disorder (WHO, 2021). Depression can be subdivided 
into two categories, the first of which is unipolar depression, where the sufferer only 
experiences depressive episodes (Cuellar et al., 2005). The term unipolar depression is 
somewhat of a broad umbrella which covers five further subcategories, major depression, 
seasonal affective disorder, adjustment disorder, postpartum depression and dysthymic 
disorder (Benazzi, 2006). The second of the two subcategories of depression, bipolar 
depression can also be subdivided into two distinct categories, bipolar I and bipolar II, which 
indicates a history of mania and hypomania (which describes periods of euphoria and is a 
milder variant of mania) respectively (Angst and Cassano, 2005). 
Similarly to the ranging types of depression, the mechanisms underlying the disorder 
are also extensive. These mechanisms vary from stemming from an inflammatory disorder, a 
dysregulation of the neurotransmitter glutamate and as a neurodegenerative disorder (to 
name a few from Lang and Borgwardt’s review (Lang and Borgwardt, 2013)). The first of these 
mechanisms involves changes in inflammatory homeostasis, with changes in interleukin-6, 
tumour necrosis factor-alpha (TNF-α), interleukin-2 receptors and c-reactive protein all 
directly affect the inflammation of the various cortical regions (Liu et al., 2012; Dowlati et al., 
2010). Elevation of these proteins (asides from TNF-α which is lowered) results in reduced 
phosphoinositide 3-kinase (PI3K) levels, which may subsequently trigger depression (Lang and 
Borgwardt, 2013). Stimulation of the mammalian target of rapamycin (mTOR) pathway 
through ketamine administration is also widely implicated in various forms of depression 
(Abelaira et al., 2014). Aside from cellular mechanisms, depression is considered as a 
neurodegenerative disorder due to its reduction in hippocampal volumes and BDNF levels 
which are both observed in depressed patients (Campbell and MacQueen, 2006; Pittenger 
and Duman, 2007). As well as decreases in these factors, neurotrophin-3, erythropoietin and 
glial cell-derived neurotrophic factor (GDNF) are all lowered in brains of depressed subjects. 
These changes result in a decrease in CREB, which subsequently reduces BDNF levels, which 
in turn reduced PI3K levels which (as was previously mentioned) that all contribute to leading 
to depression (Lang and Borgwardt, 2013). Aside from these mechanisms underpinning 
depression, depression has also been shown to occur from a reduction in DA levels 
throughout the cortex, with depressed patients showing a reduction in DA transporter 
binding when observed with a PET scan (Sarchiapone et al., 2006). As well as this reduced 
binding, depression has also been shown to stem from reduced levels of DA, which may in 
fact result in the aforementioned binding reduction (Kilbourn et al., 1992). It may therefore 
be possible that targeting the dopaminergic system may provide a therapeutic alternative 
when treating depression.  
Clinically, depression is currently treated primarily using medications that block 
neurotransmitter reuptake, including the reuptake of selective serotonin (SSRIs, such as 
citalopram, fluoxetine and sertraline) and serotonin and noradrenaline (SNRIs, including 
duloxetine and venlafaxine (Faquih et al., 2019)). Although SSRIs and SNRIs dominate clinically 
used antidepressants, there are other medications that target the dopaminergic system. 
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These medicines, such as quetiapine and bupropion, are not selective to DA receptors, acting 
on serotonergic and norepinephrine receptors as well (Kondo et al., 2013; Stahl et al., 2004).  
 
5.4.1.2   Anhedonia 
Described as the “hallmark of depression”, anhedonia is the most common characteristic 
observed in people with depression, so much so that this symptom is required for depression 
to be diagnosed. First described in 1897, anhedonia is defined as the reduced ability to 
experience pleasure (Ribot, 1897) and although it is well implicated in major depression, it is 
also a side effect of Parkinson’s disease and drug abuse (Klein, 1984; Isella et al., 2003; Volkow 
et al., 2002). Despite this reduced experience of pleasure, depressed patients have shown an 
increased refinement in their senses, with some patients showing higher sweet taste 
perception than those without depression (Berlin et al., 1998). Although the exact 
mechanisms underlying anhedonia still remain somewhat idiopathic, correlations between 
the disorder and both DA (and subsequently serotonin due to the correlation between the 
two neurotransmitters (Yan, 2000)) and glutamate receptors have still been shown (Der-
Avakian and Markou, 2012). Despite this however directly analysing and quantifying 
anhedonia in depression posseses a challenge, as the variety of mood disorders in depression 
are somewhat entangled (Gorwood, 2008). There may still be a crucial role for the LEC to play 
in anhedonia, as this subregion conveys non-spatial information from sensory cortices before 
projecting the information throughout the hippocampus. As long-term retention of non-
spatial information from the hippocampus plays a fundamental role in anhedonia (Der-
Avakian and Markou, 2012), it may be possible that the LEC plays a substantial role in its 
development (Lally et al., 2015). 
 
5.4.1.3   Flinders-Sensitive line (FSL) Rats 
Studying depression in humans holds many challenges, however using rat models may 
subsequently yield a better and alternative. DA receptors are highly conserved between the 
two species, as rats’ brains posseses a 91% identical D1 receptor and a 96% identical D2 
receptor amino acid sequence to humans (Sibley et al., 1993). As well as the receptors, DA 
transporters are highly conserved amongst mammals, with rats having a 92% homology to 
humans for these transporters (Giros et al., 1992). The Flinders-sensitive line of rats (FSL) act 
as a genetic model of depression, being used since their discovery in 1993 by D. Overstreet 
(Overstreet, 1993). This line of rats are overly sensitive to the acetylcholinesterase agonist 
diisopropyl fluorophosphate, a chemical which has recently been shown to lead to develop 
cognitive depression (Phillips and Deshpande, 2016). Comparing experiments using this 
pathophysiological model of rat to the physiological Sprague-Dawley rats may also indicate 
changes in LEC structure and function in depression, further increasing knowledge of both the 




5.4.2   Schizophrenia 
Deriving from the Greek roots of split (schizen) and mind (phren), schizophrenia affects much 
less people than depression, with approximately 20 million people worldwide suffering from 
this disorder (James et al., 2018). Where depression stems from reduced cortical DA levels, 
schizophrenia is believed to be the other side of the same coin, stemming from increased 
levels of DA (namely D2) transmission. This alteration in cortical DA levels results in a range of 
symptoms, all of which fall into three generic clusters. The first group, positive symptoms, 
defines symptoms which arise due to cortical overexcitation and includes symptoms such as 
hallucinations and erratic behaviour. This group is potentially the most important group when 
identifying schizophrenia, as at least one of these symptoms must be present for the disorder 
to be fully diagnosed (Patel et al., 2014). The second group is the opposite to the first group, 
both in name and in nature. The negative symptoms associated with schizophrenia arise from 
cortical suppression and includes symptoms such as reduced expressions and social 
withdrawal. The final group, cognitive symptoms, are associated with any side effects that do 
not fall into the aforementioned groups and primarily include diminishments in cognitive 
abilities (all three groups are discussed in Joseph et al., 2015). Similarly to that observed in 
depression, the structure of the brain is also changed in patients who suffer from 
schizophrenia, which includes an enlargement of the major ventricles (Davis et al., 1998) as 
well as a reduction in dendritic spine densities on a cellular level (Moyer et al., 2015). Although 
DA (as well as other neurotransmitters) dysfunction and cortical changes have all been well 
reported in schizophrenia, the exact cellular mechanisms underlying the disorder are still 
largely unknown.  
Clinically, schizophrenia is treated with antipsychotics, medications that subsequently 
target a range of neurotransmitter systems associated with the disorder. Antipsychotics are 
classified in two groups, the first discovered typical antipsychotics (medications which show 
more extrapyramidal symptoms, such as haloperidol and trifluoperazine) and the later 
discovered atypical antipsychotics (medications which show less extrapyramidal symptoms, 
such as aripiprazole and quetiapine (Faay et al., 2018)). Sulpiride, the D2-like antagonist 
coapplied with 100 μM and 1000 μM, is also an atypical antipsychotic, currently being used 
clinically as a treatment for schizophrenia (Lai et al., 2012). 
 
5.4.3   Clinical Significance of Results in Neurological Disorders 
As outlined in Chapter 5.4.1.2, the LEC may play a crucial role in anhedonia, as this region 
conveys non-spatial information from sensory cortices and projects the information 
throughout the hippocampus for long-term storage. If a patient suffers from diminished 
neurological glutamate and DA levels, non-spatial information is less likely to be conveyed as 
the activity of the LEC fails to suppress to allow memory to be conveyed, a mechanism which 
was outlined in Chapter 1.1.3.3. These experiments further support this statement, as more 
potentially physiological lower concentrations of DA elicit a much lower level of fEPSP 
depression than higher concentrations, which may support this link between low inter-neural 
DA and depression (which can be observed through anhedonia like symptoms). The most 
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notable of these concentrations, 100 nM, may provide a therapeutic alternative to currently 
used medications, as this facilitation of localised activity may reduce anhedonia like 
symptoms, potentially supressing symptoms of depression in patients. This facilitation of LEC 
activity could also result in an increased conveyance of non-spatial memory through the HF, 
which may provide another avenue of treatment for anhedonia. Asides from anhedonia, the 
findings in this study could influence pharmacological targets in DA related neurological 
disorder (such as Parkinson’s and schizophrenia), as localised DA application could offer new 
insights into new potential targets for treatment (Yiannopoulou and Papageorgiou, 2013). 
However, these implications cannot be fully confirmed until these experiments are 
performed against the aforementioned depressed model FSL rats, a comparison between 
which would show if any proposed therapeutic alternative may show any clinical significance. 
Furthermore, making conclusions on neurological disorders through ex vivo experiments that 
target one region, within a segment of the brain, brain would be illogical, as neurological 
disorders are complex and arise from a variety of defects from a plethora of cortices. 
 
5.5   Conclusion 
In conclusion, the role that the LEC plays under physiological conditions still remains largely 
unknown. However, this report will go some way to directly (through the experiments 
completed here) and indirectly (through further experiments completed as a result and 
expansion of the ones completed here) improving our knowledge on the mechanisms 
underlying LEC function. Tyrosine hydroxylation identification in the LEC has confirmed that 
previous and subsequent DA-mediated experiments are physiologically relevant, and that DA 
is released in islands throughout the superficial layers of the region. These experiments also 
show that DA may be expressed in the LEC at lower concentrations under physiological 
conditions, with 10 nM DA showing a statistically reliable depression during application and 
100 nM DA showing a statistically reliable facilitation during washout. Pharmacological 
analysis of dopaminergic neurones in these islands show that although desensitisation was 
induced at higher concentrations, most notably at 1000 μM, it was not convincingly blocked 
by either DA antagonist used. These experiments did however show some suggestion that the 
D1-like antagonist, SCH-23390, did elicit an effect on the rate of desensitisation, however this 
effect was not statistically significant. Paired-pulse stimulation at logarithmic IPIs also showed 
that the fEPSP generated by glutamatergic activity is affected by DA both at the presynaptic 
and the postsynaptic terminal, with short IPIs indicating the presynaptic mediation may be 
through presynaptic release probability mechanisms. These results may therefore provide a 
foundation for both future experiments, such as the identification of underlying mechanisms, 
to be conducted within this region, potentially providing results that allow clinical and 
therapeutic alternatives to treating depression and schizophrenia to be explored. Finally, in 
accordance with previous studies, the results in these experiments indicate that DA indirectly 





5.6   Future Work 
Although the conclusions drawn from this report may provide the foundation for future work 
to derive from, there are still a plethora of avenues which could be explored to further 
understand the physiological functions of the LEC. Given more time and a larger financial 
budget, all of these experiments could be expanded upon in various ways. 
 
5.6.1   Refining and Expanding Current Datasets 
Despite TH immunohistochemistry confirming the presence of dopaminergic fibres, thus 
indicating that experiments within the LEC assessing DA function are physiologically relevant, 
no further analysis was performed on these experiments. Immunohistochemical staining is 
seldom used for quantitative assessment, instead being used to qualitatively indicate the 
presence of a neurone, however semi-quantitative analysis may give a more accurate and 
conclusive interpretation of results. This can be done through optical density analysis, 
analysing percentages of stained profiles and the number of stained cells in the stained region 
(Mausset-Bonnefont et al., 2003). As well as providing semi-quantitative results on the TH 
staining, these methods would also better indicate the presence of DA islands within the LEC, 
with cell count and optical density being higher in the islands. As well as these analyses, the 
physiological concentration of DA may also be determined in vitro, either by assessment 
through high-performance liquid chromatography (Holm et al., 2016), flow cytometry 
(McKinnon, 2018) or by a standard western blot (Schoonover et al., 2016). 
The first aspects of refining current electrophysiological datasets would be to increase 
the number of control experiments in both ACSF changeover and vehicle application datasets. 
Currently, both control experiments showed an insignificantly small depression during both 
experiments, which has been concluded to stem from solution preparation inconsistencies. 
Increasing the number of experiments performed in both these controls would likely remove 
this depression, as currently both datasets only have five experiments in each. As well as 
increasing the number of control experiments in each dataset, increasing the number of 
nanomolar DA application experiments, most importantly 100 and 300 nM DA application 
would indicate whether the observed facilitation is a reliably repeatable response or if the 
facilitation was as a result of any inconsistencies as mentioned previously. 
 As well as increasing the number of experiments in each dataset, further experiments 
testing DA at more nanomolar concentrations may also give a better insight into the results 
observed. Testing the single tonic application of both 3 and 30 nM DA would complete a 
logarithmic scale for nanomolar concentrations of DA, which may in turn indicate a suggestion 
as to why 1 and 10 nM DA showed depression during its application but 100 and 300 nM DA 
showed facilitation. Asides from single tonic application experiments, applying 100 nM DA 30 
minutes after the first application (during its washout peak) may also provide a better 
understanding than its application 1 hour after its first application provided. Better 
understanding the conditions in which facilitation is observed will allow further experiments 
to be conducted which may identify an underlying mechanism. These experiments would 
likely target biomolecules involved in LTP generation, with both presynaptic and postsynaptic 
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targets present which would indicate both the mechanism and the synapse at which 
facilitation is induced. 
 Another crucial conclusion of the experiments here that would need further 
expanding would be that D1-like receptors are implicated in desensitisation within the LEC. 
As most previous reports suggest that D2-like receptors are implicated in desensitisation 
(Nimitvilai et al., 2014 and Nimitvilai and Brodie, 2010), further experimentation assessing 
the role of D1-like receptors may provide further evidence that DA desensitisation in the LEC 
differs from other regions of the cortex. Other key components of receptor desensitisation, 
asides from receptor function, includes: a required phosphatidylinositol turnover; PLC 
activation; conventional PKC presence and concentrations of residual DA within the synaptic 
cleft could also be assessed.  
 Penultimately, PPS experiments suggested that DA mediates glutamate presynaptic 
release probabilities, however definitively concluding this would require further 
experimentation. One way to assess this alteration in presynaptic release would be through 
bound vesicle labelling, which not only allows a comparison between presynaptic and 
postsynaptic activity to be drawn, but also indicates synapses which have undergone changes 
in presynaptic release probabilities (Xu et al., 2013). Another way which changes in 
presynaptic release could be measured is through glutamate concentration analysis within 
the synaptic cleft, with greater concentrations of the neurotransmitter indicating greater 
presynaptic release (Scimemi and Beato, 2009). This could also be assessed through NMDAR 
inhibition, through AP5 application, as discussed in the following chapter. 
 Lastly, assessing different biological aspects of the fEPSP may show varying results to 
those obtained than peak amplitude. Peak amplitude was assessed due to its consistency over 
long durations, however analysing how the fiber volley changes during the experiment will 
give insight into how presynaptic activity changes throughout. Furthermore, another method 
for measuring induction of plasticity is through measuring the initial slope during the peak 
produced by postsynaptic activity. Measuring how the peak amplitude varied across the 
experiment yielded very few conclusions regarding plasticity, however variations in the initial 
slope can give a significantly better indication (Liu et al., 2008).  
 
5.6.2   Supplementary Pharmacological Experiments 
The role that NMDAR, therefore glutamatergic neurones, could also be expanded upon 
through further experimentation using AP5. Although AP5 application showed a greater 
depressive effect during its coapplication with 100 μM DA, coapplying AP5 with 100 nM DA 
may indicate whether AP5 would amplify the observed response or whether its application 
would nullify it. Understanding this would give a greater understanding into the origin of the 
observed facilitation, more specifically if that facilitation is DA or glutamate mediated. 
Secondly, AP5 could also be used during PPS experiments will allow a conclusive conclusion 
to be drawn to whether the observed PPF effect is through glutamatergic modulation by DA, 
also potentially conclude if the observed effect is through presynaptic or postsynaptic 
mechanisms. Inducing PPS during the coapplication of AP5 and DA may also indicate the role 
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which DA plays on fEPSPs, as these parameters were used previously to assess the role that 
GABA plays on transmission (Davies and Collingridge, 1996).  
 As well as AP5 application during PPS, application of the D1-like antagonist (SCH-
23390) and the D2-like antagonist (sulpiride) will not only give a better understanding into 
the roles that each receptor plays in synaptic plasticity, as was outlined in Figure 10, but may 
also further show their role in how DA receptors affect glutamatergic neurones. In addition 
to this, as SCH-23390 application (D1-like inhibition) showed no desensitisation, so testing 
this across a longer time frame may give an indication into how effective this desensitisation 
inhibition is and whether this affect is only seen for a limited amount of time. As well as for 
longer durations, repeated coapplication of 100 μM DA and 10 μM SCH-23390 may indicate 
if the observed desensitisation is a temporary effect, or if there are any downstream changes. 
A concentration-response curve could also be tested for both SCH-23390 and sulpiride as well, 
as neither of these drugs are yet to have a conclusive concentration-response curve 
generated for either. This way, full saturation could be identified and experiments at this 
saturation could be performed, with saturation discrepancies potentially providing an 
explanation into why desensitisation was blocked during D1-like antagonist application but 
not D2-like antagonist application. This concentration-curve would not only allow for more 
accurate experimentation in these datasets, but it would also develop knowledge and 
understanding for both SCH-23390 and sulpiride. 
As well as the drugs used, other classifications of drugs can be used to further examine 
the roles that both D1-like and D2-like receptors play. Firstly, this can be done by testing other, 
similar DA antagonists to those used, such as SCH-39166 as a D1-like receptor antagonist or 
chlorpromazine as a D2-like receptor antagonist. Application of a stronger, more potent 
antagonist may show differing or complimentary results to those obtained, providing a more 
accurate conclusion to the results already obtained. This can also be done by testing drugs 
that target downstream signalling molecules (such as targeting PLC which has numerous 
targets (Huang et al., 2013) or by targeting Akt using AZD5363 (Ribas et al., 2015)) or by using 
receptor agonists rather than antagonists. These agonists, such as the D1-like agonist SKF-
38392 or the D2-like agonist quinpirole, would show opposing results to those shown during 
antagonist application, thus would primarily be complementary to antagonist experiments 
already completed. 
Furthermore, although Barbadin was shown to be statistically insignificant throughout 
its coapplication with 1000 μM DA, analysis of Barbadin at a lower concentration of DA (such 
as at 100 μM) may provide a better understanding into how the drug affects D2 receptor 
transmission. 
 
5.6.3   Implementing Clinical Relevance 
Finally, experiments using genetic models of rats, for example the aforementioned FSL rats, 
will allow comparisons to be drawn between physiological and pathophysiological models, 
presenting a clinical relevance to the experiments. Completing identical experiments in the 
genetic model to that completed in the Sprague-Dawley rats will indicate a physiological 
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difference between the two, potentially bettering the understanding of the 
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